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KiDney RegulAtion of SAlt AnD ACiD-BASe hoMeoStASiS
Maintaining salt and acid-base homeostasis is essential to the survival of all species. In 
terrestrial mammals, the kidneys play a central role in maintaining this homeostasis. 
The kidneys regulate salt balance by adjusting sodium reabsorption along the kidney 
tubule to dietary intake. Kidney regulation of salt balance serves to maintain the extra-
cellular fluid volume and blood pressure. Maintenance of acid-base balance is orches-
trated by the urinary excretion of non-volatile acids and the reclamation of the filtered 
base bicarbonate. The normal regulation of salt and acid-base balance is disturbed in 
patients with kidney disease. The overarching term for any type of kidney disease that 
persists for more than three months is chronic kidney disease (CKD). CKD is classified 
based on the estimated glomerular filtration rate and the degree of albuminuria.1 CKD 
impacts salt and acid-base homeostasis and may result in salt-sensitive hypertension 
and metabolic acidosis, two common complications of CKD.
SAlt-SenSitive hyPeRtenSion in CKD
The prevalence of hypertension in CKD reaches nearly 100% when the stage of kidney 
failure is reached (eGFR < 15 ml/min/1.73 m2).2 Hypertension in CKD is associated with 
an increased risk of cardiovascular disease and further progression of CKD. A main 
limitation in the development of new treatment strategies for hypertension in CKD is the 
fact that its pathophysiology is still incompletely understood. Similar to hypertension in 
patients without CKD, the origin of hypertension of CKD is multifactorial. A key element 
of its pathophysiology is a rightward shift and flattening of the pressure-natriuresis 
curve.3 In individuals with healthy kidneys, increased dietary salt intake affects blood 
pressure only minimally, because excess salt is excreted by increasing natriuresis. In 
CKD, however, a greater increase in blood pressure is necessary to excrete the same 
amount of salt. The reasons why CKD disturbs the pressure-natriuresis curve includes 
nephron loss with single-nephron hyperfiltration, disturbed glomerulotubular balance, 
and the presence of anti-natriuretic factors. Thus, CKD causes a salt-sensitive form of 
hypertension, indicating that blood pressure becomes sensitive to changes in dietary 
sodium intake. Of note, salt-sensitivity is associated with increased mortality even 
without the presence of hypertension or CKD.4
Fine-tuning of kidney sodium regulation takes place in the distal part of the nephron. 
Here, specific sodium transporters are present that are under the control of the renin-
angiotensin and sympathetic nervous systems. More recently it has also become clear 
that changes in plasma potassium modify the activity of sodium transporters.5-7 The main 
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apical sodium transporters in the distal nephron are the sodium chloride cotransporter 
(NCC) and the epithelial sodium channel (ENaC). Experimental studies in animals and 
patients indicate that dysregulation of the renin-angiotensin system (RAS), including 
increased plasma aldosterone and kidney angiotensin II, contributes to hypertension in 
CKD.8-12 Other studies suggest increased activity of NCC and ENaC in CKD.13-15 However, 
how the effects of angiotensin II, aldosterone and plasma potassium impact sodium and 
blood pressure regulation in CKD is incompletely understood. Chapter 2 reviews the 
current understanding of the pathogenesis of salt-sensitive hypertension in CKD with a 
focus on distal tubular mechanisms. In Chapter 3, a rat model of CKD and hypertension 
(the 5/6th nephrectomy model) is used to study the effect of dietary salt on RAS inhibi-
tion. A promising novel approach to target the RAS is the use of siRNA-based therapeu-
tics against liver-derived angiotensinogen. This experimental treatment is reviewed in 
Chapter 4. In Chapter 5, siRNA targeting of angiotensinogen is used to analyze the effect 
on hypertension in a rat model of CKD (again using the 5/6th nephrectomy model).
Clinically, hypertension in CKD is often resistant to treatment with drugs or dietary 
interventions such as salt restriction. Possibly, non-adherence to medication and the 
difficulty to adhere to dietary restrictions for longer periods of time restricts treatment 
efficacy. In case of treatment with diuretics, limiting factors to treatment efficacy may 
also include reduced tubular secretion of diuretics during CKD.16 However, anecdotal 
evidence suggests that thiazide-diuretics may actually still be effective for the treatment 
of hypertension in CKD.17-22 Therefore, in Chapter 6, we report the results of a random-
ized controlled trial in which we compared the effects of the distal diuretics hydrochlo-
rothiazide and amiloride with dietary sodium restriction on blood pressure in patients 
with CKD.
A specific kidney disease in which the RAS may contribute to hypertension is autosomal 
dominant polycystic kidney disease (ADPKD). ADPKD leads to progressive cyst forma-
tion, early onset salt-sensitive hypertension, and CKD.23 In the kidney, the progressive 
growth of cysts compresses normal kidney tissue, which in turn may cause ischemia 
and increase renin secretion.24-26 Renin has also been measured in cyst fluid and pre-
vious data suggest that local production occurs by epithelial cells lining the cysts.24, 25 
However, measurements of plasma renin and aldosterone in patients with ADPKD did 
not consistently show elevated levels.23, 27-37 Possibly, therefore, ADPKD may specifically 
promote intrarenal production of angiotensin II. Supporting this hypothesis, two stud-
ies showed that the urinary excretion of angiotensinogen, a precursor of angiotensin 
II, is increased in patients with ADPKD and hypertension.36, 37 However, if the urinary 
excretion of RAS components truly reflects increased intrarenal angiotensin II activity 
remains uncertain.38 Therefore, in Chapter 7, blood and urinary parameters of the RAS 
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were analyzed in patients with ADPKD and compared to patients with CKD; in a number 
of ADPKD patients who underwent nephrectomy, renin was also measured in cyst fluid.
MetABoliC ACiDoSiS of CKD
Metabolic acidosis is present in up to 40% of patients with advanced CKD.39 Similar to 
hypertension, metabolic acidosis in CKD is associated with increased cardiovascular 
and all-cause mortality.40 Moreover, clinical studies show that correction of metabolic 
acidosis in CKD slows disease progression, although the evidence-level was classified 
as low-to-moderate certainty in a recent meta-analysis and systematic review.41 How 
metabolic acidosis contributes to adverse outcomes in CKD is incompletely understood. 
A prevailing hypothesis is that initial adaptive responses to increase ammoniagenesis 
may become maladaptive and contribute to kidney injury.42 Data from animal studies 
suggest a role for angiotensin II, aldosterone and endothelin-1 in the pathogenesis of 
acidosis-induced kidney injury.43-46 Furthermore, complement activation secondary to 
increased ammoniagenesis may contribute to inflammation and subsequent fibrosis.47 
However, at present, it is unclear if these mechanisms are also present in patients with 
CKD. To address this, we analyzed the response to an acute oral acid load in patients 
with CKD and healthy subjects (Chapter 8), and analyzed the effect of 4-week alkali 
treatment in patients with CKD and metabolic acidosis on the RAS (Chapter 9).
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AiMS of the theSiS
To review the pathogenesis of salt-sensitive hypertension in chronic kidney disease 
(CKD) with a focus on distal tubular mechanisms (Chapter 2)
To analyze the role of dietary salt in the antihypertensive response of renin-angiotensin 
system (RAS) inhibition in a rat model of CKD and hypertension (Chapter 3)
To review a novel approach of RAS inhibition that targets angiotensinogen with RNA-
based therapeutics (Chapter 4)
To test the antihypertensive effect of siRNA directed against angiotensinogen in a rat 
model of CKD and hypertension (Chapter 5)
To compare the antihypertensive effects of distal diuretics and dietary salt restriction in 
patients with CKD and hypertension (Chapter 6)
To compare blood and urinary parameters of the RAS in patients with polycystic kidney 
disease and patients with CKD (Chapter 7)
To characterize the differences between the responses to an acute oral acid load in 
patients with CKD and healthy subjects (Chapter 8)
To analyze the effect of alkali treatment with sodium bicarbonate on the RAS in patients 




 1. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, De Zeeuw D, Hostetter TH, La-
meire N and Eknoyan G. Definition and classification of chronic kidney disease: a position state-
ment from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089-100.
 2. Buckalew VM, Jr., Berg RL, Wang SR, Porush JG, Rauch S and Schulman G. Prevalence of hyperten-
sion in 1,795 subjects with chronic renal disease: the modification of diet in renal disease study 
baseline cohort. Modification of Diet in Renal Disease Study Group. Am J Kidney Dis. 1996;28:811-21.
 3. Guyton AC. Blood pressure control--special role of the kidneys and body fluids. Science. 
1991;252:1813-6.
 4. Weinberger MH, Fineberg NS, Fineberg SE and Weinberger M. Salt sensitivity, pulse pressure, and 
death in normal and hypertensive humans. Hypertension. 2001;37:429-32.
 5. Terker AS, Zhang C, Erspamer KJ, Gamba G, Yang CL and Ellison DH. Unique chloride-sensing 
properties of WNK4 permit the distal nephron to modulate potassium homeostasis. Kidney Int. 
2016;89:127-34.
 6. Vallon V, Schroth J, Lang F, Kuhl D and Uchida S. Expression and phosphorylation of the Na+-Cl- 
cotransporter NCC in vivo is regulated by dietary salt, potassium, and SGK1. Am J Physiol Renal 
Physiol. 2009;297:F704-12.
 7. Hoorn EJ, Gritter M, Cuevas CA and Fenton RA. Regulation of the Renal NaCl Cotransporter and Its 
Role in Potassium Homeostasis. Physiol Rev. 2020;100:321-356.
 8. Greene EL, Kren S and Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. 
J Clin Invest. 1996;98:1063-8.
 9. Hene RJ, Boer P, Koomans HA and Mees EJ. Plasma aldosterone concentrations in chronic renal 
disease. Kidney International. 1982;21:98-101.
 10. Goncalves AR, Fujihara CK, Mattar AL, Malheiros DM, Noronha Ide L, de Nucci G and Zatz R. 
Renal expression of COX-2, ANG II, and AT1 receptor in remnant kidney: strong renoprotection 
by therapy with losartan and a nonsteroidal anti-inflammatory. Am J Physiol Renal Physiol. 
2004;286:F945-54.
 11. Graciano ML, Cavaglieri Rde C, Delle H, Dominguez WV, Casarini DE, Malheiros DM and Noronha 
IL. Intrarenal Renin-Angiotensin system is upregulated in experimental model of progressive renal 
disease induced by chronic inhibition of nitric oxide synthesis. J Am Soc Nephrol. 2004;15:1805-15.
 12. Zhang JY, Yin Y, Ni L, Long Q, You L, Zhang Q, Lin SY and Chen J. Low-protein diet supplemented 
with ketoacids ameliorates proteinuria in 3/4 nephrectomised rats by directly inhibiting the 
intrarenal renin-angiotensin system. Br J Nutr. 2016;116:1491-1501.
 13. Kwon TH, Frokiaer J, Fernandez-Llama P, Maunsbach AB, Knepper MA and Nielsen S. Altered 
expression of Na transporters NHE-3, NaPi-II, Na-K-ATPase, BSC-1, and TSC in CRF rat kidneys. Am 
J Physiol. 1999;277:F257-70.
 14. Kim S, Heo NJ, Jung JY, Son MJ, Jang HR, Lee JW, Oh YK, Na KY, Joo KW and Han JS. Changes in 
the sodium and potassium transporters in the course of chronic renal failure. Nephron Physiol. 
2010;115:p31-41.
Chapter 1 15
Introduction and aims of the thesis 
 15. Layton AT, Edwards A and Vallon V. Adaptive changes in GFR, tubular morphology, and trans-
port in subtotal nephrectomized kidneys: modeling and analysis. Am J Physiol Renal Physiol. 
2017;313:F199-F209.
 16. Hoorn EJ and Ellison DH. Diuretic Resistance. Am J Kidney Dis. 2017;69:136-142.
 17. Bank N, Lief PD and Piczon O. Use of diuretics in treatment of hypertension secondary to renal 
disease. Arch Intern Med. 1978;138:1524-9.
 18. Jones B and Nanra RS. Double-blind trial of antihypertensive effect of chlorothiazide in severe 
renal failure. Lancet. 1979;2:1258-60.
 19. Acchiardo SR and Skoutakis VA. Clinical efficacy, safety, and pharmacokinetics of indapamide in 
renal impairment. Am Heart J. 1983;106:237-44.
 20. Dussol B, Moussi-Frances J, Morange S, Somma-Delpero C, Mundler O and Berland Y. A pilot study 
comparing furosemide and hydrochlorothiazide in patients with hypertension and stage 4 or 5 
chronic kidney disease. J Clin Hypertens (Greenwich). 2012;14:32-7.
 21. Agarwal R, Sinha AD, Pappas MK and Ammous F. Chlorthalidone for poorly controlled hyperten-
sion in chronic kidney disease: an interventional pilot study. Am J Nephrol. 2014;39:171-82.
 22. Cirillo M, Marcarelli F, Mele AA, Romano M, Lombardi C and Bilancio G. Parallel-group 8-week 
study on chlorthalidone effects in hypertensives with low kidney function. Hypertension. 
2014;63:692-7.
 23. Doulton TW, Saggar-Malik AK, He FJ, Carney C, Markandu ND, Sagnella GA and MacGregor GA. The 
effect of sodium and angiotensin-converting enzyme inhibition on the classic circulating renin-
angiotensin system in autosomal-dominant polycystic kidney disease patients. J Hypertens. 
2006;24:939-45.
 24. Torres VE, Donovan KA, Scicli G, Holley KE, Thibodeau SN, Carretero OA, Inagami T, McAteer JA 
and Johnson CM. Synthesis of renin by tubulocystic epithelium in autosomal-dominant polycys-
tic kidney disease. Kidney Int. 1992;42:364-73.
 25. Graham PC and Lindop GB. The anatomy of the renin-secreting cell in adult polycystic kidney 
disease. Kidney Int. 1988;33:1084-90.
 26. Loghman-Adham M, Soto CE, Inagami T and Cassis L. The intrarenal renin-angiotensin system in 
autosomal dominant polycystic kidney disease. Am J Physiol Renal Physiol. 2004;287:F775-88.
 27. Valvo E, Gammaro L, Tessitore N, Panzetta G, Lupo A, Loschiavo C, Oldrizzi L, Fabris A, Rugiu C, 
Ortalda V and et al. Hypertension of polycystic kidney disease: mechanisms and hemodynamic 
alterations. Am J Nephrol. 1985;5:176-81.
 28. Bell PE, Hossack KF, Gabow PA, Durr JA, Johnson AM and Schrier RW. Hypertension in autosomal 
dominant polycystic kidney disease. Kidney Int. 1988;34:683-90.
 29. Chapman AB, Johnson A, Gabow PA and Schrier RW. The renin-angiotensin-aldosterone system 
and autosomal dominant polycystic kidney disease. N Engl J Med. 1990;323:1091-6.
 30. Harrap SB, Davies DL, Macnicol AM, Dominiczak AF, Fraser R, Wright AF, Watson ML and Briggs JD. 
Renal, cardiovascular and hormonal characteristics of young adults with autosomal dominant 
polycystic kidney disease. Kidney Int. 1991;40:501-8.
 31. Watson ML, Macnicol AM, Allan PL and Wright AF. Effects of angiotensin converting enzyme inhibi-
tion in adult polycystic kidney disease. Kidney Int. 1992;41:206-10.
16  
 
 32. Barrett BJ, Foley R, Morgan J, Hefferton D and Parfrey P. Differences in hormonal and renal 
vascular responses between normotensive patients with autosomal dominant polycystic kidney 
disease and unaffected family members. Kidney Int. 1994;46:1118-23.
 33. Martinez-Vea A, Valero FA, Bardaji A, Gutierrez C, Broch M, Garcia C, Richart C and Oliver JA. Left 
ventricular hypertrophy in hypertensive patients with autosomal dominant polycystic kidney 
disease: influence of blood pressure and humoral and neurohormonal factors. Am J Nephrol. 
2000;20:193-200.
 34. Ramunni A, Saracino A, Esposito T, Saliani MT and Coratelli P. Renal vascular resistance and renin-
angiotensin system in the pathogenesis of early hypertension in autosomal dominant polycystic 
kidney disease. Hypertens Res. 2004;27:221-5.
 35. Kurultak I, Sengul S, Kocak S, Erdogmus S, Calayoglu R, Mescigil P, Keven K, Erturk S, Erbay B 
and Duman N. Urinary angiotensinogen, related factors and clinical implications in normotensive 
autosomal dominant polycystic kidney disease patients. Ren Fail. 2014;36:717-21.
 36. Kocyigit I, Yilmaz MI, Unal A, Ozturk F, Eroglu E, Yazici C, Orscelik O, Sipahioglu MH, Tokgoz B and 
Oymak O. A link between the intrarenal renin angiotensin system and hypertension in autosomal 
dominant polycystic kidney disease. Am J Nephrol. 2013;38:218-25.
 37. Park HC, Kang AY, Jang JY, Kim H, Han M, Oh KH, Kim SH, Noh JW, Cheong HI, Hwang YH and 
Ahn C. Increased urinary Angiotensinogen/Creatinine (AGT/Cr) ratio may be associated with 
reduced renal function in autosomal dominant polycystic kidney disease patients. BMC Nephrol. 
2015;16:86.
 38. Roksnoer LC, Verdonk K, van den Meiracker AH, Hoorn EJ, Zietse R and Danser AH. Urinary mark-
ers of intrarenal renin-angiotensin system activity in vivo. Curr Hypertens Rep. 2013;15:81-8.
 39. Moranne O, Froissart M, Rossert J, Gauci C, Boffa JJ, Haymann JP, M’Rad M B, Jacquot C, Houillier 
P, Stengel B, Fouqueray B and NephroTest Study G. Timing of onset of CKD-related metabolic 
complications. J Am Soc Nephrol. 2009;20:164-71.
 40. Navaneethan SD, Schold JD, Arrigain S, Jolly SE, Wehbe E, Raina R, Simon JF, Srinivas TR, Jain A, 
Schreiber MJ, Jr. and Nally JV, Jr. Serum bicarbonate and mortality in stage 3 and stage 4 chronic 
kidney disease. Clin J Am Soc Nephrol. 2011;6:2395-402.
 41. Navaneethan SD, Shao J, Buysse J and Bushinsky DA. Effects of Treatment of Metabolic Acidosis 
in CKD: A Systematic Review and Meta-Analysis. Clin J Am Soc Nephrol. 2019;14:1011-1020.
 42. Wesson DE, Buysse JM and Bushinsky DA. Mechanisms of Metabolic Acidosis-Induced Kidney 
Injury in Chronic Kidney Disease. J Am Soc Nephrol. 2020;31:469-482.
 43. Phisitkul S, Hacker C, Simoni J, Tran RM and Wesson DE. Dietary protein causes a decline in the 
glomerular filtration rate of the remnant kidney mediated by metabolic acidosis and endothelin 
receptors. Kidney Int. 2008;73:192-9.
 44. Wesson DE and Simoni J. Acid retention during kidney failure induces endothelin and aldoste-
rone production which lead to progressive GFR decline, a situation ameliorated by alkali diet. 
Kidney Int. 2010;78:1128-35.
 45. Wesson DE, Jo CH and Simoni J. Angiotensin II receptors mediate increased distal nephron acidi-
fication caused by acid retention. Kidney Int. 2012;82:1184-94.
 46. Wesson DE, Jo CH and Simoni J. Angiotensin II-mediated GFR decline in subtotal nephrectomy is 
due to acid retention associated with reduced GFR. Nephrol Dial Transplant. 2015;30:762-70.
Chapter 1 17
Introduction and aims of the thesis 
 47. Nath KA, Hostetter MK and Hostetter TH. Pathophysiology of chronic tubulo-interstitial disease 




Salt-sensitive hypertension in chronic 
kidney disease: distal tubular mechanisms
Dominique M. Bovée, Catharina Cuevas Gallardo, Robert Zietse, 
A.H. Jan Danser, Katrina M. Mirabito Colafella, Ewout J. Hoorn




Chronic kidney disease (CKD) causes salt-sensitive hypertension that is often resistant 
to treatment and contributes to the progression of kidney injury and cardiovascular dis-
ease. A better understanding of the mechanisms contributing to salt-sensitive hyperten-
sion in CKD is essential to improve these outcomes. This review critically explores these 
mechanisms by focusing on how CKD affects distal nephron sodium (Na+) reabsorption. 
CKD causes glomerulotubular imbalance with reduced proximal Na+ reabsorption and 
increased distal Na+ delivery and reabsorption. Aldosterone secretion further contrib-
utes to distal Na+ reabsorption in CKD and is not only mediated by renin and potassium, 
but also by metabolic acidosis, endothelin-1, and vasopressin. CKD also activates the 
intrarenal renin-angiotensin system (RAS) generating intratubular angiotensin II to pro-
mote distal Na+ reabsorption. High dietary Na+ intake in CKD contributes to Na+ retention 
by an aldosterone-independent activation of the mineralocorticoid receptor mediated 
through Rac1. High dietary Na+ also produces an inflammatory response mediated by T 
helper 17 cells and cytokines increasing distal Na+ transport. CKD is often accompanied 
by proteinuria, which contains plasmin capable of activating the epithelial Na+ channel. 
Thus, CKD causes both local and systemic changes that together promote distal neph-
ron Na+ reabsorption and salt-sensitive hypertension. Future studies should address 
remaining knowledge gaps, including the relative contribution of each mechanism, the 
influence of sex, differences between stages and etiologies of CKD, and the clinical rel-
evance of experimentally identified mechanisms. Several pathways offer opportunities 
for intervention, including with dietary Na+ reduction, distal diuretics, RAS-inhibitors, 
mineralocorticoid receptor antagonists, and potassium or hydrogen ion binders.
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intRoDuCtion
The Global Burden of Disease Study recently reported that the 2017 global prevalence 
of chronic kidney disease (CKD) was 9.1%, a percentage that has increased by 29% since 
1990 1. The death toll of CKD was 1.2 million, and CKD contributed to another 1.4 million 
cardiovascular disease-related deaths 1. The disease burden of CKD was found to be 
highest in countries with a lower socio-demographic index 1. There was also inequality 
between the sexes, with the age-standardized prevalence of CKD 1.29 times higher in 
females than males, yet, mortality was 1.39 times greater in males than females 1. Thus, 
CKD represents an important global health issue that requires attention not only from 
public health and clinical medicine, but also from basic science, including the physi-
ological sciences.
CKD is defined as kidney damage or a glomerular filtration rate (GFR) < 60 ml/min for 
three months or more, irrespective of cause 2. The most common causes of CKD are type 
2 diabetes and hypertension, while inherited and auto-immune diseases are less com-
mon causes of CKD. CKD reduces nephron number which often results in a progressive 
decline in GFR. CKD is also frequently accompanied by albuminuria, indicating damage 
to the glomerular filtration barrier. CKD disturbs normal kidney physiology and will 
therefore impact on the kidney’s central role in sodium (Na+) homeostasis and blood 
pressure regulation 3. Indeed, CKD is not only a consequence of hypertension, but also 
contributes to hypertension. Accordingly, the prevalence of hypertension increases as 
CKD progresses, reaching nearly 100% in CKD stage G5 (GFR < 15 ml/min) 4. Furthermore, 
hypertension in CKD is often uncontrolled and resistant to treatment meaning that 
blood pressure targets are not achieved despite three anti-hypertensive drugs including 
a diuretic 5. Hypertension in CKD introduces a vicious cycle as it contributes to the pro-
gression of CKD and the high cardiovascular risk in this patient population. Therefore, 
a clearer understanding of the pathophysiology of hypertension in CKD is essential to 
improve treatment and outcomes.
In a large CKD cohort study higher extracellular water (measured by bioimpedance 
spectroscopy), older age, and higher albuminuria were identified as independent deter-
minants of uncontrolled and resistant hypertension in patients with CKD 6. The associa-
tion between extracellular water and hypertension indicates that hypertension in CKD 
is accompanied by an increase in the extracellular fluid volume. Because extracellular 
fluid volume expansion implies Na+ retention, hypertension in CKD can be classified as 
a salt-sensitive form of hypertension 7, 8. In fact, some have argued that kidney dysfunc-
tion is a requirement for all forms of salt-sensitive hypertension 9. In this view, kidney 
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dysfunction impairs pressure natriuresis and secondarily increases vascular resistance 
and therefore blood pressure.
In normal kidney physiology, glomerulotubular balance and tubuloglomerular feedback 
maintain a constant Na+ delivery to the distal nephron 10. Because the distal nephron 
fine-tunes Na+ reabsorption, salt-sensitive hypertension is often caused by increased 
distal nephron Na+ reabsorption 11. The distal nephron is defined as the nephron seg-
ments originating after the macula densa and consists of the distal convoluted tubule, 
connecting tubule, and collecting duct 12. The term “distal tubule” is used differently in 
different contexts, but here we use it to refer to the region between the macula densa 
and the initial collecting tubule 12. The major Na+ transport proteins in the distal nephron 
are the Na+-chloride (Cl-) cotransporter (NCC), the epithelial Na+ channel (ENaC), Na+-
dependent bicarbonate exchanger, and Na+-K+-ATPase 11. Importantly, there is a close 
interaction between ion transport in the distal nephron, with several interdependencies 
between Na+, Cl-, and potassium (K+) transport 13, 14. The majority of the Na+ transport 
proteins in the distal nephron are regulated by angiotensin II and aldosterone, and this 
portion of the nephron is therefore sometimes referred to as the aldosterone-sensitive 
distal nephron 11, 15, 16. In addition, it is becoming increasingly clear that basolateral chan-
nels in the distal nephron sense ambient Na+ and K+ concentrations and the accompany-
ing change in membrane potential. In turn, these signals can be relayed to modify NCC 
and ENaC activity 13, 17, 18.
Although the mechanisms of salt-sensitive hypertension have been studied extensively 
in humans and animals with normal kidney function, remarkably little has been reported 
on the kidney mechanisms of salt-sensitive hypertension in CKD. In this review, we will 
discuss six mechanisms that focus on distal nephron Na+ handling, including (1) CKD-
induced changes in distal nephron Na+ handling, (2) renin-independent aldosterone 
secretion, (3) activation of the intrarenal renin-angiotensin system (RAS), (4) the role of 
dietary salt, (5) metabolic acidosis, and (6) proteinuria-induced Na+ reabsorption (figure 
1). Although the reviewed literature provides a relatively clear picture of the mechanisms 
contributing to salt-sensitive hypertension in CKD, including their interactions, several 
knowledge gaps remain and are to be addressed in future research (table 1). While this 
review focuses on the distal tubular mechanisms of salt-sensitive hypertension in CKD, 
it is important to emphasize that other mechanisms also mediate hypertension in CKD, 
including reduced GFR, an activated central or sympathetic nervous system, and altered 
vascular reactivity 19.
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CKD-inDuCeD ChAngeS in DiStAl nePhRon nA+ hAnDling
Most experimental studies investigating the interactions between CKD, Na+ handling, and 
blood pressure have relied on CKD models in rats or mice. Although several experimental 
models for CKD exist, a common model is 5/6th nephrectomy in which uninephrectomy 
is followed by polar excision or renal artery ligation of the remaining kidney (ablation or 
ligation model) 20, 21. These so-called subtotal nephrectomy or remnant kidney models 
recapitulate human CKD, because they are characterized by low GFR, proteinuria, and 
hypertension. Indeed, incremental reductions in kidney mass increase the incidence 
and severity of hypertension in rats fed a high Na+ diet 22, 23. Conversely, a low Na+ diet 
prevents hypertension in rats after 5/6th nephrectomy 24. Of note, the method used to 
reduce kidney mass determines whether hypertension develops 25. The ligation model 
typically generates hypertension, whereas this is not always the case for the ablation 
model. This suggests that the ablation model requires additional factors such as a high 
salt diet or further progression of CKD over time for hypertension to develop. CKD causes 
anatomical and functional adaptations in surviving nephrons, including elevations in 
single-nephron GFR and tubular hypertrophy 26, 27. After 5/6th nephrectomy fractional Na+ 
figure 1. Working hypothesis for how chronic kidney disease increases distal nephron sodium (Na+) reab-
sorption to cause salt-sensitive hypertension. The key elements are shown in red font. Arrows indicate a 
stimulatory effect. If known, mediators of the indicated effects are shown in italic font. See text for details. 
ACTH, adrenocorticotropic hormone; AVP, arginine vasopressin; ET-1, endothelin-1; GFR, glomerular filtra-
tion rate; IF-g, interferon gamma; IL-17-A, interleukin-17-A; K+, potassium; SGK1, serum and glucocorticoid-
induced kinase 1; Th17, T helper 17 cells; TNF-α, tumor necrosis factor alpha.
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reabsorption in the proximal tubule is reduced 28. In a model of anti-glomerular base-
ment membrane glomerulonephritis, Na+ delivery was higher at the end of the proximal 
tubule but lower at the end of the collecting duct 29. Thus, CKD appears to cause glo-
merulotubular imbalance with a shift of Na+ reabsorption from the proximal to the distal 
nephron. A modeling study indeed predicted that uninephrectomy or 5/6th nephrectomy 
increases the protein density of the Na+-K+-Cl- cotransporter (NKCC2), NCC, ENaC, and 
Na+-K+-ATPase 26. The three studies that have analyzed kidney Na+ transporters in rats 
with CKD are largely in agreement with these predictions, although changes over time in 
individual transporters were observed 27, 30, 31. When using other maneuvers to increase 
distal Na+ delivery, such as loop diuretics, the distal nephron undergoes ultrastructural 
changes that coincide with a 4- to 5-fold increase in Na+ reabsorption capacity 32, 33. In 
this regard, increased Na+ reabsorption by the distal nephron is a function of increased 
delivery. In addition, increased tubular flow may also directly increase transporter 
activity 34. Although this is most evident for K+ secretion (flow-mediated kaliuresis), a 
number of studies indicate that Na+ reabsorption through ENaC can also be regulated 
by fluid shear stress and mechanosensory mechanisms 35-37. Thus, from the viewpoint 
of balance, it seems logical that distal nephron Na+ reabsorption increases in CKD to 
maintain Na+ balance. However, this does not explain why CKD results in salt-sensitive 
hypertension. This raises the possibility that the changes in the distal nephron second-
ary to CKD are maladaptive or that CKD causes additional changes that further enhance 
distal nephron Na+ reabsorption (figure 1).
Renin-inDePenDent AlDoSteRone SeCRetion
Angiotensin II and plasma K+ are the two main secretagogues for aldosterone secretion 
by zona glomerulosa cells in the adrenal gland. Therefore, the presence of hyperrenin-
emia or hyperkalemia in CKD could contribute to an increase in plasma aldosterone, 
and therefore Na+ reabsorption (figure 1). Indeed, CKD is often accompanied by hyper-
reninemia and hyperkalemia, although this varies depending on the underlying cause 
and stage of CKD. In patients with non-diabetic CKD and hypertension, plasma renin 
activity was approximately twice as high as in control subjects, despite the discontinu-
ation of anti-hypertensive drugs 38. The observation that plasma renin activity plays a 
role in hypertension in patients with CKD is also illustrated by older observations that 
bilateral nephrectomy in hemodialysis patients resolves resistant hypertension 39. 
However, there are examples of kidney disease that exhibit a low-renin state and in 
which aldosterone still plays a role in hypertension and disease progression. The prime 
example is diabetic kidney disease in which not only the intrarenal RAS 40, but also al-
dosterone contributes to resistant hypertension 41. The remnant kidney models of CKD 
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also affect plasma renin differently with the ablation model reducing plasma renin and 
the ligation model increasing plasma renin 24. The role of aldosterone in the remnant 
kidney model was clearly illustrated by showing that exogenous aldosterone nullified 
the protective effects of combined enalapril and losartan treatment on hypertension, 
proteinuria and glomerulosclerosis 42. Hyperkalemia is the other recognized driver for 
aldosterone secretion and becomes more prevalent as CKD progresses, increasing from 
2% with a measured GFR between 60 to 90 ml/min to 42% when GFR falls < 20 ml/min 
43. One study showed that lowering of plasma K+ in CKD with the K+ binder patiromer 
also reduced plasma aldosterone and blood pressure 44. However, many normokalemic 
patients with advanced CKD were also shown to be in a state of hyperaldosteronism 45. 
Similarly, in patients with CKD whose plasma K+ and renin were within the normal range, 
plasma aldosterone was still usually elevated 46. Patients with kidney failure treated 
with hemodialysis also had inappropriately high aldosterone levels for the degree of 
volume expansion, a finding that was not explained by plasma K+ 47. Patients with CKD, 
but not patients with essential hypertension, were found to have a positive correlation 
between the urinary excretion of Na+ and the mineralocorticoid metabolite tetrahy-
droaldosterone 48. Furthermore, patients with CKD failed to suppress aldosterone upon 
a Na+ challenge, either as intravenous NaCl or dietary salt 49. Together, these studies 
table 1. Knowledge gaps in mechanisms of salt-sensitive hypertension in CKD
General questions
In salt-sensitive hypertension, does increased Na+ reabsorption coincide with or precede the increase in 
vascular resistance? 
How does CKD cause glomerulotubular imbalance with increased distal Na+ delivery? 
How do the mechanisms of salt-sensitive hypertension in CKD differ across CKD stage and CKD etiology and 
between the sexes? 
What is the role of vasopressin in salt-sensitive hypertension in CKD? 
Does inflammation play a primary or secondary role in salt-sensitive hypertension in CKD and could it be a 
therapeutic target? 
Aldosterone 
Does plasma K+-induced aldosterone release contribute to hypertension in patients with CKD? 
Which plasma renin- and K+-independent factors are most relevant in mediating aldosterone secretion in CKD? 
Why does CKD impair the aldosterone escape mechanism? 
Intrarenal renin-angiotensin system 
What are markers and therapeutic targets of intrarenal RAS activity in humans? 
Can intratubular angiotensin II promote Na+ reabsorption through apical angiotensin receptors in distal 
nephron cells? 
Dietary salt 
Does the experimental evidence of high dietary Na+ intake activating Rac1 and the mineralocorticoid receptor 
translate to patients with CKD? 
Proteinuria 




suggest that (1) CKD changes the aldosterone-volume and aldosterone-Na+ relation-
ships and (2) factors other than hyperreninemia and hyperkalemia must contribute to 
the inappropriately high aldosterone levels in CKD. Several candidate secretagogues for 
inappropriate aldosterone secretion in CKD have been identified, including metabolic 
acidosis and endothelin-1 (discussed below), adrenocorticotropic hormone (ACTH) 50, 
catecholamines 51, 52, adipocyte-derived factors 53-55, and vasopressin (figure 1). The role 
of vasopressin in CKD has recently gained interest, because plasma copeptin, a peptide 
derived from the pre-pro-hormone of vasopressin and used as a surrogate marker for 
vasopressin, is associated with the development and progression of CKD in the general 
population 56. Whether this effect is mediated through hypertension is unclear, but it 
is clear that in animals the effects of vasopressin extend beyond water regulation and 
also includes the regulation of blood pressure and Na+ homeostasis 57. Vasopressin can 
stimulate aldosterone secretion through V1a receptor activation on cells of the adrenal 
cortex 58-60. In addition, vasopressin can directly stimulate Na+ reabsorption through ef-
fects on NKCC2 and NCC 61-63. Of interest, pharmacological or genetic inhibition of the 
V1a receptor prevents salt-sensitive hypertension in mice after 5/6th nephrectomy 64, 65. 
Whether these effects are explained by reduced aldosterone or tubular Na+ and water 
handling is unknown. Thus, it is unclear whether the role of vasopressin on Na+ reab-
sorption and hypertension translates from rodents to humans. Another consideration is 
that 5/6th nephrectomized animals but not humans with CKD develop a urinary concen-
trating defect, which will raise plasma vasopressin levels 66. In a randomized clinical trial 
increased water intake in patients with CKD reduced plasma copeptin, but did not slow 
the decline in kidney function 67. In summary, CKD may introduce several reasons for 
renin-independent aldosterone secretion. Under normal physiological circumstances, 
the kidneys are capable of ‘escaping’ persistent high levels of aldosterone and increase 
Na+ excretion by downregulating NCC 68. In CKD this aldosterone escape phenomenon 
may no longer operate effectively. In line with this, obese Zucker rats have reduced kid-
ney function and an impaired response to aldosterone infusion, which may be mediated 
by increases in NKCC2 and ENaC or reduced nitric oxide bioavailability 69.
ACtivAtion of the intRARenAl Renin-AngiotenSin SySteM
Although the presence of an intrarenal RAS is generally accepted, its independence from 
the circulating RAS remains a subject of debate. Previous data suggested renin synthesis 
in the collecting duct being regulated in a manner opposite to renin regulation in the 
juxtaglomerular apparatus 70. However, Tang et al. were unable to demonstrate migra-
tion of renin lineage cells to this site, and thus the presence of renin at this site likely 
reflects reabsorption rather than local synthesis 71. Angiotensinogen can be synthesized 
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in the proximal tubule 72, and angiotensin converting enzyme (ACE) activity is present 
throughout the nephron with the highest activities in the proximal tubule and collecting 
duct 73. Micropuncture studies have shown that the concentrations of angiotensin I and 
II in proximal tubule fluid exceed circulating levels by a factor of 1000, suggesting local 
release or generation 74, 75. Similarly, the tissue concentrations of cortical and medullary 
angiotensin II are up to 100 and 60 times higher than in blood, respectively, suggest-
ing compartmentalization through receptor-mediated binding to cells or endocytosis 
76, 77. However, the intrarenal RAS likely depends on the circulating RAS for filtration 
and reabsorption of renin and angiotensinogen via the endocytic receptor megalin in 
the proximal tubule 78, 79. Indeed, liver-specific knock-out of angiotensinogen markedly 
reduced the levels of angiotensinogen and angiotensin II in the kidney, both under nor-
mal and pathological circumstances 80, 81. There are, however, settings in which plasma 
renin is suppressed, while prorenin, renin, angiotensinogen, and angiotensin II are 
elevated in the kidney and urine 82. Although this could be viewed as support for the 
independent operation of the intrarenal RAS, variations in megalin expression need to 
be considered 71, 79. Such variations would allow a different degree of reuptake and thus 
non-parallel changes in circulating and intrarenal RAS activity. Several regulators of the 
intrarenal RAS have been postulated, including the (pro)renin receptor, Wnt/β-catenin 
signaling, and the prostaglandin E2 EP4 receptor (positive regulators), and Klotho, the 
vitamin D receptor, and liver X receptors (negative regulators) 78, 83. Increased intrarenal 
RAS activity increases angiotensin II in tubular fluid. In turn, angiotensin II in tubular 
fluid can activate amiloride-sensitive Na+ transport in the distal nephron by activating 
the angiotensin II type 1 receptor localized at the apical plasma membrane 84.Using a 
cross-transplantation strategy, Crowley et al. showed that renal rather than extrarenal 
angiotensin II type 1 receptors mediate salt-sensitive hypertension 85. In mice, overex-
pression of mouse angiotensinogen in the proximal tubule causes salt-sensitive hyper-
tension without recruitment of the systemic RAS 86. Conversely, in mice lacking kidney 
ACE, angiotensin II is no longer able to activate NKCC2, NCC, ENaC, pendrin and their 
regulating kinases SPAK and OSR1 87. However, the mouse model used for this study 
(so-called ACE 10/10 mice with ectopic ACE expression in myelomonocytic cells) does 
not rule out a role for other ACE-expressing tissues or for systemic renin upregulation 
88, 89. Thus, although the kidney expresses several RAS components, the independent 
contribution to Na+ or blood pressure homeostasis remains uncertain. Comparison 
between studies is also complicated by the technical challenges of measuring angio-
tensin peptide concentrations in tissue. Despite these unanswered questions, it appears 
likely that the intrarenal RAS is also directly involved in distal nephron Na+ reabsorption 
(figure 1). Kidney disease may activate the intrarenal RAS and mediate progressive 
kidney injury. When kidney disease is induced experimentally by 5/6th nephrectomy 
or by inhibition of nitric oxide synthesis, the number of interstitial cells expressing 
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angiotensin II increases 90, 91. Losartan and the immunosuppressive drug mycopheno-
late mofetil prevent these changes and the related progression of kidney injury 90, 91. 
Similarly, unilateral ureteral obstruction increases renin, ACE activity, and angiotensin II 
concentration in the obstructed kidney 92. Studies using two different experimental CKD 
models – 5/6th nephrectomy and chronic nephritis induced with anti-thymocyte serum 
– showed that angiotensin II in the kidney cortex increased after high dietary salt intake, 
whereas they decreased in healthy rats 93, 94. A high salt diet in 5/6-nephrectomized 
rats activated the intrarenal but not the systemic RAS, and increased NADPH oxidase, 
inflammation, blood pressure, and albuminuria 95. Thus, a high salt diet can further 
augment activation of the intrarenal RAS in experimental CKD. Proteinuria may play an 
independent role in increasing kidney angiotensin II by providing the substrates for its 
local synthesis (figure 1). In albumin-loaded uninephrectomized rats, proteinuria was 
accompanied by increased kidney angiotensin II in an NFKB-dependent manner with 
an increase in angiotensinogen and decrease in ACE2 96. A decrease in ACE2 is expected 
to lead to higher angiotensin II because ACE2 can convert angiotensin II to angiotensin 
1-7 97. These pre-clinical studies suggest that the intrarenal RAS likely plays a role in 
human CKD. However, this has been difficult to confirm in the absence of established 
non-invasive read-outs for intrarenal RAS activity in humans 98. Although urinary 
angiotensinogen has been proposed as marker for the intrarenal RAS in humans 99, its 
excretion pattern largely follows that of urinary albumin, and therefore likely reflects 
glomerular damage 100. Urinary renin is filtered in larger amounts than albumin, and the 
presence of renin in urine reflects impaired reabsorption by the proximal tubule rather 
than local release by the kidney 71, 98. In agreement, the elevated urinary renin observed 
in patients and mice with type 1 diabetes mellitus and diabetic kidney disease is likely 
attributed to altered glomerular filtration and impaired proximal tubular reabsorption 
71. Patients with type 1 diabetes who developed diabetic kidney disease had less change 
in renal vascular resistance in response to an angiotensin II infusion than the patients 
who did not develop diabetic kidney disease 101. Thus, diabetic kidney disease exagger-
ates intrarenal RAS activity. This also explains the relative resistance to a rise in plasma 
renin upon RAS-inhibition in patients with diabetic kidney disease, and suggests higher 
dosing of RAS-inhibitors may be required 102.
the Role of DietARy SAlt
Salt-sensitive hypertension is unmasked with high dietary salt (NaCl) intake. Dietary Na+ 
loading without Cl- or dietary Cl- loading without Na+ does not increase blood pressure, 
illustrating that the anion accompanying Na+ plays an important role in salt-sensitive 
hypertension 103, 104. In salt-resistant subjects, high dietary salt intake induces pressure 
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natriuresis and suppresses the systemic RAS. In salt-sensitive subjects, however, high 
salt intake may promote Na+ reabsorption independent of the RAS by direct activation 
of the mineralocorticoid receptor (figure 1) 105, 106. The link between dietary salt and the 
mineralocorticoid receptor is mediated by the small GTPase Rac1 107. In rodent models 
of salt-sensitive hypertension, a high salt diet activated Rac1, increased blood pressure, 
and caused kidney injury, despite suppressing aldosterone 105. Conversely, in salt-resis-
tant strains, high dietary salt reduced Rac1 activity. This suggests that either genetic 
differences in these strains mediates differential regulation of Rac1 or that paracrine 
factors, such as local angiotensin II synthesis, activate the mineralocorticoid receptor. 
In humans, genetic variants of Rac1 have been linked to increased salt sensitivity 108. 
Rac1 is also expressed in the glomerulus and its aberrant activity in podocytes leads to 
proteinuria, which can also contribute to distal nephron Na+ reabsorption (see ‘protein-
uria’ section below) 109. In addition to Rac1, high dietary salt can increase serum and 
glucocorticoid-induced kinase 1 (SGK1) in salt-sensitive Dahl rats independent of aldo-
sterone 110. Because SGK1 is a downstream effector of mineralocorticoid receptor signal-
ing and regulates ENaC and NCC activity 111-114, one might postulate that this is another 
pathway through which dietary salt directly increases distal nephron Na+ reabsorption. 
However, several other factors related to a high Na+ diet may also explain the effects 
on Rac1 and SGK1. Both Rac1 and SGK1 can be activated by mechanical stretch 115, 116, 
while SGK1 is also regulated by changes in cell volume, transforming growth factor beta, 
diabetes and proteinuria 117-120. Recent data suggest that the link between high dietary 
salt intake and hypertension could also be mediated through inflammation (figure 1). 
The role of the immune system in hypertension was illustrated by studies showing that 
immune deficient mice are resistant to hypertensive stimuli such as angiotensin II or 
DOCA-salt 121, 122. Similarly, a high salt diet increased blood pressure in immunocompe-
tent mice after 5/6th nephrectomy but not in mice lacking T-cells suggesting that T-cells 
are required for salt-sensitive hypertension in CKD 123. Dietary salt can activate a specific 
subtype of T cells, namely T helper 17 cells (Th17) through an effect on SGK1 124, 125. The 
clinical relevance of this effect was supported by the observation that a high salt diet 
exaggerated an experimental model of multiple sclerosis through SGK1-mediated 
Th17-induction 124, 125. Conversely, patients with salt-losing tubulopathies (salt deple-
tion) show reduced Th17 polarization, impaired interleukin 17 responses, and a higher 
incidence of mucosal infections and allergic disease compared to controls 126. Th17 cells 
may also influence distal tubular Na+ handling.   Incubation of distal tubular epithelial 
cells with interleukin 17A, a cytokine produced by Th17 cells, increased NCC expression 
via SGK1 127. In mice with angiotensin II-induced hypertension, the pressor response 
and upregulation of NCC and ENaC were blunted by genetic interleukin 17A deficiency 
127. In mice with DOCA-salt hypertension CD8+ T cells physically interacted with distal 
tubular cells to change the intracellular Cl- concentration and subsequently activate 
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NCC 128. Interferon gamma, a cytokine produced by CD8+ T cells, can also activate NCC 
129. As CD8+ T cells can be activated by Th17 cells, the interaction between these T cell 
subsets may increase distal nephron Na+ reabsorption 130-132. In clinical medicine, Th17 
and γδ T cells play a pathogenic role in psoriasis and, indeed, patients with psoriasis 
more often have hypertension and antipsoriasis therapies reduce blood pressure 133. Re-
cently, tumor necrosis factor alpha (TNF-)alpha was also implicated in the pathogenesis 
of salt-sensitive hypertension in both the adenine and aristolochic acid nephropathy 
mouse models of CKD, but not in the 5/6th nephrectomy model 31. TNF-alpha was shown 
to increase distal nephron Na+ reabsorption by increasing WNK1, possibly through an 
effect on the ubiquitin-protein ligase Nedd4-2, which subsequently promoted SPAK and 
NCC phosphorylation.
MetABoliC ACiDoSiS
A normal diet in developed countries typically generates a surplus of hydrogen ions (H+). 
This H+ is excreted by the kidneys as ammonium and titratable acid. In CKD, ammonium 
excretion is impaired and often results in metabolic acidosis once GFR falls below 40 
ml/min 43, 134. In response to metabolic acidosis, the renin-angiotensin and endothelin 
systems are activated to enhance urinary acidification 135. Angiotensin II increases 
bicarbonate (HCO3-) reabsorption and ammonium production in the proximal tubules 
and increases H+-ATPase activity in the distal nephron 136-140. Aldosterone increases 
distal urinary acidification directly by activation of H+-ATPases, and indirectly because 
ENaC-mediated Na+ reabsorption increases the lumen-negative voltage and therefore 
stimulates H+ secretion 141-144. Although these actions of angiotensin II and aldosterone 
serve to restore acid-base homeostasis, a secondary effect may be increased distal 
nephron Na+ reabsorption (figure 1) 135. Plasma levels of aldosterone increase in re-
sponse to experimental acidosis in healthy humans 145-150. Conversely, acute treatment 
with HCO3- lowers plasma aldosterone 151. Two-thirds nephrectomy in rats, a model 
of early CKD, increases plasma aldosterone, which is reversed by supplementation of 
CaHCO3 152. In patients with CKD stage G2, 1-month treatment with oral NaHCO3 reduced 
plasma and urinary aldosterone 153. Previous studies indicate that the rise in plasma 
aldosterone during metabolic acidosis occurs independent of plasma renin 145, 148. Four 
possible mechanisms for the renin-independent aldosterone secretion in metabolic aci-
dosis have been proposed, including an effect of hyperkalemia, endothelin-1, ACTH, or 
interstitial pH. The first of these mechanisms, hyperkalemia, may be caused directly by 
metabolic acidosis. In healthy subjects, however, plasma aldosterone increased without 
a commensurate increase in plasma K+ 145, 148. Recently, we compared the response to an 
acute acid load in healthy subjects and patients with CKD 154. In patients with CKD the 
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metabolic acidosis that followed after the acute acid load persisted for a longer time and 
did increase plasma K+ as well as plasma aldosterone. The second mechanism for al-
dosterone secretion by acidosis is endothelin-1. Plasma levels of endothelin-1 increase 
in response to acidosis and decrease after oral alkali treatment 152, 153, 155. Endothelin-1 
directly promotes H+ secretion through its action on the endothelin type-B receptors 
in the kidney 156-158. Plasma levels of endothelin-1 are elevated in patients with CKD 
and gradually rise during progression of the disease 153, 159. Endothelin-1 can directly 
stimulate the adrenal cortex and, additionally, increase its sensitivity to other hormones 
160, 161. The increase in plasma aldosterone required to excrete an acid load is dependent 
on endothelin-1 162. The third possibility is that ACTH increases plasma aldosterone. 
Plasma ACTH is increased in patients with kidney failure 50. Although ACTH increases 
during acidosis 163, acute acid-loading in healthy volunteers does not increase plasma 
cortisol 145, 148. Furthermore, the contribution of ACTH to aldosterone secretion in CKD-
related metabolic acidosis has not been investigated. Finally, it has been proposed that 
intracellular pH might stimulate aldosterone secretion 145. Interstitial H+ is higher in CKD 
152, 164 but this is not always reflected by changes in plasma pH, considering that most 
H+ is buffered by HCO3- and intracellular buffers. In isolated perfused rabbit and canine 
adrenals a lower pH of the perfusate did not change adrenal aldosterone secretion rates 
165, 166. However, when the adrenals were stimulated with angiotensin II under low pH 
conditions, higher rates of aldosterone secretion where observed. Similarly, low pH con-
ditions in a culture of adrenal zona glomerulosa cells increased angiotensin II, possibly 
through increased angiotensin receptor binding 167. In the kidney, a lower interstitial 
pH increases sensitivity of proximal tubular cells to angiotensin II 168. Mice treated with 
ammonium chloride (NH4Cl) showed increased expression of the angiotensin II type 1 
receptor in proximal tubules. Similar responses were observed in a proximal tubule cell 
line cultured in low pH medium 168. Moreover, after stimulating the same cells with an-
giotensin II, higher production rates of ammonium were measured. In addition to these 
systemic effects, metabolic acidosis also increases the components of the intrarenal 
RAS (figure 1). Subtotal nephrectomy in rats causes acid retention and increases kidney 
angiotensin II 140, 169. In normal rats, one week of NH4Cl increased angiotensinogen, ACE, 
and angiotensin II levels in the kidney 170. The induction of chronic metabolic acidosis by 
NH4Cl in mice was also accompanied by increased NCC activity, which was dependent 
on the binding of angiotensin II to the angiotensin II type 1 receptor 171. Another pathway 
through which metabolic acidosis may contribute to increased distal nephron Na+ reab-
sorption is proteinuria (figure 1) 155, 170, 172, 173. In healthy rats acute and chronic changes 
in acid-base balance correspond with urinary protein excretion 172, 173. Acidosis may 
increase proteinuria by causing hyperfiltration 146, 174, affecting podocyte function 175, 176, 
or by facilitating recycling of the megalin receptor 177 (figure 1). In turn, proteinuria 
may be aggravated by the secondary effects of acidosis on aldosterone and activation 
32  
 
of the complement system 42, 178, 179. In animal models of CKD, complement activation 
leads to more proteinuria and higher concentrations of angiotensin II in the kidney 179, 180. 
Finally, metabolic acidosis may be linked to activity of the prorenin receptor. Apart from 
its potential role in the intrarenal RAS, the prorenin-receptor is a functional subunit 
of the H+-ATPase in the cortical collecting duct, and its expression is increased during 
metabolic acidosis 181, 182. Previous studies showed that the prorenin-receptor is neces-
sary for increased open probability of ENaC and the rise in blood pressure in response 
to angiotensin II 183, 184. Although these findings were observed in healthy animals with 
normal kidney function, they do provide a potential link between CKD-related metabolic 
acidosis, distal nephron Na+ reabsorption, and salt-sensitive hypertension.
PRoteinuRiA-inDuCeD nA+ ReABSoRPtion
Kidney disease may also manifest as the nephrotic syndrome. The nephrotic syndrome 
is usually caused by a distinct etiology of kidney diseases called “podocytopathies”, 
which selectively affect the podocyte’s role in the glomerular filtration barrier and 
therefore cause massive proteinuria while often leaving GFR intact 185. Clinically, the 
nephrotic syndrome is characterized by edema secondary to hypoalbuminemia and 
avid Na+ retention by the kidneys. Na+ retention in the nephrotic syndrome has a unique 
pathophysiology because it often develops in the context of a suppressed RAS. In those 
patients with nephrotic syndrome in whom the RAS is activated, treatment with an 
ACE-inhibitor or albumin suppresses the RAS, but does not improve Na+ retention 186. 
A breakthrough in the understanding of Na+ retention in nephrotic syndrome was the 
demonstration that nephrotic urine can activate ENaC 187. ENaC activation depended 
on urinary serine protease activity and mass spectrometry identified plasmin as the 
probable candidate. Plasmin increased the open probability of ENaC by cleavage and by 
releasing an inhibitory peptide from the gamma subunit 187. Plasmin is not filtered by the 
glomerulus but rather converted in the tubular lumen from plasminogen and urokinase-
type plasminogen activator (uPA) by the uPA-receptor 188. Conditional knockout of podo-
cin in mice mimics human nephrotic syndrome with nephrotic range proteinuria, weight 
gain, edema, and Na+ accumulation 189. These changes were reversed by treatment 
with the ENaC-blocker amiloride, which also prevented the conversion of plasminogen 
to plasmin. Similarly, treatment with an antibody targeting uPA also abolished urine 
activation of plasminogen, attenuated Na+ accumulation, and prevented cleavage of 
g-ENaC. Urinary serine protease activity in nephrotic urine can also be inhibited by the 
trypsin inhibitor aprotinin 190. In mice with doxorubicin-induced nephrotic syndrome, 
treatment with either aprotinin or amiloride normalized urinary serine protease activity 
and prevented Na+ accumulation. In Xenopus laevis oocytes expressing ENaC, aprotinin 
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had no direct effect on ENaC but did prevent proteolytic ENaC activation. Together, these 
studies show that proteinuria by itself can contribute to distal nephron Na+ reabsorp-
tion through ENaC (figure 1), which can be prevented by amiloride or the inhibition of 
urinary serine protease activity. Because nephrotic syndrome is characterized by mas-
sive proteinuria, a relevant question was whether the phenomenon of plasmin-induced 
Na+ reabsorption was also present in more moderate stages of proteinuria as observed 
in CKD. This question was addressed in a cross-sectional study by Schork et al., who 
analyzed fluid status and urinary plasmin in 117 patients with CKD 191. Proteinuria was 
the strongest independent predictor for overhydration. The urinary excretion of plasmin 
correlated strongly with proteinuria and overhydration. In addition, the range of urinary 
plasmin concentrations was sufficient to activate ENaC currents in vitro. The relevance 
of this phenomenon has also been extended to other proteinuric conditions, including 
pre-eclampsia, diabetic kidney disease, and kidney transplantation 192-194. Although 
these studies clearly indicate that proteinuria by itself contributes to Na+ retention, the 
link with salt-sensitive hypertension has been less clear. One study did provide insight 
into this issue by analyzing the effect of adding amiloride to patients with type 2 dia-
betes and resistant hypertension 195. The study showed that amiloride lowered blood 
pressure, albuminuria, and urine plasminogen excretion and activation.
influenCe of Sex
While it is generally accepted that the prevalence of CKD is greater in women than in 
men, the decline in kidney function occurs at a faster rate in men which coincides with 
the higher mortality rate attributable to CKD in men 1, 196, 197. A caveat of this is that the 
estimated decline in kidney function depends on a number of factors including the 
population studied, diabetes mellitus, age, and body composition. Nevertheless, these 
sex differences in CKD likely reflect the longer life expectancy in women and the sex-and 
age-dependent decline in kidney function 198-201, with premenopausal women protected 
from the development of hypertension and CKD as compared to age-matched men and 
postmenopausal women 196, 202. Plasma aldosterone levels and extracellular fluid volume 
are highest during the luteal phase of the menstrual cycle 203, 204. However, compared to 
men, plasma aldosterone levels and extracellular fluid volume are lower in premeno-
pausal women 205-207. In women, salt-sensitivity of blood pressure is inversely associated 
with estrogens and progesterone 208. In particular women with a history of preeclampsia 
have an increased risk for salt-sensitive hypertension, cardiovascular disease, and 
chronic kidney disease 209, 210. Although the exact mechanisms remain incompletely 
understood, an enhanced vascular response to injury due to preeclampsia, immune 
system activation, and imbalance of NO:ET-1 might contribute 211-213. Both surgical and 
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natural menopause increases salt-sensitivity, with the pressure-natriuresis curve of 
postmenopausal women shifted to the right 214-216. In Dahl salt-sensitive rats fed a high 
salt diet, the increase in blood pressure is lower in ovary-intact females as compared 
to males and ovariectomized females 217, supporting an important role for ovarian 
hormones in regulation of salt-sensitivity of blood pressure. Similarly, with age and 
reproductive senescence, the chronic pressure-natriuresis in ovary-intact female mice 
is shifted rightward 218. While animal models of CKD suggest that estrogen replacement 
219, 220 and androgen deprivation 221 are protective against the development of CKD, the 
situation is less clear in humans 196. Studies in rodents have demonstrated that females 
exhibit a lower abundance and activity of proximal transporters and a higher abundance 
and activity of distal transporters including, NKCC2, NCC and ENaC 222-224, indicating a 
greater role for the distal nephron in Na+ reabsorption in females than males. Conse-
quently, in the setting of salt-sensitive hypertension in CKD this pattern of increased Na+ 
reabsorption in the distal nephron is likely to be enhanced in females. Certainly, this is 
the case in response to angiotensin II-induced hypertension in rodents 224. As described 
above, in addition to CKD-induced changes in Na+ handling, other mechanisms includ-
ing renin-independent aldosterone secretion, activation of the intrarenal RAS, dietary 
salt, metabolic acidosis and proteinuria induced Na+ reabsorption may all contribute to 
the development of salt-sensitive hypertension in CKD. Importantly, these mechanisms 
are likely to be influenced by sex. For example, the sex hormone milieu is known to 
modulate the synthesis and activity of nitric oxide, reactive oxygen species, endothe-
lin-1, transforming growth factor beta, and the pressor:depressor balance of the RAS 
(particularly within the kidney) with estrogen downregulating these pathways and 
testosterone upregulating them 196, 199, 202. Sex differences in the actions of vasopressin 
may account for a greater tendency for men to concentrate their urine 225, and may con-
tribute to the faster progression of CKD in men than women. While experimental studies 
suggest that sex influences acid-base homeostasis, studies in humans are inconclusive 
226-229. A similar controversy exists regarding expression of sodium-glucose cotransport-
er-2 (SGLT2) 230, 231. Further, experimental studies suggest that the T-cell profile differs 
between the sexes, particularly within the kidney with males having a higher proportion 
of pro-inflammatory T cells such as Th17 than females 232. This may potentiate the effect 
of the higher dietary salt consumption in men 233 on the development of salt-sensitive 
hypertension in CKD. Evidence from spontaneously hypertensive rats and CKD patients 
suggest that ACE-inhibition may have a greater effect on reducing proteinuria in females 
than males 234, 235, however the effect on blood pressure, at least in rats, was greater in 
males. Finally, sex-specific risk factors e.g., complications of pregnancy and menopause 
202, may also contribute sex differences in hypertension and CKD. Detailed mechanistic 
studies are required to dissect out the cellular and molecular mechanisms by which 
sex influences distal nephron Na+ handling in salt-sensitive hypertension in CKD. Un-
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derstanding sex-differences in salt-sensitive hypertension in CKD will inform whether 
treatment should be administered using a personalized medicine approach.
CliniCAl PeRSPeCtive
A relevant question is how the mechanisms discussed above translate to treatment 
options in clinical practice. The most obvious and straightforward approach to treat 
salt-sensitive hypertension in CKD is to reduce dietary salt intake. Worldwide people 
generally consume a high salt diet that exceeds recommendations by the World Health 
Organization and the Institute of Medicine, and patients with CKD are no exception 236, 237. 
Approximately 80% of dietary salt consumed has been added by food manufacturers 
showing little to no reduction over time 238. Dietary salt restriction may be even more 
challenging for patients with CKD as their taste threshold for salt is increased 239. In clini-
cal trials dietary Na+ restriction consistently improves blood pressure, body weight, and 
proteinuria in patients with CKD 240-243. With the proposed central role of distal nephron 
Na+ reabsorption in CKD-related hypertension (figure 1), another attractive strategy 
would be to employ distal diuretics. Diuretics have long been considered ineffective 
in CKD, especially with GFR < 30 ml/min, because they require tubular secretion 244, 245. 
To address this, we recently performed a randomized cross-over trial to compare the 
anti-hypertensive effects of dietary Na+ restriction to a combination of distal diuretics 
(hydrochlorothiazide and amiloride) 246. We showed that distal diuretics actually pro-
duced a greater reduction in systolic blood pressure and extracellular water than dietary 
Na+ restriction, and that diuretic sensitivity was maintained even at lower GFR 246. It 
would be of interest to know if this effect was primarily due to NCC or ENaC inhibition, 
or both. The PATHWAY-trial showed that in patients with uncontrolled hypertension 
the combination of hydrochlorothiazide and amiloride was more effective than either 
treatment alone 247. Especially patients with low-renin hypertension – which signals salt 
retention – may benefit from this combination of distal diuretics 248. In patients with 
resistant hypertension, sequential diuretic therapy had a greater anti-hypertensive ef-
fect than sequential RAS inhibition 249. As monotherapy, amiloride has been tested in 
patients with diabetic kidney disease in whom it effectively lowered blood pressure 250. 
An ongoing trial is comparing chlorthalidone with placebo in patients with CKD stage 
G4 251. Another focus for future studies should be to explore whether amiloride could 
prevent plasmin-induced Na+ reabsorption in patients with CKD (table 1), as was previ-
ously shown in experimental nephrotic syndrome 190, and in patients with hypertension 
and diabetes 195. Additional rationales for using a combination of diuretics is to prevent 
diuretic resistance and maintain plasma K+ (when combining a K+ sparing and non-K+ 
sparing diuretic) 246, 252. Because diuretics typically cause a hemodynamic reduction 
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in GFR, longer-term studies are necessary to evaluate if this is offset by the beneficial 
effects of diuretics on blood pressure and extracellular fluid volume. Of interest in 
this regard are the positive effects of SGLT2-inhibitors on kidney and cardiovascular 
outcomes in patients with CKD, because these drugs also have natriuretic and anti-
hypertensive properties and reduce GFR initially 253-255. SGLT2-inhibitors not only target 
the proximal tubule, but also the distal convoluted tubule by improving the dysregula-
tion of kelch-like 3, WNK kinases, and NCC 256. Because of the pre-clinical evidence that 
a high Na+ diet activates the mineralocorticoid receptor through Rac1 (figure 1), the 
application of mineralocorticoid receptor antagonists or Rac1-inhibitors (in develop-
ment phase), may be another rational strategy for salt-sensitive hypertension in CKD 257. 
A recent systematic review and meta-analysis showed that mineralocorticoid receptor 
antagonists reduce blood pressure in patients with diabetic and non-diabetic CKD as 
compared to placebo, but are not more effective than non-K+ sparing diuretics 258. The 
use of mineralocorticoid receptor antagonists in patients with CKD is often limited by 
the development of hyperkalemia. Of interest in this regard is the recent development 
of non-steroidal mineralocorticoid receptor antagonists, which cause hyperkalemia less 
frequently and will be tested in patients with CKD and hypertension 259, 260. Instead of a 
pharmacological approach, another interesting dietary approach would be to address 
the effects of increasing dietary K+ intake in patients with CKD. The general population 
as well as patients with CKD generally consume a low K+ diet 261. An increasing body 
of evidence suggests that higher urinary K+ excretion (as proxy for dietary K+ intake) is 
associated with better kidney outcomes 262. A low K+ diet activates NCC to reduce distal 
Na+ delivery, but, in turn, contributes to Na+ retention and hypertension 263, 264. Indeed, 
dietary K+ exerts anti-hypertensive effects, which in part may be attributable to NCC 
inactivation 265, 266. In this regard, dietary K+ could serve as a “natural diuretic”. Whether 
supplementing dietary K+ in patients with CKD reduces blood pressure and slows the 
progression of CKD is unknown, but this is currently being investigated in a random-
ized clinical trial 261. A potential limitation of this approach is that a higher plasma K+ 
increases plasma aldosterone, although K+-induced NCC inactivation occurs despite 
an elevation in aldosterone 267. An unresolved question is whether K+-induced aldoste-
rone release can contribute to hypertension in patients with CKD (table 1). As noted 
previously, one study showed that the K+ binder patiromer reduced aldosterone and 
blood pressure 44. In salt-loaded uninephrectomized rats, high dietary K+ suppressed 
the activity of NCC and blunted salt-sensitive hypertension 268. A high K+ diet may have 
the additional benefit that it is usually part of an alkaline diet. In patients with CKD, 
metabolic acidosis is common and contributes to the progression of CKD 152, 269-271. Long-
term alkali treatment slows CKD progression 270, 272, 273. A diet rich in fruits and vegetables 
improves metabolic acidosis and reduces kidney injury to a similar degree as treatment 
with NaHCO3 271. In addition to an alkaline diet and NaHCO3, the non-absorbable H+ and 
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Cl- binder veverimer is under development for the treatment of metabolic acidosis in 
CKD 274. Of interest, the K+ binder sodium zirconium cyclosilicate also increases plasma 
HCO3-, likely through gastro-intestinal ammonium trapping 275. Although kidney trans-
plantation improves quality of life and mortality, salt-sensitive hypertension remains a 
challenge in the kidney transplant recipient and contributes to graft loss 276. The patho-
genesis of salt-sensitive hypertension in kidney transplant recipients is multifactorial 
277, but calcineurin inhibitors play a prominent role due to their ability to activate NCC 
and thereby promote distal tubular Na+ reabsorption 278, 279. Which of the treatments, or 
combinations of treatments, is most effective for the individual patient with CKD and 
salt-sensitive hypertension, is difficult to recommend. Generally speaking, we believe 
that dietary approaches and distal diuretics deserve more emphasis, while the exact 
positioning of SGLT2-inhibitors will become clear in the next few years.  In summary, 
ample opportunities are available to treat salt-sensitive hypertension in CKD, raising 
the expectation that this might improve long-term kidney and cardiovascular outcomes.
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Chronic kidney disease (CKD) contributes to hypertension, but the mechanisms are 
incompletely understood. To address this, we applied the 5/6th nephrectomy rat model 
to characterize hypertension and the response to dietary salt and renin-angiotensin 
inhibition. 5/6th nephrectomy caused low-renin, salt-sensitive hypertension with hyper-
kalemia and unsuppressed aldosterone. Compared to sham, 5/6Nx rats had lower NHE3, 
NKCC2, NCC, a-ENaC and Kir4.1, but higher SKG1, prostasin, g-ENaC, and Kir5.1. These 
differences correlated with plasma renin, aldosterone, and/or potassium. On a normal 
salt diet, adrenalectomy (0 ± 9 mmHg) and spironolactone (-11 ± 10 mmHg) prevented a 
progressive rise in blood pressure (10 ± 8 mmHg), and this was enhanced in combination 
with losartan (-41 ± 12 mmHg and -43 ± 9 mmHg). A high salt diet caused skin sodium 
and water accumulation and aggravated hypertension that could only be attenuated by 
spironolactone (-16 ± 7 mmHg) and in which the additive effect of losartan was lost. Spi-
ronolactone also increased natriuresis, reduced skin water accumulation and restored 
vasorelaxation. In summary, in the 5/6th nephrectomy rat CKD model, salt-sensitive hy-
pertension develops with a selective increase in g-ENaC and despite appropriate trans-
porter adaptations to low renin and hyperkalemia. With a normal salt diet, hypertension 
in 5/6th nephrectomy depends on angiotensin II and aldosterone, while a high salt diet 
causes more severe hypertension mediated through the mineralocorticoid receptor.
new & noteworthy
Chronic kidney disease (CKD) causes salt-sensitive hypertension, but the interactions 
between dietary salt and the renin-angiotensin system (RAS) are incompletely under-
stood.  In rats with CKD on a normal salt diet targeting aldosterone, the mineralocorti-
coid receptor (MR) and especially angiotensin II reduced blood pressure. On a high salt 
diet, however, only MR-blockade attenuated hypertension. These results reiterate the 
importance of dietary salt restriction to maintain RAS-inhibitor efficacy and specify the 
MR as target in CKD.
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intRoDuCtion
Hypertension is a major complication of chronic kidney disease (CKD) and contributes 
to progression of CKD and cardiovascular morbidity and mortality 1. With decreasing 
glomerular filtration rate (GFR), the incidence of hypertension increases to >90% for 
CKD stage G5 2. Hypertension in CKD is a salt-sensitive form of hypertension 3, but it 
is incompletely understood how CKD conveys salt-sensitivity, and how the various 
systems that govern sodium balance and blood pressure interact in CKD 4. A reduction in 
nephron number will limit the capacity to excrete salt and water and the ensuing pres-
sure natriuresis will contribute to hypertension in CKD 5. A number of anti-natriuretic 
factors may be also be at play in CKD to further enhance salt-sensitive hypertension 
4.  For example, in CKD, plasma aldosterone is often elevated without a rise in plasma 
renin, which may be caused by hyperkalemia or metabolic acidosis 6-9. In addition, CKD 
may activate the intrarenal renin-angiotensin system (RAS) with local synthesis of angio-
tensin II in the kidney 10. It has also been reported that high dietary salt can activate the 
mineralocorticoid receptor (MR) in an aldosterone-independent fashion 11. Angiotensin 
II, aldosterone, and the mineralocorticoid receptor activate sodium transport proteins in 
the kidney, including the sodium chloride cotransporter (NCC) and the epithelial sodium 
channel (ENaC) 12-14.
Therefore, we hypothesize that aldosterone, angiotensin II, and the mineralocorticoid 
receptor, contribute to hypertension in CKD. Furthermore, we hypothesize that dietary 
salt interacts with these three pathways and therefore modifies their contributions to 
hypertension. To address our hypothesis, we used the 5/6th nephrectomy model in rats 
to mimic human CKD. Using this model, we first characterized hypertension by analyzing 
the RAS, kidney sodium and potassium transport proteins, and salt-sensitivity. Subse-
quently, we targeted the three pathways central to our hypothesis using adrenalectomy, 
losartan, and spironolactone. To analyze the role of dietary salt, all treatments were 
given both during a normal salt diet and a high salt diet. Our results show that dietary 
salt modifies the blood pressure response to RAS-inhibition and indicates that a switch 
occurs from predominantly angiotensin II-dependent hypertension during a normal salt 
diet to MR-dependent hypertension during a high salt diet.
MAteRiAlS AnD MethoDS
Animals and interventions
All animal experiments were approved by the Animal Welfare Committee of the 
Erasmus Medical Center (protocol number 16-790-02). Male Sprague Dawley rats (6 
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weeks old, average weight 200 g) were obtained from Envigo (United Kingdom). 5/6th 
nephrectomy was performed in two steps, including right uninephrectomy (combined 
with telemetry implantation and, in selected animals, right adrenalectomy) followed 
by resection of the left kidney poles ten days later (figure 1) 15. After a recovery period 
of five weeks, osmotic minipumps were implanted and, in selected animals, left ad-
renalectomy was performed. Rats were allocated to treatment groups on the basis of 
blood pressure and glomerular filtration rate (GFR) to ensure similar values between 
treatment groups (figure S1). Rats were subsequently treated for three weeks with 
vehicle, spironolactone, losartan, or spironolactone + losartan (table S1 and S2). 
These treatments were combined with a normal salt diet (0.4% NaCl) or a high salt diet 
(4.0% NaCl; both Envigo). During the 3-week treatment period, vehicle (10% ethanol, 
15% DMSO, 75% PEG), dexamethasone (12 μg/kg/day, as glucocorticoid replacement 
after adrenalectomy) 16 or losartan (30 mg/kg/day) 17 were administered by osmotic 
minipump (Alzet, USA), while spironolactone (80 mg/kg/day) 18 was given by daily 
subcutaneous injection. The primary outcome parameter of the treatments was blood 
pressure, which was analyzed for 13 days Secondary outcome parameters were skin 
sodium and water content (to analyze the interstitium), heart weight (normalized for 
tibia length), and vasoreactivity.
Measurements
Blood pressure was recorded continuously via radiotelemetry transmitters (Data Sci-
ences, USA). Because the GFR measurements and housing in metabolic cages interferes 
with blood pressure recordings, telemetry data were analyzed until the start of the 
final GFR measurements (figure 1). GFR was measured using transcutaneous measure-
ment of injected fluorescein isothiocyanate-labeled sinistrin 19. Urine total protein was 
measured by the clinical chemistry laboratory of the Erasmus Medical Center. Plasma 
aldosterone was measured by radioimmunoassay (Demeditec, Germany), and plasma 
renin by an in-house enzyme-kinetic assay. The latter assay yields a value expressed in 
figure 1. Overview of experimental design and maneuvers. Telemetry was recorded until the start of the 
final FITC-sinistrin GFR measurements. FITC, fluorescein isothiocyanate; * In selected animals.
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μg Ang I/L.hr, which was converted ng renin based on the observation that 1 μg Ang I/L.
hr equals 2.6 ng of renin. Plasma concentrations of losartan-carboxylic acid (the active 
metabolite of losartan, also called EXP3174) and canrenone (the active metabolite of 
spironolactone) were measured by liquid chromatography coupled to mass spectrom-
etry (Thermo Fisher, USA) 20. For measurement of skin sodium (in mmol/mL water) and 
skin water (in mL/gram dry weight), skin samples (1x1 cm) were freeze-dried, dissolved 
in nitric acid and hydrogen peroxide, centrifuged and filtered, after which sodium was 
measured by flame photometry.
immunoblot
To compare transporter abundance between the intact healthy kidney and the remnant 
kidney we developed a method to normalize by estimated nephron number (figure S2). 
Using this method, the weight of the remnant kidney at the time of the uninephrectomy 
can be estimated by the following equation: weight kidney poles at 2/3rd nephrectomy 
(“A”) * 0.65 * (weight right kidney at the time of uninephrectomy * 0.9908 / (A + [A*0.65]). 
Subsequently, 20-70 μg of protein (protein assay Bio-Rad, USA) was separated by SDS-
PAGE and transferred to a membrane with a trans-blot turbo system (Bio-Rad). Mem-
branes were blocked in 5% milk or bovine serum albumin and incubated overnight at 4 
°C with the primary antibody (table S3).
Myograph studies
Immediately after sacrifice, mesenteric arteries were dissected, placed in a cold, oxy-
genated buffer solution, cut into 2-mm segments and mounted on myographs (Danish 
Myo Technology, Denmark). Subsequent experiments were performed as reported 
previously 21.  Briefly, contractile capacity was examined by adding KCl (30 and 100 mM), 
and concentration-response curves were constructed for the vasodilatory response to 
acetylcholine (after pre-contraction with the thromboxane A2 analogue U46619 at 10 
nM), and acetylcholine in combination with the nitric oxide synthase inhibitor L-NG-
Nitroarginine Methyl Ester (L-NAME, 100 μM).
Statistics
Results are presented as the mean ± standard error of the mean for normally distributed 
data and median with interquartile range for non-normally distributed data. Non-nor-
mally distributed data were log-transformed for statistical analysis. Group comparisons 
were performed with one-way ANOVA and two-way ANOVA for repeated measurements. 
If significant, selected post-hoc analyses were performed between individual groups by 
controlling for a false-discovery rate of 5% 22. Correlations were analyzed using Pear-
son’s correlation coefficient. If a correlation was present between normally distributed 
data and log-transformed data, nonlinear regression using a linear-logarithm model 
66 Part 1
Salt
was used to fit the original data. For myograph data, pEC50 (negative log of the agonist 
concentration needed to reach half of its maximal effect) and Emax (maximal response) 
between control and treated groups were analyzed using a paired T-test. Data were 
analyzed using GraphPad Prism (version 8.2.0, USA). P ≤ 0.05 was considered statistically 
significant.
ReSultS
5/6th nephrectomy causes low-renin hypertension
The 5/6th nephrectomy model was first characterized by comparing blood pressure, 
GFR, proteinuria, and the RAS before 5/6th nephrectomy, 5 weeks after 5/6th nephrec-
tomy (start of treatment) and 8 weeks after 5/6th nephrectomy (end of treatment). 5/6th 
nephrectomy reduced GFR by 71% (figure 2C) and was accompanied by a progressive 
rise in systolic and diastolic blood pressure (figure 2A and 2B) and proteinuria (figure 
2D), and a decrease in plasma renin (figure 2e). The decrease in plasma renin was 
not accompanied by a decrease in plasma aldosterone (figure 2f), and therefore the 
aldosterone-to-renin ratio increased over time (figure 2g). A lower GFR correlated with 
a higher aldosterone-to-renin ratio (figure 2h). 5/6th nephrectomy caused hyperkalemia 
with higher urinary sodium and potassium excretion (table S4, figure S3).
5/6th nephrectomy causes salt-sensitive hypertension with cardiac 
hypertrophy
Compared to the normal salt diet, 5/6th nephrectomy with a high salt diet resulted in 
a significantly higher urinary sodium excretion and higher blood pressure, confirming 
salt-sensitivity of the model (figure 3A and B, 4A, and S3). 5/6th nephrectomy with 
the normal salt diet increased heart weight, and this was increased further by high salt 
(figure 3C). Plasma renin was reduced by the high salt diet in sham rats and by 5/6th 
nephrectomy (figure 3D). Plasma aldosterone was significantly higher in 5/6th nephrec-
tomy rats on high salt compared with sham-operated rats on high salt (figure 3e). A 
high salt diet or 5/6th nephrectomy alone did not lead to sodium or water accumulation 
in skin, whereas the combination did (figure 3f and g).
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figure 2. 5/6th nephrectomy reduces glomerular filtration rate and plasma renin, and increases proteinuria 
and blood pressure. (A-B) The average systolic and diastolic blood pressure is shown on two consecutive 
days after uninephrectomy (n = 27), and three (n = 37) and five weeks (n = 65) after 5/6th nephrectomy. (C-
g) Glomerular filtration rate (GFR), proteinuria, plasma renin, plasma aldosterone were measured before 
uninephrectomy (n = 78), 5 weeks after 5/6th nephrectomy (5/6th Nx, n = 59) and 8 weeks after 5/6th Nx (n = 8). 
(h) Correlation between GFR and aldosterone-to-renin ratio (n = 70). * P ≤ 0.05
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figure 3. High salt exacerbates hypertension and cardiac hypertrophy, and increases skin sodium and wa-
ter in rats after 5/6th nephrectomy (Nx). (A-g) Effects of normal and high salt diet on systolic and diastolic 
blood pressure, heart weight, plasma renin, plasma aldosterone, skin sodium (Na+) concentration, and skin 
water (H2O) content (n = 7 vs. 8 in panels A-B, n = 3–11 in panels C-G). * P ≤ 0.05.
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figure 4. Telemetry data showing the effects on blood pressure of the high salt diet (A) and the various 
treatments (B). The dashed lines represent the SEMs (A). Telemetry was recorded during 13 days of the 
3-week treatment (until the start of the final FITC-sinistrin measurements, see figure 1). BP, blood pres-
sure; Adx, adrenalectomy.
Kidney transporter profile of 5/6th nephrectomy
Compared to sham, 5/6th nephrectomy reduced the abundances of NHE3, total and 
phosphorylated NKCC2, total NCC, a-ENaC, and Kir5.1 regardless of the diet (figure 5A 
and B). The decrease in phosphorylated NCC was statistically significant only for the 
high salt diet. Conversely, on both diets, 5/6th nephrectomy increased the abundances 
of SGK1, prostasin, g-ENaC, and Kir4.1 compared to sham (figure 5A and B). Of note, 
no shift in the molecular weight of g-ENaC was observed. Next, we analyzed if these 
changes in transporter abundances correlated with known regulators, including the RAS 
and serum potassium. This analysis showed that higher plasma aldosterone correlated 
with higher g-ENaC; a trend for a correlation with blood pressure was also found (figure 
6A). Lower plasma renin correlated with lower NHE3, total NCC, and a-ENaC, but higher 
SGK1 and prostasin (figure 6B). Finally, higher serum potassium correlated with lower 
NHE3, total NCC, and phosphorylated NCC, but higher Kir4.1; a trend for a correlation 









figure 5. Rat kidney transporter profile after sham or 5/6th nephrectomy and on normal or high salt diets. 
(A) Immunoblots of transporters and regulatory proteins in kidney homogenates from sham rats and 5/6th 
nephrectomy (5/6th Nx) rats on a normal and high salt diet (n = 6/group). 
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figure 5. Rat kidney transporter profile after sham or 5/6th nephrectomy and on normal or high salt diets. 
(B) Densitometry was analyzed by unpaired t-test. See figure S2 for normalization method. * P ≤ 0.05. 
NHE3, sodium-hydrogen exchanger type 3; NKCC2, sodium potassium chloride cotransporter 2; pNKCC2, 
phosphorylated NKCC2; NCC, sodium chloride cotransporter; pNCC, phosphorylated NCC at threonine 
53/58; ENaC, epithelial sodium channel; Sgk1, serum and glucocorticoid-regulated kinase 1; Rac1, Ras-
related C3 botulinum toxin substrate 1; Kir, inwardly rectifying potassium channel.
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figure 6. Correlations between the renin-angiotensin system, serum potassium, blood pressure, transport-
ers, and regulatory proteins. (A) Correlations between plasma aldosterone, mean arterial pressure (MAP), 
and g-ENaC (n = 24 and n = 12; MAP was not measured in sham). (B) Correlations between plasma renin, 
NHE3, total NCC (tNCC), α-ENaC, serum and glucocorticoid-regulated kinase 1 (Sgk1), and prostasin (n = 
24). (C) Correlations between serum potassium (K+), NHE3, phosphorylated NKCC2 (pNKCC2), tNCC, phos-
phorylated NCC (pNCC), Kir4.1, and Kir5.1 (n = 24).
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figure 7. Blood pressure response to renin-angiotensin interventions and dietary salt. (A-D) The changes in 
systolic and diastolic blood pressure are shown on a normal salt diet (A, C) and a high salt diet (B, D). Rats 
(n = 6-8/group) were treated with a normal salt (0.4% NaCl) or high salt (4.0% NaCl) diet and with vehicle 
(V), adrenalectomy (Adx), spironolactone (S), adrenalectomy and losartan (Adx + L), or spironolactone and 
losartan (S + L). (e, f) Losartan carboxyl acetate (losartan-ca) and canrenone concentrations were mea-
sured at the day of sacrifice in rats (n = 7/group) receiving losartan and/or spironolactone. * P ≤ 0.05 versus 
vehicle, # P ≤ 0.05 versus spironolactone, § P ≤ 0.05 versus adrenalectomy.
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high salt diet modifies treatment response
First, we compared the anti-hypertensive effect of the RAS-interventions on a normal 
salt diet (figure 4B, 7A and C). Blood pressure increased with vehicle (10 ± 8 mmHg), 
and was stabilized by adrenalectomy (0 ± 9 mmHg, not significant vs. vehicle) and 
reduced by spironolactone (-11 ± 10 mmHg, P < 0.05 vs. vehicle). The combinations of 
losartan with adrenalectomy or losartan with spironolactone had the strongest anti-hy-
pertensive effects (-41 ± 12 and -43 ± 9 mmHg, respectively). Next, the anti-hypertensive 
effects of the same RAS-interventions were compared on a high salt diet. The high salt 
diet caused a progressive rise in blood pressure of 38 ± 16 mmHg that was resistant to 
most interventions (figure 4B, 7B and D). Spironolactone was the only treatment that 
significantly attenuated this rise in blood pressure (-16 ± 7 mmHg). The lack of effect of 
the treatments with losartan on high salt was not explained by lower drug exposure, 
because no significant differences between the blood concentrations of losartan car-
boxylic acid on normal and high salt diet were observed (figure 7e). Of note, the lower 
losartan carboxylic acid concentrations were likely due to spironolactone increasing the 
metabolism of losartan through induction of cytochrome P450 3A4 23. In both the normal 
and high salt groups, plasma aldosterone levels after adrenalectomy were below the 
limit of detection.
treatment effects on skin sodium, skin water, and heart weight
None of the interventions reduced skin sodium concentration (figure 8A), but some 
interventions did reduce skin water content (figure 8B). Spironolactone with losartan 
significantly lowered skin water content on both diets; spironolactone monotherapy 
also had this effect with the high salt diet. On the high salt diet, adrenalectomy, ad-
renalectomy with losartan, and spironolactone with losartan reduced heart weight; 
spironolactone with losartan also reduced heart weight on the normal salt diet (figure 
8C). When combining the data of all rats, we identified positive correlations between 
blood pressure and heart weight (figure 8D), skin water and blood pressure (figure 
8e), and skin water and heart weight (figures 8f). On a normal salt diet, the interven-
tions with losartan increased plasma renin, and the interventions with spironolactone 
increased plasma aldosterone; these effects, however, did not occur in rats fed a high 
salt diet (figure S4). On a normal salt diet, all interventions prevented an increase in 
proteinuria; a high salt diet increased proteinuria despite the interventions (figure S4).
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figure 8. Effects of treatments on skin sodium, skin water, and heart weight, and relation with blood pressure. (A-C) Skin 
sodium (Na+) concentration, skin water (H2O) content, and heart weight were measured in the different treatment groups 
receiving the normal or high salt diet (n = 6–8/group). (D-f) Correlations between mean arterial pressure (MAP), heart 
weight, and skin H2O content were calculated including rats from all experimental groups (n = 63–82). * P ≤ 0.05. A, adrenal-
ectomy; A+L, adrenalectomy + losartan; S, spironolactone; S+L, spironolactone + losartan; V, vehicle.
high salt impairs vasodilation which is relieved by spironolactone
On normal salt diets, the maximal responses to acetylcholine were unaffected by 5/6th 
nephrectomy; in contrast, on high salt intake, nephrectomized rats exhibited a sup-
pressed maximal dilation (Emax 93 ± 5% vs. 73 ± 23%, P < 0.05, figure 9A). The calculated 
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figure 9. In 5/6th nephrectomy rats, high salt impairs vasodilation which is relieved by spironolactone. (A) The vasodilatory 
responses are shown in sham-operated rats and 5/6th nephrectomy rats on a normal salt or high salt diet (upper panels) 
and in 5/6th nephrectomy rats after treatment with vehicle, adrenalectomy (Adx), adrenalectomy with losartan, or spi-
ronolactone (lower panels). n = 4–8/group. (B) Vasodilatory responses to acetylcholine with or without L-NG-Nitroarginine 
Methyl Ester (L-NAME) in sham-operated rats (n = 6) and 5/6th nephrectomy (5/6th Nx) rats treated with vehicle or spirono-
lactone on a high salt diet (n =8/group). The three curves without L-NAME are also shown in panel A. Vasodilatory respons-
es of mesenteric arteries are expressed as percentage of the pre-contraction induced by U46619. Curves covering the full 
sigmoidal range were analyzed by means of a computerized curve fitting technique to obtain the pEC50 value (negative log 
of the molar concentration of an agonist needed to reach half of its maximal effect). The relaxation obtained at the high-
est concentration of an agonist was considered as Emax (maximal response). Data are expressed as mean ± SEM. * P ≤ 0.05.
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pEC50 values were also lower in 5/6th nephrectomy rats on high salt compared with sham-
operated rats on high salt (pEC50 7.2 ± 0.62 vs. 7.9 ± 0.31, P < 0.05). In 5/6th nephrectomy 
rats on high salt, spironolactone improved the vasorelaxation to acetylcholine, although 
this was only statistically significant when compared to adrenalectomy (Emax 90 ± 10% vs. 
55 ± 31%, P < 0.05). Furthermore, spironolactone also restored the contribution of nitric 
oxide to the vasodilatory response of acetylcholine (figure 9B). Vasoreactivity was not 
tested in 5/6th nephrectomy rats treated with spironolactone and losartan.
DiSCuSSion
Here, we used the 5/6th nephrectomy rat model to analyze hypertension in chronic kid-
ney disease (CKD) and the response to dietary salt and renin-angiotensin system (RAS) 
interventions. Our study produced three novel findings. First, hypertension after 5/6th 
nephrectomy was characterized as a low-renin, salt-sensitive form of hypertension with 
hyperkalemia. This was accompanied by a selective increase in γ-ENaC and its regula-
tory proteins SGK1 and prostasin, possibly contributing to salt retention. In turn, low 
renin and hyperkalemia were linked to appropriate changes in other kidney sodium and 
potassium transporters. Second, on a normal salt diet, especially angiotensin II con-
tributed to hypertension, whereas the roles of aldosterone and the mineralocorticoid 
receptor were less prominent. A high salt diet completely changed this picture with spi-
ronolactone being the only treatment that attenuated the rise in blood pressure. Third, 
5/6th nephrectomy with a high salt diet increased skin sodium and water content, likely 
reflecting interstitial accumulation. Skin water correlated with blood pressure and heart 
weight, and was reduced by spironolactone; spironolactone also increased natriuresis 
and restored vasorelaxation.
Although our transporter data are descriptive, the correlation analysis suggests that 
hyperkalemia decreased Kir4.1 and NCC, and increased Kir5.1, while aldosterone in-
creased γ-ENaC. This is consistent with previous data from healthy animals 24, 25, but has 
not been analyzed previously in a CKD model. Kir4.1/5.1 forms heterotetramers which 
are crucial for excreting a dietary potassium load 26, 27. This is the first study to analyze 
these channels in the context of hyperkalemia. It is not clear whether NHE3 and NKCC2 
were also reduced secondary to hyperkalemia or other changes after 5/6th nephrec-
tomy 28, 29. Previous 5/6th nephrectomy studies in rats also showed reduced NHE3 and 
increased ENaC, whereas NKCC2 and NCC showed an initial increase but subsequent 
decrease 30, 31. A recent study showed that inflammation increased NCC in both the 
aristolochic acid and adenine models of CKD, but not after 5/6th nephrectomy 32. Our 
data suggest that the mechanisms of NCC dephosphorylation by serum potassium is 
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intact after 5/6th nephrectomy 24. A selective effect on ENaC subunits has been observed 
previously in diabetic rats with high aldosterone 33. Because the rats were proteinuric, 
urinary proteases such as plasmin may also have contributed to increased γ-ENaC 34. 
Despite proteolytic processing prostasin-cleavage of γ-ENaC is not always detectable 
in the kidney 35. Another relevant question is why 5/6th nephrectomy increases Sgk1. 
Although this could also be driven by aldosterone, other Sgk1 activating mechanisms 
pertaining to CKD may have contributed, including proteinuria, transforming growth 
factor b, mechanical stretch, and changes in cell volume 4. Thus, these data suggest an 
important role for hyperkalemia and aldosterone. The clinical relevance of this interac-
tion for hypertension was illustrated in a study in which the potassium binder patiromer 
reduced hyperkalemia, aldosterone, and blood pressure in patients with CKD 36
With regard to the response to RAS-inhibition, a relevant question is why losartan loses 
its blood pressure lowering effect during a high salt diet. In rats with intact kidneys, high 
salt suppresses plasma and kidney angiotensin II, but increases tubular angiotensin II 
37. Therefore, we propose three possible explanations: (1) losartan is unable to inhibit 
tubular angiotensin II, (2) 5/6th nephrectomy with high salt requires a higher dose of 
losartan, or (3) high salt activates other hypertensive pathways. In a previous study 
losartan (similar dose as in this study) also failed to reduce blood pressure in normal 
rats on a high salt diet, but it did reduce kidney RAS components, and proteinuria 38. Of 
note, previous studies showed that angiotensin receptor blockers can still lower blood 
pressure in 5/6th nephrectomized animals on a high salt diet 39-43. However, the design of 
these studies differed from ours, including higher losartan dosing 42, intravenous dosing 
39, the use of spontaneously hypertensive rats 40, Dahl salt-sensitive rats 44, or C57BL/6 
mice 43. Of note, in mice RAS activity 45 and response to 5/6th nephrectomy 46 are differ-
ent. A strength of our study is that we used a dose of losartan that produced similar 
concentrations of the active metabolite as it does in patients 47.
The observation that spironolactone but not adrenalectomy attenuated the rise in 
blood pressure with high salt suggests activation of the mineralocorticoid receptor 
during a high salt diet. Alternatively, glucocorticoid replacement may have limited 
treatment response, despite the fact that a physiological replacement dose was used 
48. Aldosterone-independent activation of the mineralocorticoid receptor can occur 
through activation of Rac1 49. However, we observed no clear change in Rac1, although 
Rac1-inhibitors would be required to address this more conclusively. Another pos-
sibility is that the mineralocorticoid receptor in endothelial cells is involved 50. CKD 
causes endothelial dysfunction that is characterized by reduced nitric oxide mediated 
vasodilation 51, 52. Mineralocorticoid receptor blockade increases the bioavailability of 
nitric oxide and improves endothelial function 53. Consistent with this observation, we 
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show that after 5/6th nephrectomy, the high salt diet reduced the vasodilatory response 
of mesenteric arteries to acetylcholine, and that spironolactone treatment restored the 
contribution of nitric oxide to this response. A related mechanism that could contribute 
is b-adrenergic overstimulation, which can be caused by both CKD and a high salt diet 
54, 55. Indeed, vasoconstriction induced by b-adrenergic overstimulation in rats was 
blunted by spironolactone but not by losartan and this occurred through restoration of 
nitric oxide bioavailability 56.
Although the primary focus of this study was on blood pressure, we also analyzed effects 
on heart weight (as measure of left ventricular hypertrophy) and skin sodium and water 
content (as measure of interstitial accumulation). Our data confirm previous findings 
that 5/6th nephrectomy increases heart weight, and that the addition of a high salt 
diet increases this even further 57; this relationship is likely explained by hypertension. 
Recent data indicate that the phenomenon of skin sodium accumulation is associated 
with left ventricular hypertrophy in patients with CKD 58. However, our interventions did 
not reduce skin sodium but rather skin water content, which also correlated with heart 
weight. A higher skin water content likely reflects interstitial fluid accumulation and 
might signal extracellular fluid volume expansion, which is an independent determinant 
of resistant hypertension in patients with CKD 59.
Although RAS-interventions have been extensively studied in rat CKD models, the 
strength of this study was that it dissected the roles of individual RAS-components 
on a normal and high salt diet. However, a number of limitations should also be men-
tioned. First, no CKD model fully translates to human CKD, although we do believe the 
characteristics of the 5/6th nephrectomy model are appropriate to study CKD-related 
hypertension 3, 7. Second, we only performed the analysis in male rats, because we al-
ready studied several variables (multiple RAS-interventions, normal and high salt diet). 
Because sex differences in tubular transport and salt-sensitive hypertension are increas-
ingly recognized 60, 61, future studies should address this topic in female rats. Third, no 
cumulative sodium balance measurements were performed, because we did not obtain 
approval for continuous housing in metabolic cages. Finally, the transporter profile was 
descriptive and future intervention studies should address which sodium reabsorptive 
pathways contribute to hypertension in CKD.
If our data allow translation, they reiterate the importance of restricting dietary sodium 
in CKD to maintain the efficacy of RAS-inhibitors. Previous clinical trials have shown 
that a low sodium diet enhances RAS-inhibitor efficacy in CKD 62, 63, again emphasizing 
the close interaction between dietary salt and the RAS in CKD. We recently showed that 
dietary sodium restriction and distal diuretics effectively lowered blood pressure in 
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patients with CKD in the absence of RAS-inhibitors 64. Thus, RAS-inhibitors and mineralo-
corticoid receptor antagonists are not required for blood pressure lowering in CKD, but 
have been shown to provide blood pressure independent end-organ protection 10, 65-67. 
Although the use of mineralocorticoid receptor antagonists in more advanced CKD is 
often limited by hyperkalemia, the non-steroidal mineralocorticoid receptor antagonist 
finerenone causes hyperkalemia less frequently, and reduces the surrogate outcome 
markers albuminuria and NT-pro-BNP 68, 69. Future studies should address whether 
salt-induced activation of the mineralocorticoid receptor also occurs in human CKD and 
further explore the signaling pathways involved 70.
In summary, in the 5/6th nephrectomy rat CKD model, salt-sensitive hypertension devel-
ops with a selective increase in g-ENaC and despite appropriate transporter adaptations 
to volume expansion and hyperkalemia. With normal salt, hypertension after 5/6th 
nephrectomy depends on angiotensin II and aldosterone, while high salt aggravates 
hypertension with enhanced sensitivity of the mineralocorticoid receptor.
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normal salt (0.4% NaCl)
Sham – vehicle Sham Sham No Vehicle
5/6Nx – vehicle 5/6th Nx Sham No Vehicle
5/6Nx –Adx 5/6th Nx Adx Yes Vehicle
5/6Nx – Spiro 5/6th Nx Sham No Spiro
5/6Nx – Adx+Los 5/6th Nx Adx Yes Los
5/6Nx – Spiro+Los 5/6th Nx Sham No Spiro+Los
high salt (4.0% NaCl)
Sham – vehicle Sham Sham No Vehicle
5/6Nx – vehicle 5/6th Nx Sham No Vehicle
5/6Nx –Adx 5/6th Nx Adx Yes Vehicle
5/6Nx – Spiro 5/6th Nx Sham No Spiro
5/6Nx – Adx+Los 5/6th Nx Adx Yes Los
5/6Nx – Spiro+Los 5/6th Nx Sham No Spiro+Los
Adx, adrenalectomy; CKD, chronic kidney disease; Los, losartan; Nx, nephrectomy; Spiro, spironolactone.
table S2. Body weight, food and water intake






normal salt (0.4% NaCl)
Sham - vehicle 407 ± 24 40 ± 5 15 ± 3 19 ± 4*
5/6th Nx – vehicle 413 ± 24 42 ± 14 22 ± 4 54 ± 15‡
5/6th Nx – Adx 360 ± 28*‡ -6 ± 15*‡ 20 ± 6 48 ± 12‡
5/6th Nx – Spiro 355 ± 35*‡ 15 ± 35 19 ± 2 48 ± 5‡
5/6th Nx – Adx + Los 333 ± 48*‡ -32 ± 44*‡ 24 ± 9 52 ± 28‡
5/6th Nx – Spiro + Los 393 ± 31 32 ± 20 27 ± 9‡ 48 ± 26‡
high salt (4.0% NaCl)
Sham - vehicle 431 ± 23* 29 ± 8 14 ± 3 33 ± 4
5/6th Nx – vehicle 370 ± 33‡ 15 ± 36 15 ± 8 78 ± 43‡
5/6th Nx – Adx 343 ± 35‡ 8 ± 57 16 ± 4 83 ± 20‡
5/6th Nx – Spiro 380 ± 31‡ 11 ± 21 22 ± 6 113 ± 27‡
5/6th Nx – Adx + Los 352 ± 33‡ 4 ± 34 14 ± 6 86 ± 35‡
5/6th Nx – Spiro + Los 409 ± 10 43 ± 10 21 ± 6 107 ± 31‡
Data are shown as mean ± standard deviation. Body weight was measured at the day of sacrifice, while the difference in 
body weight was between start of the interventions and sacrifice (3 weeks). Food and water intake were derived from 
metabolic cage housing during the 24 hours before sacrifice. Groups were analyzed separately for the normal and high 
salt diets which was performed by one-way ANOVA with post-hoc corrections according to Dunnett. * P ≤ 0.05 versus 5/6th 
nephrectomy (5/6th Nx)-vehicle treatment, ‡ P ≤ 0.05 versus sham-vehicle treatment.
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table S4. Plasma sodium (Na+), serum potassium (K+), and urinary Na+ and K+ excretions
Plasma Na+ 
(mmol/L)




normal salt (0.4% NaCl)
Sham - vehicle 129 ± 8 4.5 ± 0.5 0.9 ± 0.3 1.6 ± 0.3
5/6th Nx – vehicle 134 ± 7 6.0 ± 0.4‡ 2.0 ± 1.0‡ 2.2 ± 0.6‡
5/6th Nx – Adx 133 ± 4 6.0 ± 1.0‡ 1.5 ± 0.6 2.2 ± 0.8
5/6th Nx – Spiro 131 ± 11 6.1 ± 1.0‡ 1.6 ± 0.2‡ 1.8 ± 0.3
5/6th Nx – Adx + Los 136 ± 3 6.6 ± 0.4‡ 1.6 ± 0.3 2.1 ± 0.8
5/6th Nx – Spiro + Los 127 ± 4 N.M. 1.9 ± 0.2‡ 2.7 ± 0.2‡
high salt (4.0% NaCl)
Sham - vehicle 135 ± 3 5.3 ± 0.7 9.7 ± 1.7 2.0 ± 0.2
5/6th Nx – vehicle 139 ± 7 6.8 ± 1.6‡ 9.5 ± 4.1 2.0 ± 0.5
5/6th Nx – Adx 132 ± 13 6.2 ± 1.1 9.3 ± 4.2 2.1 ± 0.5
5/6th Nx – Spiro 131 ± 11 6.0 ± 0.6 14.8 ± 3.2*‡ 2.5 ± 0.3
5/6th Nx – Adx + Los 140 ± 4 6.7 ± 1.2 8.8 ± 3.3 2.3 ± 0.4
5/6th Nx – Spiro + Los 129 ± 6 N.M. 14.3 ± 2.3 2.6 ± 0.3
Data are shown as mean ± standard deviation. Blood for measurements was collected at the day of sacrifice. Urine col-
lections for sodium and potassium excretion were performed using metabolic cage housing during the 24 hours before 
sacrifice. Groups were analyzed separately for the normal and high salt diets which was performed by one-way ANOVA 
with post-hoc corrections according to Dunnett. N.M. Not measured. * P ≤ 0.05 versus 5/6th nephrectomy (5/6th Nx)-vehicle 







figure S1. Group allocations
Figure shows the mean arterial pressure (MAP) and glomerular filtration rate (GFR) five weeks after 5/6th nephrectomy. 
These data were used to allocate equal numbers of each quadrant (A–D) to the treatment groups to ensure similar MAP 
and GFR prior to treatment between groups.
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 figure S2. Overview of normalization method for kidney weight
 After uninephrectomy the remaining kidney hypertrophies and gains weight, but not nephrons. To allow normalization by 
nephron number, we developed a method to estimate the weight of 1/3rd of remnant kidney of central section (i.e., before 
hypertrophy). By doing so we assume that kidney weight correlates with nephron number and that the nephrons are dis-
tributed homogeneously in the kidney.1,2 First, we measured the weight of the right kidney directly after uninephrectomy. 
This weight was used to calculate the expected weight of the left kidney based on the established weight differences 
between the right and left male rat kidney at the age of 7 weeks (correction factor 0.9908).3 Second, we performed a pilot 
study in which we weighed the two poles and the remnant kidney to establish the fractions of each segment. We estab-
lished that the remnant kidney weight was on average 65% of the combined weight of the two poles. Third, we weighed 
the two poles after the 2/3rd nephrectomy and calculated the weight of the remnant kidney by multiplying it by 0.65. 
Subsequently, we added the actual weights of the poles to the projected weight of the remnant kidney to estimate the 
weight of the left kidney at the time of 2/3rd nephrectomy. Fourth, we calculated a correction factor by dividing the esti-
mated weight of the left kidney at 2/3rd nephrectomy by the left kidney at uninephrectomy. This correction factor was used 
to deduce the weight of 1/3rd of the left kidney prior to uninephrectomy. In the healthy rats, there was a slight difference 
between the actual weight of the left kidneys at sacrifice and the estimated weight of the left kidney at uninephrectomy. 
Therefore, we also used a correction factor (mean left kidney weight at sacrifice/mean of estimated left kidney weight at 
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figure S3. Urine sodium and potassium excretions
Urine sodium (Na+) and potassium (K+) excretion are shown before 5/6th nephrectomy (Nx) and 5 or 8 weeks thereafter (A, 
B). Furthermore, urine Na+ and K+ excretions are shown for rats after sham or 5/6th nephrectomy on normal and high salt 
diets (C, D).
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 figure S4. Treatment responses in plasma renin, plasma aldosterone, and proteinuria
Responses in plasma renin, plasma aldosterone, and proteinuria after treatment with vehicle, adrenalectomy (Adx), spi-
ronolactone (Spiro), adrenalectomy with losartan (Adx + L), or spironolactone with losartan (S + L). Data are shown before 
(B) and after (A) treatment. In addition, the data are shown for the normal (A, C, E) and high salt diet (B, D, F). * P ≤ 0.05.
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Purpose of review: To summarize all available data on targeting angiotensinogen with 
RNA-based therapeutics as a new tool to combat cardiovascular diseases.
Recent findings: Liver-targeted, stable antisense oligonucleotides and small interfering 
RNA targeting angiotensinogen are now available, and may allow treatment with at most 
a few injections per year, thereby improving adherence. Promising results have been 
obtained in hypertensive animal models, as well as in rodent models of atherosclerosis, 
polycystic kidney disease and pulmonary fibrosis. The next step will be to evaluate the 
optimal degree of suppression, synergy with existing renin-angiotensin-aldosterone 
system blockers, and to determine harmful effects of suppressing angiotensinogen in 
the context of common comorbidities such as heart failure and chronic kidney disease.
Summary: Targeting angiotensinogen with RNA-based therapeutics is a promising new 
tool to treat hypertension and diseases beyond. Their long-lasting effects are particu-
larly exciting, and if translated to a clinical application of at most a few administrations 
per year, may help to eliminate non-adherence.
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intRoDuCtion
Although more than 100 commercial drugs and drug combinations are available for the 
treatment of hypertension, a substantial proportion of the hypertensive population 
remains uncontrolled or sub-optimally controlled. This could relate to non-adherence 
and/or drug ineffectiveness. The latter might be due to counterregulatory mechanisms 
(like a rise in renin 1) that eliminate or diminish the initial blood pressure-lowering ef-
fect. Hence, given the deleterious consequences of uncontrolled blood pressure, there 
still is a need for novel treatment options that preferably are not counterbalanced by the 
upregulation of contractile mechanisms and circumvent non-adherence. An attractive 
option is targeting angiotensinogen (AGT) with RNA-based therapeutics. Since all an-
giotensins stem from AGT, deleting AGT will suppress angiotensin (Ang) formation, even 
when renin levels rise. Furthermore, the dosing frequency with this approach might go 
down to a few times per year, thereby potentially reducing the clinical and economic 
burden of non-adherence.
RnA theRAPeutiC APPRoACheS
RNA-based therapies bind to RNA and change the expression of any protein, even those 
not amenable to traditional approaches involving small-molecule drugs. A number of 
RNA therapeutic approaches have been developed 2, 3, with antisense oligonucleotides 
(ASO) that inhibit RNA translation and oligonucleotides that function via the RNA 
interference (RNAi) pathway being the most clinically relevant. ASO-based therapies 
utilize Watson-Crick’s base-pairing rules and single-stranded DNA containing 15 to 30 
nucleotides, which are designed in antisense orientation to the pre-mRNA and mRNA 
of interest. Mature mRNA is formed in the nucleus by splicing the introns of pre-mRNA. 
ASOs are able to modulate alternative splicing by binding to the pre-mRNA producing 
different protein variants and changing the prevalence of one variant. When ASOs bind 
to their target mRNA, RNase H1 cleaves the RNA in an RNA-DNA duplex in both the cy-
toplasm and nucleus 4 destroying the mRNA and inhibiting the translation of the target 
protein (figure 1A). Chemically modified ASOs with phosphorothioate linkages can 
trigger RNA cleavage even in the absence of transfection reagent 5, 6. In contrast to the 
ASO approach, RNAi-based therapies utilize double-stranded RNA and exploit the RNAi 
process, an evolutionary conserved mechanism for the regulation of gene expression. 
At present, the majority of RNAi-based therapies employ non-coding small interfering 
RNA (siRNA) that are 21 to 23 bases in length and work naturally in the cell as a part 
of the RNA-Induced Silencing Complex (RISC). Unlike ASOs, when siRNA enters the cell 
it stays inactive until loaded by transactivation responsive RNA-binding protein into 
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Argonaute where the passenger strand is removed and the remaining antisense strand 
binds complementary mRNA targets, leaving Argonaute endoribonuclease to cleave 
the mRNA, thus preventing protein translation 7 (figure 1B). In mammals, Argonaute 
contains an RNase H domain, but cleaves RNA in an RNA-RNA duplex 8. The majority 
of RNA-based therapies in clinical pipeline utilize the RNAi approach (Table 1). This is 
unsurprising given that a major advantage of RNAi over ASO for therapeutic applications 




figure 1. inhibition of RnA translation by A) antisense oligonucleotide (ASo) or B) RnA interference. 
See text for further explanation. ASGPR, asialoglycoprotein receptor; Ago-2, argonaute-2; RISC, RNA-in-
duced silencing complex.
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RNAi (miRNA) Phase 1/2
Clear cell renal cell carcinoma
HIF-2a Arrowhead ARO-HIF2 RNAi (siRNA) Pre-IND
Cholangiocarcinoma
 TGF-b1 and COX2 Sirnaomics STP705L RNAi (siRNA) Phase 1
Non-melanoma skin cancer
TGF-b1 and COX2 Sirnaomics STP705 RNAi (siRNA) Phase 2
Pancreatic cancer
KRAS G12D Silenseed KRAS-LODER RNAi (siRNA) Phase 2 10
Prostate cancer











Hepatic Factor XI Ionis-Bayer IONIS-FXIRx ASO Phase 2 11







RNAi (siRNA) Phase 3 12-16
Hepatic Apo C-III Arrowhead ARO-APOC3 RNAi (siRNA) Phase 1
Ionis-Akcea/Novartis AKCEA-APOCIII-LRx ASO Phase 2
Ionis-Akcea Waylivra
(Volanesorsen)
ASO Phase 3 17-23




Hepatic Apo A Arrowhead-
Amgen
AMG 890 RNAi (siRNA) Phase 1
Ionis-Akcea/
Novartis






















Hepatic AGT Alnylam ALN-AGT RNAi (siRNA) Phase 1
Ionis IONIS-AGT-LRx ASO Phase 2
Ischemia
miR-92a miRagen-Servier MRG-110 RNAi (miRNA) Phase 1
Type 2 diabetes
Hepatic glucagon receptors Ionis IONIS-GCGR(Rx) ASO Phase 2 25
enDoCRine DiSoRDeRS
Acromegaly
Growth hormone receptor Ionis IONIS-GHR-LRx ASO Phase 2
fiBRoSiS
Hypertrophic scar reduction











Hepatic TMPRSS6 Ionis IONIS-TMPRSS6-LRx ASO Phase 2
Silence
Therapeutics
SLN124 RNAi (siRNA) CTA approved
Complement-mediated diseases
Hepatic C5 Alnylam Cemdisiran
(ALN-CC5)





RNAi (siRNA) Phase 1/2
Hepatic complement factor B Ionis-Roche IONIS-FB-LRx ASO Phase 2
Cystic Fibrosis
Pulmonary aENaC Arrowhead ARO-ENaC RNAi (siRNA) Pre-IND
Ionis IONIS-ENAC-2.5Rx ASO Phase 2
Hemophilia and are bleeding disorders
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Prekallikrein Ionis IONIS-PKK-LRx ASO Phase 2
Primary hyperoxaluria
Hepatic glycolate oxidase type 1 Alnylam Lumasiran
(ALN-GO1)
RNAi (siRNA) Phase 3
Dicerna DCR-PHXC RNAi (siRNA) Phase 1
Transthyretin-mediated (ATTR) amyloidosis
Hepatic transthyretin Alnylam Vutrisiran
(ALN-TTRsc02)
RNAi (siRNA) Phase 3
Ionis-Akcea AKCEA-TTR-LRx ASO Phase 1
KiDney DiSeASeS
Delayed graft function
Pro-apoptotic gene p53 Quark QRK306 (QPI-1002) RNAi (siRNA) Phase 3
AKI following cardiac surgery
Pro-apoptotic gene p53 Quark QRK209 (QPI-1002) RNAi (siRNA) Phase 2
liveR DiSoRDeRS
AATD-associated liver disease
Hepatic mutant AAT Arrowhead ARO-AAT RNAi (siRNA) Phase 2
Alnylam ALN-AAT02 RNAi (siRNA) Phase 1/2
Dicerna DCR-A1AT RNAi (siRNA) Pre-IND
Acute hepatic porphyria
Hepatic ALAS1 Alnylam Givosiran (ALN-AS1) RNAi (siRNA) Phase 3 26
ARLD/NAFLD
HSD17B13 Arrowhead ARO-HSD RNAi (siRNA) Pre-IND
HBV




RNAi (siRNA) Phase 2
Arbutus AB-729 RNAi (siRNA) Phase 1
Alnylam VIR-2218 
(ALN-HBV02)
RNAi (siRNA) Phase 1/2
Ionis-GSK IONIS-HBV-LRx ASO Phase 2
Ionis-GSK IONIS-HBVRx ASO Phase 2
Dicerna DCR-HBVS RNAi (siRNA) Phase 1
neuRologiCAl DiSoRDeRS
Huntington’s disease
Huntingtin protein Ionis-Roche IONIS-HTTRx ASO Phase 3 27
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ASO Phase 3 28
Mutated CORF72 gene Ionis-Biogen IONIS-C9Rx
(BIIB078)
ASO Phase 2










RNAi (siRNA) Phase 3
Glaucoma
b-adrenergic receptor 2 Sylentis Bamosiran
(SLY040012)
RNAi (siRNA) Phase 2 29, 30
aENaC, epithelial sodium channel alpha subunit; AAT, Alpha-1 antitrypsin; AATD, Alpha-1 antitrypsin deficiency; AGT, an-
giotensinogen; AKI, acute kidney injury; ALAS1, aminolevulinic acid synthase 1; ANGPTL3, angiopoietin-like protein 3; Apo 
A, apolipoprotein A; Apo C-III, apolipoprotein C-III; ARLD/NAFLD, Alcohol-related liver disease and non-alcoholic fatty liver 
disease; ASO, antisense oligonucleotide; C5, complement component 5; CORF72, chromosome 9 open reading frame 72; 
CTA, clinical trial authorization; HBV, hepatitis B virus; HIF-2a, hypoxia inducible factor 2a; HSD17B13, 17b-Hydroxysteroid 
dehydrogenase type 13; IND, United States Food and Drug Administration investigational new drug application; MAPT, 
microtubule-associated protein tau; PCSK9, proprotein convertase subtilisin kexin type 9; miRNA, microRNA; RNAi, RNA 
interference; siRNA, small interfering RNA; SOD1, superoxide dismutase 1; STAT3, signal transducer and activator of tran-
scription factor 3; TMPRSS6, Transmembrane protease serine 6; TRPV1, Transient receptor potential vanilloid-1.
The clinical translation of RNAi-based therapies has faced a number of challenges includ-
ing off-target effects, siRNA delivery, immune reactions and toxicity 2. The biggest hurdle 
has been delivery since siRNAs do not readily cross the cell membrane. Various ap-
proaches have been proposed to solve the problem of siRNA delivery in vivo e.g., viruses, 
cationic lipids, polymers, nanoparticles 31, 32. One of the most promising approaches to 
improve the delivery and safety of siRNA is bioconjugation, the covalent connection of 
siRNAs with biogenic molecules such as lipophilic molecules, antibodies, aptamers, 
ligands, peptides, or polymers which also cause less immunoreaction 33, 34. The develop-
ment of trivalent N-acetylgalactosamine (GalNAc)-siRNA conjugates for targeted delivery 
of siRNA to the liver is the most successful. GalNAc binds to the asialoglycoprotein recep-
tor that is highly expressed on hepatocytes resulting in rapid endocytosis 35. The GalNAc 
approach has also been employed to enhance ASO delivery to hepatocytes by ~10-fold 
versus free ASOs in preclinical models, resulting in a significant dose reduction 36. In a 
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phase 2 clinical trial, hepatocyte-directed GalNAc-siRNA molecules have been shown 
to yield incredible results with stable suppression of proprotein convertase subtilisin/
kexin type 9 (PCSK9) achieved for at least 6 months 16. RNA-based therapies will not only 
fundamentally change the way we treat diseases, but may also provide treatments for 
diseases with unmet clinical need. This has led to RNA-based therapeutics becoming 
one of the most rapidly advancing fields in drug discovery.
CuRRent APPliCAtion of RnA-BASeD theRAPieS
To date, four ASOs and one siRNA-based therapy have been approved for clinical use. 
Fomivirsen, an intravitreally injected inhibition ASO indicated for the treatment of ocu-
lar cytomegalovirus retinitis (CMV) in acquired immunodeficiency syndrome (AIDS) indi-
viduals, was the first ever RNA-based therapy to be approved by the U.S. Food and Drug 
Administration (FDA) in 1998 and by the European Medical Association (EMA) in 1999 37. 
However, in the early 2000’s, fomivirsen was withdrawn from the market as the introduc-
tion of highly active antiretroviral therapy (HAART) dramatically reduced the number of 
cases of CMV. A second inhibition ASO, mipomersen, which is injected subcutaneously 
and targets mRNA encoding apolipoprotein B for the treatment of homozygous familial 
hypercholesterolemia, was approved for clinical use in 2014 38. Two splice modulating 
ASOs, nusinersen for the treatment of spinal muscular atrophy (2017) 39, 40 and eteplirsen 
for the treatment of Duchenne muscular dystrophy (2016) 41, are also approved for clini-
cal use. In 2018, patisiran, an siRNA encapsulated in a lipid nanoparticle for delivery to 
hepatocytes, became the first globally (FDA and EMA) approved RNAi therapeutic. Pa-
tisiran is indicated for the treatment of hereditary transthyretin-mediated amyloidosis 
(hATTR) in adults 42. In addition, >50 RNA-based therapies for diseases as varied as cancer, 
neurodegenerative disease and cardiovascular disease are currently in clinical develop-
ment with several investigational new drug and clinical trial applications expected to be 
filed within the next 2 years (Table 1). Interestingly, a number of ASO and RNAi therapies 
are being developed for the same disease targets (Table 1), including hepatic AGT for the 
treatment of hypertension which are in phase 2 and phase 1 respectively.
Agt RnA-BASeD theRAPy in hyPeRtenSion
Since AGT is the sole precursor of the potent vasoconstrictor Ang II, it is a promising tar-
get for gene silencing. At present, inhibition of the renin-Ang-aldosterone system (RAAS) 
is the mainstay for the treatment of hypertension, heart failure and chronic kidney 
disease 43, 44. Yet, the long-term management of these conditions remains complicated 
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by RAAS escape phenomena, during which a counterregulatory rise in plasma renin 
often restores Ang II to its original pre-treatment values 45-47. As a consequence, blood 
pressure control commonly requires multiple antihypertensive drugs, but is impeded 
by a decline in therapy adherence with every drug added to the treatment regimen 48, 49.
The clinical need for an antihypertensive therapeutic which prevents Ang reactivation 
has long been recognized and may be achieved by blocking the RAAS at the AGT level. As 
opposed to classical RAAS inhibitors, a compensatory rise in renin could even potentiate 
blood pressure lowering as it would facilitate depletion of the remaining AGT (figure 
2A). This can be explained as follows. Normally, AGT is present at levels that exceed 
Ang levels by many orders of magnitude. Under such conditions, blocking renin, Ang 
I-converting enzyme (ACE) or the Ang receptor results in a renin rise which either (par-
tially) restores Ang II, or increases Ang II above its original level (in order to overcome 
blockade of its receptor). This is easily achievable, simply because there is ample AGT 
around to allow this. Even a 100-fold rise in Ang I generation (sufficient to overcome 99% 
renin inhibition!) is feasible. Yet, if the renin rises are substantial, it is possible that at 
a certain moment AGT levels start to decrease. During AGT suppression by RNA-based 
therapy, AGT levels are down already, and now a rise in renin might be sufficient to result 
in complete AGT depletion, particularly when simultaneously introducing other types of 
RAAS blockade, which induce further rises in renin. Restoration of Ang II levels is then 
no longer possible.
While initial ASO constructs targeting Agt lowered circulating AGT, Ang II and blood pres-
sure in parallel in spontaneously hypertensive rats, these methods lacked potency and 
specificity: AGT levels were halved at most, and the effects were short-lived (<1 week) 
51-53. Similar problems also impeded the use of Agt-directed siRNA. The introduction of 
lipid nanoparticle delivery enhanced AGT downregulation, although stable suppres-
sion still necessitated weekly intravenous dosing 54. Additionally, treatment with lipid 
delivery vehicles causes an inflammatory reponse and must therefore be given with 
histamine receptor antagonists, non-steroidal anti-inflammatory drugs and relatively 
high doses of glucocorticoids 55.
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 figure 2. Near elimination of AGT is required for lowering of Ang II. 
A) Inhibition of the renin-angiotensin-aldosterone-system (RAAS) at the angiotensinogen (AGT) level may prevent RAAS 
reactivation, because a rise in plasma renin levels, due to a lack of  negative feedback exerted by angiotensin (Ang) II on 
renin production, could now facilitate depletion of remaining AGT. B) Plasma AGT, C) active plasma renin concentration 
(APRC), D) plasma Ang II, e) renal Ang II and f) mean arterial pressure (MAP) of spontaneously hypertensive rats aft er four 
weeks of vehicle, valsartan, AGT siRNA or valsartan+siRNA treatment (all groups n=8). Data, modified from Uijl et al. 50, 
are represented as means ± SEM and analyzed using two-way ANOVA and post-hoc Bonferroni (MAP) or transformed to 
natural logarithms before analysis by one-way ANOVA and post-hoc Bonferroni (RAS parameters). *P<0.05, *** P≤0.001, 
****P≤0.0001 vs. vehicle or otherwise indicated; # P≤0.0001.
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Conjugating GalNAc to ASO and RNAi molecules enabled general therapeutic applica-
tion. Subsequent selective accumulation in the liver permitted minimal invasive delivery 
via subcutaneous injection and optimization of AGT downregulation, since circulating 
AGT levels are determined by hepatic synthesis 56, 57. Indeed, by improving liver activity 
8-fold, GalNAc-conjugation potentiated AGT inhibition of ASOs to maximally 88% in a 
dose-dependent manner 58. Interestingly, a reduction of at least 75% was required to 
simultaneously lower blood pressure, which then remained low for a period of 7-10 days 
after a single dose. This relates to the above-mentioned upregulation of renin. In fact, 
in a study employing GalNAc-siRNA to target Agt 50, even when AGT was decreased by 
97.9%, circulating Ang II remained intact due to renin upregulation. Only a 99.8% re-
duction, achieved by combining siRNA with valsartan (which further upregulates renin, 
thereby additionally lowering AGT), was required to deplete both systemic and renal 
Ang II (figure 2B-e). The latter observation implies that renal Ang generation relies on 
AGT of hepatic origin. Consequently, AGT siRNA monotherapy provided similar antihy-
pertensive and cardioprotective efficacy as conventional RAAS inhibition, whereas near 
elimination of AGT by addition of valsartan yielded a synergistic reduction in blood pres-
sure and cardiac hypertrophy, without adversely affecting renal function (figure 2f). 
Unique to GalNAc-siRNA is its long-lasting effectiveness 42, as opposed to an ASO liver 
half-life of 2 to 4 weeks 58. These findings suggest that, in clinical practice, AGT inhibition 
mediated by RNAi may not only prevent RAAS reactivation but also improve cardiovas-
cular outcome and therapy adherence due to a sustained and stable single-dose efficacy 
lasting weeks to months 5
Agt RnA-BASeD theRAPy in otheR DiSeASeS
While the potential for clinical translation is currently being investigated in patients, 
preclinical studies now focus on safety and efficacy in models of chronic kidney disease 
and heart failure. However, the application of AGT inhibition is not limited to hyperten-
sion and related end-organ damage. Polycystic kidney disease (PKD) appears an espe-
cially promising target, with multiple recent studies showing beneficial effects in animal 
models of this disease 59-61. PKD is caused by mutations in the Pkd1 and Pkd2 gene. In 
affected patients, these mutations lead to early onset hypertension, the progressive 
growth of renal cysts and kidney failure. Conventional treatment with ACE inhibitors or 
Ang receptor blockers (ARBs) effectively lowers blood pressure in PKD, but whether this 
treatment also reduces the decline in kidney function is unclear 62, 63. Experimentally, 
PKD may be studied in mice with targeted knockout of the Pkd1 or Pkd2 gene, with both 
models developing progressive intrarenal cysts and kidney failure 64, 65. In Pkd2 knockout 
mice, treatment with AGT ASO resulted in a reduction in kidney size, lower total cyst 
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volume and improved kidney function compared to control treatment (scrambled ASO) 
59. Pkd1 knockout mice displayed similar reductions in kidney size and cyst volume after 
treatment with AGT ASO 60, 61. Interestingly, in the latter model, the effects of AGT ASO 
on cyst growth were independent of changes in systolic blood pressure. In contrast, 
ACE inhibition with lisinopril significantly lowered systolic blood pressure, but did not 
reduce kidney size to a similar degree as AGT ASO and had no effect on cyst volume 60.
Experimental evidence indicates that AGT ASO may also be effective in the treatment 
of atherosclerosis. Increased activity of the RAAS promotes atherosclerosis through 
activation of AT1A receptors 66-68. Treatment of spontaneous hypertensive rats on a diet 
enriched with high fat and vitamin D3 (i.e., to induce atherosclerosis) with Gal-PEG-Et 
(GPE) nanoparticles carrying short hairpin RNA (shRNA) that specifically targets Agt in 
the liver decreased systolic blood pressure and attenuated the development of ath-
erosclerotic lesions compared with control animals 69. Similar effects were observed in 
another animal model for atherosclerosis and obesity, i.e., LDL receptor knockout mice 
fed with a saturated fat-enriched diet 70. In these mice, treatment with AGT ASO resulted 
in decreased blood pressure, less atherosclerosis, and diminished body weight gain. 
Correspondingly, previous clinical studies also showed beneficial effects of ACE inhibi-
tors and ARBs on the progression of atherosclerotic plaques 71, 72. However, whether AGT 
ASO is effective in the treatment of atherosclerosis in patients has yet to be investigated.
Finally, AGT ASO treatment has been used as a therapeutic strategy against experimen-
tal pulmonary fibrosis. Currently, treatment options for idiopathic pulmonary fibrosis 
are limited, leaving most patients with a poor prognosis – the median survival rate is 
2–5 years. Several studies in animals (i.e., mice and rats) with bleomycin-induced lung 
injury showed that Ang II contributes to pulmonary fibrosis, whereas treatment with 
renin inhibitors, ACE inhibitors and ARBs attenuates disease progression 73-77. In this 
same animal model, intratracheal administration of AGT ASO was found to decrease 
pulmonary AGT concentrations and lung fibrosis 78, but no comparison was made to 
conventional RAAS inhibitors.
ConCluSion
Targeting AGT with RNA-based therapeutics is a promising new tool to treat hypertension 
and diseases beyond, including heart failure, atherosclerosis, diabetic nephropathy, 
polycystic kidney disease and pulmonary fibrosis. The long-lasting effects of RNA-based 
therapeutics are particularly exciting, and if translated to a clinical application of at most 
a few administrations per year, may help to eliminate non-adherence. To what degree 
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the effects of such therapeutics are fully identical to those of other RAAS blockers (given 
the fact that they eliminate all Ang metabolites) remains to be determined. It will also be 
important to determine to what level AGT should be suppressed to induce meaningful 
effects, and whether there is a role for AGT synthesized outside the liver 79. Synergy in 
combination with other RAAS blockers needs to be evaluated, as well as the potential 
harmful effects of suppressing AGT in the context of common comorbidities such as 
heart failure and chronic kidney disease, where AGT might already be suppressed.
Key PointS
Liver-targeted, stable antisense oligonucleotides and small interfering RNA targeting 
angiotensinogen, capable of suppressing angiotensinogen in a dose-dependent man-
ner, are now available.
Suppressing angiotensinogen exerts similar effects as classical blockers of the renin-
angiotensin-aldosterone system (RAAS) in hypertensive animal models, as well as in 
rodent models for atherosclerosis, polycystic kidney disease and pulmonary fibrosis.
Future studies should evaluate their safety, e.g. in the context of common comorbidities 
such as heart failure and chronic kidney disease, and synergy with existing RAAS block-
ers.
The long-lasting effects of this approach are particularly exciting, and if translated to 




finAnCiAl SuPPoRt AnD SPonSoRShiP
K.M.MC. was supported by a National Health and Medical Research Council of Australia 
CJ Martin Fellowship (1112125). L.R. was supported by a National Natural Science Foun-
dation of China grant (no. 81900668).
Chapter 4 107
Targeting angiotensinogen with RNA-based therapeutics
RefeRenCeS
 1. Balcarek J, Sevá Pessôa B, Bryson C, Azizi M, Ménard J, Garrelds IM, McGeehan G, Reeves RA, 
Griffith SG, Danser AHJ and Gregg R. Multiple ascending dose study with the new renin inhibitor 
VTP-27999: nephrocentric consequences of too much renin inhibition. Hypertension. 2014;63:942-
50.
 2. Setten RL, Rossi JJ and Han SP. The current state and future directions of RNAi-based therapeu-
tics. Nat Rev Drug Discov. 2019;18:421-446.
 3. Levin AA. Treating Disease at the RNA Level with Oligonucleotides. N Engl J Med. 2019;380:57-70.
 4. Liang XH, Sun H, Nichols JG and Crooke ST. RNase H1-Dependent Antisense Oligonucleotides 
Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus. Molecular 
therapy : the journal of the American Society of Gene Therapy. 2017;25:2075-2092.
 5. Wang S, Allen N, Vickers TA, Revenko AS, Sun H, Liang XH and Crooke ST. Cellular uptake mediated 
by epidermal growth factor receptor facilitates the intracellular activity of phosphorothioate-
modified antisense oligonucleotides. Nucleic Acids Res. 2018;46:3579-3594.
 6. Wang S, Allen N, Liang XH and Crooke ST. Membrane Destabilization Induced by Lipid Species 
Increases Activity of Phosphorothioate-Antisense Oligonucleotides. Mol Ther Nucleic Acids. 
2018;13:686-698.
 7. Li C and Zamore PD. RNA Interference and Small RNA Analysis. Cold Spring Harb Protoc. 
2019;2019:pdb top097436.
 8. Daugaard I and Hansen TB. Biogenesis and Function of Ago-Associated RNAs. Trends in genetics : 
TIG. 2017;33:208-219.
 9. Bertrand JR, Pottier M, Vekris A, Opolon P, Maksimenko A and Malvy C. Comparison of anti-
sense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun. 
2002;296:1000-4.
 10. Golan T, Khvalevsky EZ, Hubert A, Gabai RM, Hen N, Segal A, Domb A, Harari G, David EB, Raskin 
S, Goldes Y, Goldin E, Eliakim R, Lahav M, Kopleman Y, Dancour A, Shemi A and Galun E. RNAi 
therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic 
cancer patients. Oncotarget. 2015;6:24560-70.
 11. Buller HR, Bethune C, Bhanot S, Gailani D, Monia BP, Raskob GE, Segers A, Verhamme P, Weitz JI 
and Investigators F-AT. Factor XI antisense oligonucleotide for prevention of venous thrombosis. 
N Engl J Med. 2015;372:232-40.
 12. Fitzgerald K, White S, Borodovsky A, Bettencourt BR, Strahs A, Clausen V, Wijngaard P, Horton 
JD, Taubel J, Brooks A, Fernando C, Kauffman RS, Kallend D, Vaishnaw A and Simon A. A Highly 
Durable RNAi Therapeutic Inhibitor of PCSK9. N Engl J Med. 2017;376:41-51.
 13. Ray KK, Stoekenbroek RM, Kallend D, Nishikido T, Leiter LA, Landmesser U, Wright RS, Wijngaard 
PLJ and Kastelein JJP. Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol 
Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial. JAMA Cardiol. 2019.
 14. Leiter LA, Teoh H, Kallend D, Wright RS, Landmesser U, Wijngaard PLJ, Kastelein JJP and Ray 
KK. Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized 
Clinical Trial. Diabetes Care. 2019;42:173-176.
108 Part 1
Salt
 15. Ray KK, Stoekenbroek RM, Kallend D, Leiter LA, Landmesser U, Wright RS, Wijngaard P and 
Kastelein JJP. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins. 
Circulation. 2018;138:1304-1316.
 16. Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, Hall T, Troquay RP, Turner T, 
Visseren FL, Wijngaard P, Wright RS and Kastelein JJ. Inclisiran in Patients at High Cardiovascular 
Risk with Elevated LDL Cholesterol. N Engl J Med. 2017;376:1430-1440.
 17. Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, Yang Q, Hughes SG, 
Geary RS, Arca M, Stroes ESG, Bergeron J, Soran H, Civeira F, Hemphill L, Tsimikas S, Blom DJ, 
O’Dea L and Bruckert E. Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syn-
drome. N Engl J Med. 2019;381:531-542.
 18. Hegele RA, Berberich AJ, Ban MR, Wang J, Digenio A, Alexander VJ, D’Erasmo L, Arca M, Jones A, 
Bruckert E, Stroes ES, Bergeron J, Civeira F, Witztum JL and Gaudet D. Clinical and biochemical 
features of different molecular etiologies of familial chylomicronemia. J Clin Lipidol. 2018;12:920-
927 e4.
 19. Digenio A, Dunbar RL, Alexander VJ, Hompesch M, Morrow L, Lee RG, Graham MJ, Hughes SG, 
Yu R, Singleton W, Baker BF, Bhanot S and Crooke RM. Antisense-Mediated Lowering of Plasma 
Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 
Diabetes. Diabetes Care. 2016;39:1408-15.
 20. Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG and Tybjaerg-Hansen A. Loss-of-function 
mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371:32-41.
 21. Graham MJ, Lee RG, Bell TA, 3rd, Fu W, Mullick AE, Alexander VJ, Singleton W, Viney N, Geary 
R, Su J, Baker BF, Burkey J, Crooke ST and Crooke RM. Antisense oligonucleotide inhibition of 
apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. 
Circ Res. 2013;112:1479-90.
 22. Gaudet D, Alexander VJ, Baker BF, Brisson D, Tremblay K, Singleton W, Geary RS, Hughes SG, Viney 
NJ, Graham MJ, Crooke RM, Witztum JL, Brunzell JD and Kastelein JJ. Antisense Inhibition of 
Apolipoprotein C-III in Patients with Hypertriglyceridemia. N Engl J Med. 2015;373:438-47.
 23. Gaudet D, Brisson D, Tremblay K, Alexander VJ, Singleton W, Hughes SG, Geary RS, Baker BF, Gra-
ham MJ, Crooke RM and Witztum JL. Targeting APOC3 in the familial chylomicronemia syndrome. 
N Engl J Med. 2014;371:2200-6.
 24. Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, Marcovina SM, Hughes SG, Graham 
MJ, Crooke RM, Crooke ST, Witztum JL, Stroes ES and Tsimikas S. Antisense oligonucleotides 
targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, 
placebo-controlled, dose-ranging trials. Lancet. 2016;388:2239-2253.
 25. Morgan ES, Tai LJ, Pham NC, Overman JK, Watts LM, Smith A, Jung SW, Gajdosik M, Krssak M, 
Krebs M, Geary RS, Baker BF and Bhanot S. Antisense Inhibition of Glucagon Receptor by IONIS-
GCGRRx Improves Type 2 Diabetes Without Increase in Hepatic Glycogen Content in Patients With 
Type 2 Diabetes on Stable Metformin Therapy. Diabetes Care. 2019;42:585-593.
 26. Sardh E, Harper P, Balwani M, Stein P, Rees D, Bissell DM, Desnick R, Parker C, Phillips J, Bonkovsky 
HL, Vassiliou D, Penz C, Chan-Daniels A, He Q, Querbes W, Fitzgerald K, Kim JB, Garg P, Vaishnaw 
A, Simon AR and Anderson KE. Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent 
Porphyria. N Engl J Med. 2019;380:549-558.
Chapter 4 109
Targeting angiotensinogen with RNA-based therapeutics
 27. Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, Wild EJ, Saft C, Barker RA, Blair NF, Craufurd D, Priller 
J, Rickards H, Rosser A, Kordasiewicz HB, Czech C, Swayze EE, Norris DA, Baumann T, Gerlach I, 
Schobel SA, Paz E, Smith AV, Bennett CF, Lane RM and Phase 1-2a I-HSST. Targeting Huntingtin 
Expression in Patients with Huntington’s Disease. N Engl J Med. 2019;380:2307-2316.
 28. Miller TM, Pestronk A, David W, Rothstein J, Simpson E, Appel SH, Andres PL, Mahoney K, Allred 
P, Alexander K, Ostrow LW, Schoenfeld D, Macklin EA, Norris DA, Manousakis G, Crisp M, Smith R, 
Bennett CF, Bishop KM and Cudkowicz ME. An antisense oligonucleotide against SOD1 delivered 
intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, 
first-in-man study. Lancet Neurol. 2013;12:435-42.
 29. Martinez T, Gonzalez MV, Roehl I, Wright N, Paneda C and Jimenez AI. In vitro and in vivo efficacy 
of SYL040012, a novel siRNA compound for treatment of glaucoma. Molecular therapy : the journal 
of the American Society of Gene Therapy. 2014;22:81-91.
 30. Moreno-Montanes J, Sadaba B, Ruz V, Gomez-Guiu A, Zarranz J, Gonzalez MV, Paneda C and 
Jimenez AI. Phase I clinical trial of SYL040012, a small interfering RNA targeting beta-adrenergic 
receptor 2, for lowering intraocular pressure. Molecular therapy : the journal of the American 
Society of Gene Therapy. 2014;22:226-32.
 31. Osborn MF and Khvorova A. Improving siRNA Delivery In Vivo Through Lipid Conjugation. Nucleic 
Acid Ther. 2018;28:128-136.
 32. Yalcin E, Kara G, Celik E, Pinarli FA, Saylam G, Sucularli C, Ozturk S, Yilmaz E, Bayir O, Korkmaz 
MH and Denkbas EB. Preparation and characterization of novel albumin-sericin nanoparticles as 
siRNA delivery vehicle for laryngeal cancer treatment. Prep Biochem Biotechnol. 2019:1-12.
 33. Chernikov IV, Vlassov VV and Chernolovskaya EL. Current Development of siRNA Bioconjugates: 
From Research to the Clinic. Front Pharmacol. 2019;10:444.
 34. Qu X, Hu Y, Wang H, Song H, Young M, Xu F, Liu Y and Cheng G. Biomimetic Dextran–Peptide Vec-
tors for Efficient and Safe siRNA Delivery. ACS Applied Bio Materials. 2019;2:1456-1463.
 35. Springer AD and Dowdy SF. GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi 
Therapeutics. Nucleic Acid Ther. 2018;28:109-118.
 36. Prakash TP, Graham MJ, Yu J, Carty R, Low A, Chappell A, Schmidt K, Zhao C, Aghajan M, Murray 
HF, Riney S, Booten SL, Murray SF, Gaus H, Crosby J, Lima WF, Guo S, Monia BP, Swayze EE and 
Seth PP. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-
acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res. 2014;42:8796-807.
 37. Roehr B. Fomivirsen approved for CMV retinitis. Journal of the International Association of Physi-
cians in AIDS Care. 1998;4:14-6.
 38. Wong E and Goldberg T. Mipomersen (kynamro): a novel antisense oligonucleotide inhibitor for 
the management of homozygous familial hypercholesterolemia. P & T : a peer-reviewed journal 
for formulary management. 2014;39:119-22.
 39. Stein CA and Castanotto D. FDA-Approved Oligonucleotide Therapies in 2017. Molecular therapy : 
the journal of the American Society of Gene Therapy. 2017;25:1069-1075.
 40. Aartsma-Rus A. FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of 
Splice Modulating Oligonucleotides. Nucleic Acid Ther. 2017;27:67-69.
 41. Aartsma-Rus A and Krieg AM. FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The 
Next Chapter in the Eteplirsen Saga. Nucleic Acid Ther. 2017;27:1-3.
110 Part 1
Salt
 42. Hoy SM. Patisiran: First Global Approval. Drugs. 2018;78:1625-1631.
 43. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Sim-
one G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, 
Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, 
Tsioufis C, Aboyans V and Desormais I. 2018 ESC/ESH Guidelines for the management of arterial 
hypertension. European heart journal. 2018;39:3021-3104.
 44. Arendse LB, Danser AHJ, Poglitsch M, Touyz RM, Burnett JC, Jr., Llorens-Cortes C, Ehlers MR and 
Sturrock ED. Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associ-
ated Peptides in Hypertension and Heart Failure. Pharmacol Rev. 2019;71:539-570.
 45. van den Meiracker AH, Admiraal PJ, Janssen JA, Kroodsma JM, de Ronde WA, Boomsma F, Sis-
smann J, Blankestijn PJ, Mulder PG, Man In ‘t Veld AJ and et al. Hemodynamic and biochemical 
effects of the AT1 receptor antagonist irbesartan in hypertension. Hypertension (Dallas, Tex : 
1979). 1995;25:22-9.
 46. Mooser V, Nussberger J, Juillerat L, Burnier M, Waeber B, Bidiville J, Pauly N and Brunner HR. 
Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. 
Journal of cardiovascular pharmacology. 1990;15:276-82.
 47. Sealey JE and Laragh JH. Aliskiren, the first renin inhibitor for treating hypertension: reactive 
renin secretion may limit its effectiveness. Am J Hypertens. 2007;20:587-97.
 48. Gupta P, Patel P, Strauch B, Lai FY, Akbarov A, Maresova V, White CMJ, Petrak O, Gulsin GS, Patel 
V, Rosa J, Cole R, Zelinka T, Holaj R, Kinnell A, Smith PR, Thompson JR, Squire I, Widimsky J, Jr., 
Samani NJ, Williams B and Tomaszewski M. Risk Factors for Nonadherence to Antihypertensive 
Treatment. Hypertension (Dallas, Tex : 1979). 2017;69:1113-1120.
 49. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Hol-
land J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT, Jr., Alderman MH, Weiss RJ, Piller 
L, Bettencourt J, Walsh SM and Group ACR. Success and predictors of blood pressure control in 
diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent 
heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4:393-404.
 50. Uijl E, Mirabito Colafella KM, Sun Y, Ren L, van Veghel R, Garrelds IM, de Vries R, Poglitsch M, 
Zlatev I, Kim JB, Hoorn EJ, Foster D and Danser AHJ. Strong and Sustained Antihypertensive Ef-
fect of Small Interfering RNA Targeting Liver Angiotensinogen. Hypertension (Dallas, Tex : 1979). 
2019;73:1249-1257.
 51. Tomita N, Morishita R, Higaki J, Aoki M, Nakamura Y, Mikami H, Fukamizu A, Murakami K, Kaneda 
Y and Ogihara T. Transient decrease in high blood pressure by in vivo transfer of antisense oligo-
deoxynucleotides against rat angiotensinogen. Hypertension (Dallas, Tex : 1979). 1995;26:131-6.
 52. Wielbo D, Simon A, Phillips MI and Toffolo S. Inhibition of hypertension by peripheral administra-
tion of antisense oligodeoxynucleotides. Hypertension (Dallas, Tex : 1979). 1996;28:147-51.
 53. Makino N, Sugano M, Ohtsuka S and Sawada S. Intravenous injection with antisense oligodeoxy-
nucleotides against angiotensinogen decreases blood pressure in spontaneously hypertensive 
rats. Hypertension (Dallas, Tex : 1979). 1998;31:1166-70.
 54. Olearczyk J, Gao S, Eybye M, Yendluri S, Andrews L, Bartz S, Cully D and Tadin-Strapps M. Tar-
geting of hepatic angiotensinogen using chemically modified siRNAs results in significant and 
sustained blood pressure lowering in a rat model of hypertension. Hypertension research : official 
journal of the Japanese Society of Hypertension. 2014;37:405-12.
Chapter 4 111
Targeting angiotensinogen with RNA-based therapeutics
 55. Crooke ST, Witztum JL, Bennett CF and Baker BF. RNA-Targeted Therapeutics. Cell Metab. 
2018;27:714-739.
 56. Matsusaka T, Niimura F, Shimizu A, Pastan I, Saito A, Kobori H, Nishiyama A and Ichikawa I. Liver 
angiotensinogen is the primary source of renal angiotensin II. J Am Soc Nephrol. 2012;23:1181-9.
 57. Ye F, Wang Y, Wu C, Howatt DA, Wu CH, Balakrishnan A, Mullick AE, Graham MJ, Danser AHJ, Wang 
J, Daugherty A and Lu HS. Angiotensinogen and Megalin Interactions Contribute to Atherosclero-
sis-Brief Report. Arterioscler Thromb Vasc Biol. 2019;39:150-155.
 58. Mullick AE, Yeh ST, Graham MJ, Engelhardt JA, Prakash TP and Crooke RM. Blood Pressure Lower-
ing and Safety Improvements With Liver Angiotensinogen Inhibition in Models of Hypertension 
and Kidney Injury. Hypertension. 2017;70:566-576.
 59. Ravichandran K, Ozkok A, Wang Q, Mullick AE and Edelstein CL. Antisense-mediated angioten-
sinogen inhibition slows polycystic kidney disease in mice with a targeted mutation in Pkd2. Am 
J Physiol Renal Physiol. 2015;308:F349-57.
 60. Saigusa T, Dang Y, Mullick AE, Yeh ST, Zile MR, Baicu CF and Bell PD. Suppressing angiotensinogen 
synthesis attenuates kidney cyst formation in a Pkd1 mouse model. FASEB J. 2016;30:370-9.
 61. Fitzgibbon WR, Dang Y, Bunni MA, Baicu CF, Zile MR, Mullick AE and Saigusa T. Attenuation of 
accelerated renal cystogenesis in Pkd1 mice by renin-angiotensin system blockade. Am J Physiol 
Renal Physiol. 2018;314:F210-F218.
 62. Jafar TH, Stark PC, Schmid CH, Strandgaard S, Kamper AL, Maschio G, Becker G, Perrone RD, 
Levey AS and Group ACEIiPRDS. The effect of angiotensin-converting-enzyme inhibitors on 
progression of advanced polycystic kidney disease. Kidney Int. 2005;67:265-71.
 63. Irazabal MV, Abebe KZ, Bae KT, Perrone RD, Chapman AB, Schrier RW, Yu AS, Braun WE, Steinman 
TI, Harris PC, Flessner MF, Torres VE and Investigators H. Prognostic enrichment design in clinical 
trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial. Nephrol Dial 
Transplant. 2017;32:1857-1865.
 64. Piontek KB, Huso DL, Grinberg A, Liu L, Bedja D, Zhao H, Gabrielson K, Qian F, Mei C, Westphal H 
and Germino GG. A functional floxed allele of Pkd1 that can be conditionally inactivated in vivo. J 
Am Soc Nephrol. 2004;15:3035-43.
 65. Wu G, D’Agati V, Cai Y, Markowitz G, Park JH, Reynolds DM, Maeda Y, Le TC, Hou H, Jr., Kucherlapati 
R, Edelmann W and Somlo S. Somatic inactivation of Pkd2 results in polycystic kidney disease. 
Cell. 1998;93:177-88.
 66. Cassis LA, Rateri DL, Lu H and Daugherty A. Bone marrow transplantation reveals that recipient 
AT1a receptors are required to initiate angiotensin II-induced atherosclerosis and aneurysms. 
Arterioscler Thromb Vasc Biol. 2007;27:380-6.
 67. Daugherty A, Rateri DL, Lu H, Inagami T and Cassis LA. Hypercholesterolemia stimulates angio-
tensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor. Circula-
tion. 2004;110:3849-57.
 68. Eto H, Miyata M, Shirasawa T, Akasaki Y, Hamada N, Nagaki A, Orihara K, Biro S and Tei C. The 
long-term effect of angiotensin II type 1a receptor deficiency on hypercholesterolemia-induced 
atherosclerosis. Hypertens Res. 2008;31:1631-42.
 69. Lu P, Yuan L, Wang Y, Du Q and Sheng J. Effect of GPE-AGT nanoparticle shRNA transfection system 
mediated RNAi on early atherosclerotic lesion. Int J Clin Exp Pathol. 2012;5:698-706.
112 Part 1
Salt
 70. Lu H, Wu C, Howatt DA, Balakrishnan A, Moorleghen JJ, Chen X, Zhao M, Graham MJ, Mullick AE, 
Crooke RM, Feldman DL, Cassis LA, Vander Kooi CW and Daugherty A. Angiotensinogen Exerts 
Effects Independent of Angiotensin II. Arterioscler Thromb Vasc Biol. 2016;36:256-65.
 71. Lonn E, Yusuf S, Dzavik V, Doris C, Yi Q, Smith S, Moore-Cox A, Bosch J, Riley W, Teo K and 
Investigators S. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate ca-
rotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation. 
2001;103:919-25.
 72. Shinoda E, Yui Y, Kodama K, Hirayama A, Nonogi H, Haze K, Sumiyoshi T, Hosoda S, Kawai C and 
Japan Multicenter Investigation for Cardiovascular Diseases BSG. Quantitative coronary angio-
gram analysis: nifedipine retard versus angiotensin-converting enzyme inhibitors (JMIC-B side 
arm study). Hypertension. 2005;45:1153-8.
 73. Marshall RP, Gohlke P, Chambers RC, Howell DC, Bottoms SE, Unger T, McAnulty RJ and Laurent 
GJ. Angiotensin II and the fibroproliferative response to acute lung injury. Am J Physiol Lung Cell 
Mol Physiol. 2004;286:L156-64.
 74. Otsuka M, Takahashi H, Shiratori M, Chiba H and Abe S. Reduction of bleomycin induced lung 
fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist. Thorax. 2004;59:31-
8.
 75. Li X, Rayford H and Uhal BD. Essential roles for angiotensin receptor AT1a in bleomycin-induced 
apoptosis and lung fibrosis in mice. Am J Pathol. 2003;163:2523-30.
 76. Wang R, Ibarra-Sunga O, Verlinski L, Pick R and Uhal BD. Abrogation of bleomycin-induced epi-
thelial apoptosis and lung fibrosis by captopril or by a caspase inhibitor. Am J Physiol Lung Cell 
Mol Physiol. 2000;279:L143-51.
 77. Asker SA, Mazroa SA, Boshra V and Hassan AM. Biochemical and histological impact of direct re-
nin inhibition by aliskiren on myofibroblasts activation and differentiation in bleomycin induced 
pulmonary fibrosis in adult mice. Tissue Cell. 2015;47:373-81.
 78. Li X, Zhuang J, Rayford H, Zhang H, Shu R and Uhal BD. Attenuation of bleomycin-induced 
pulmonary fibrosis by intratracheal administration of antisense oligonucleotides against angio-
tensinogen mRNA. Curr Pharm Des. 2007;13:1257-68.
 79. Ren L, Lu X and Danser AHJ. Revisiting the Brain Renin-Angiotensin System-Focus on Novel 
Therapies. Curr Hypertens Rep. 2019;21:28.
Bulleted References (12-18 month old)
Ref 2 (2019) ** Excellent review on the design and development of RNAi drugs
Ref 3 (2019) ** Overview of therapeutic oligonucleotides at this moment
Ref 36 (2019) * First evaluation of angiotensinogen antisense oligonucleotide in atherosclerosis
Ref 38 (2019) ** Extensive biochemical evaluation of angiotensinogen siRNA in hypertensive rats






renoprotective effects of small interfering 
RNA targeting liver angiotensinogen in 
experimental chronic kidney disease
Dominique M. Bovée*, Liwei Ren*, Estrellita Uijl, Marian C. Clahsen-van Groningen, 
Richard van Veghel, Ingrid M. Garrelds, Oliver Domenig, Marko Poglitsch, 
Ivan Zlatev, Jae B. Kim, Stephen Huang, Lauren Melton, 
Ewout J. Hoorn, Don Foster, A.H. Jan Danser
*D.B. and L.R. contributed equally to this work.




Small interfering RNA targeting liver angiotensinogen (AGT siRNA) lower blood pres-
sure, but their effectiveness in hypertensive chronic kidney disease (CKD) is unknown. 
Considering that the kidney may generate its own AGT, we assessed the effectiveness of 
liver-targeted AGT siRNA in the 5/6th nephrectomy (5/6Nx) rat, a hypertensive CKD model. 
Five weeks after 5/6Nx (baseline), rats were subjected to vehicle, AGT siRNA, AGT siRNA 
+ losartan, losartan, or losartan + captopril. Baseline MAP was 160±6 mm Hg. Over the 
course of 4 weeks, MAP increased further by ≈15 mm Hg during vehicle treatment. This 
rise was prevented by AGT siRNA. Losartan reduced MAP by 37±6 mm Hg, and increased 
plasma angiotensin II. Both AGT siRNA and captopril suppressed these effect of losartan, 
suggesting that its blood pressure-lowering effect relied on stimulation of vasodilator 
angiotensin II type 2 receptors by high angiotensin II levels. Proteinuria and cardiac 
hypertrophy increased with vehicle and these increases were similarly abrogated by 
all treatments. No intervention improved GFR, while siRNA and losartan equally dimin-
ished glomerulosclerosis. AGT siRNA ± losartan reduced plasma AGT by >95%, and this 
was accompanied by almost complete elimination of angiotensin II in kidney and heart, 
without decreasing renal AGT mRNA. Multiple linear regression confirmed both MAP 
and renal angiotensin II as independent determinants of proteinuria. In conclusion, AGT 
siRNA exerts renoprotection in the 5/6Nx model in a blood pressure-independent man-
ner. This relies on the suppression of renal angiotensin II formation from liver-derived 
AGT. Consequently, AGT siRNA may prove beneficial in human CKD.
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novelty AnD SignifiCAnCe
What is new?
•	 Small	 interfering	 RNA	 targeting	 liver	 angiotensinogen	 (AGT)	 provide	 cardio-	 and	
renoprotection in a blood pressure-independent manner in the 5/6th nephrectomy 
rat, a hypertensive chronic kidney disease model.
•	 Multiple	linear	regression	confirmed	both	blood	pressure	and	renal	angiotensin	II	as	




•	 Given	 its	stable	and	sustained	efficacy,	 lasting	weeks,	RNA	 interference	may	prove	
beneficial in human chronic kidney disease.
SuMMARy
Small interfering RNA (siRNA) targeting liver angiotensinogen abrogated proteinuria, 
glomerulosclerosis and cardiac hypertrophy in the 5/6th nephrectomy rat, a hypertensive 
chronic kidney disease model, to the same degree as the angiotensin II type 1 receptor 
blocker losartan. Angiotensinogen siRNA reduced plasma angiotensinogen by >95%, and 
this was accompanied by almost complete elimination of angiotensin II in kidney and 
heart. Multiple linear regression confirmed both blood pressure and renal angiotensin 
II as independent determinants of proteinuria. Given its stable and sustained efficacy, 





Treatment of chronic kidney disease (CKD) often involves the use of renin-angiotensin 
system (RAS) blockers to treat hypertension and confer renoprotection. The latter is be-
lieved to be due to interference with either the generation or effects of angiotensin (Ang) 
II at renal tissue sites. Here it has often been argued that apart from renin synthesis in 
the kidney, angiotensinogen (AGT) is also synthesized at renal tissue sites, for instance in 
the proximal tubule.1 Given the broad expression of ACE in the kidney,2 this implies that 
all components required to synthesize Ang II are present in the kidney,3 thereby allowing 
locally synthesized Ang II to exert its effects fully independently from circulating Ang II, 
i.e., by stimulating angiotensin II type 1 and 2 (AT1, AT2) receptors at renal tissue sites.
RAS blockade is hampered by counterbalancing mechanisms, the most important of 
which is renin upregulation.4 As a consequence, the degree of RAS suppression may 
be less than anticipated, even more so if organs express their own AGT. Furthermore, 
particularly during AT1 receptor blocker (ARB) treatment, the elevated Ang II levels might 
stimulate vasodilator AT2 receptors, thereby lowering blood perssure.5
A novel approach of interfering with the RAS is the use of small interfering RNAs (siRNAs) 
targeting AGT.6 Currently siRNA designs exist with hepatocyte-directed, N-acetylgalac-
tosamine (GalNAc)-conjugated molecules which allow stable suppression of hepatic 
proteins like proprotein convertase subtilisin/kexin type 9, requiring only biannual dos-
ing in humans.7 Given the hepatic origin of circulating AGT, this approach could allow 
a similar suppression of AGT. Importantly, under such circumstances counterbalancing 
renin rises should no longer be able to restore Ang II in blood, simply because AGT is 
lacking. Indeed, a GalNAc-conjugated siRNA targeting AGT was highly effective in sup-
pressing circulating AGT in spontaneously hypertensive rats (SHR),6 thereby reducing 
blood pressure to the same degree as ACE inhibitors (ACEi) and ARB. Moreover, combin-
ing this AGT siRNA with an ARB virtually eliminated Ang II, because the accompanying 
further renin rise now cleaved any remaining AGT and thus exhausted the source of 
angiotensin peptides.
A remaining question is to what degree this approach also exerts beneficial effects at 
tissue sites, in particular in the kidney, given its own AGT synthesis. Here, it should be 
noted that RAS blockade has a limit, and that too much RAS blockade (e.g., by combining 
multiple RAS blockers at the same time) may result in hypotension, acute kidney injury 
and hyperkalemia. Disappointingly, a two-week treatment of the 5/6th nephrectomy (Nx) 
rat, a CKD model which is responsive to RAS blockade,8-10 with AGT antisense oligonucle-
otides (liver-specific or non-specific) revealed no beneficial effect on proteinuria or renal 
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histology.11 Non-specific AGT suppression even impaired renal function (evidenced by a 
reduced creatinine clearance) and worsened histology, while hepatic-specific suppres-
sion was indistinguishable from vehicle treatment. Based on this, the authors argued 
that non-specific AGT suppression is potentially deleterious, because it lowers renal 
Ang II too much. Yet, they did not report renal angiotensin levels. Moreover, their results 
were obtained while exposing the 5/6th Nx rats to a very low-salt diet (0.015 % NaCl). 
Since this will greatly upregulate the dependency of renal function on the RAS, it may 
explain why no beneficial effects of AGT suppression were observed.
Therefore, in the present study we set out to investigate the effects of liver-targeted 
AGT siRNA in the same CKD model (the 5/6th Nx rat) under normal salt conditions, ap-
plying treatment for a longer time period (4 weeks) and making a comparison versus 
the ARB losartan or dual RAS blockade (AGT siRNA + losartan and captopril + losartan). 
We focused on blood pressure, proteinuria, glomerular filtration rate (GFR) and renal 
histology, and additionally measured angiotensins in blood, kidney and heart, to obtain 
a complete insight into the consequences of hepatic AGT deletion in the circulation and 
at tissue sites in this CKD model.
MethoDS
Animal studies
All animal experiments were approved by the Animal Welfare Committee of the Erasmus 
MC (protocol number 16-790-06). Male 6-weeks old Sprague-Dawley (SD) rats were 
obtained from Envigo (Huntingdon, United Kingdom) and maintained on a standard 
sodium diet. 5/6th Nx was performed in a two-step procedure as previously described.12 
Briefly, right uninephrectomy was performed under isoflurane anesthesia, followed by 
resection of the poles of the left kidney 10 days later. Right uninephrectomy was com-
bined with telemetry device (HD-S10, Data Sciences International, St. Paul, USA) implan-
tation as previously described.13, 14 Animals were allowed to recover for 5 weeks, as this 
period is necessary for the remnant kidney to attain a new steady-state condition.15 Sub-
sequently, animals were treated for 4 weeks with vehicle (n=10), AGT siRNA (10-30 mg/
kg fortnightly by subcutaneous injection, n=12; Alnylam Pharmaceuticals, Cambridge, 
MA, USA), AGT siRNA + losartan (30 mg/kg per day; n=7; Sigma Aldrich, Zwijndrecht, 
The Netherlands), losartan (n=8), or losartan + captopril (6 mg/kg per day, n=8; Sigma 
Aldrich). The siRNA consisted of a chemically modified antisense strand with sequence 
UUGAUUUUUGCCCAGGAUAGCUC, hybridized with a chemically modified sense strand 
of sequence GCUAUCCUGGGCAAAAAUCAA. Oligonucleotides were synthesized as previ-
ously described.6 To ensure selective and efficient delivery to hepatocytes, a trianten-
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nary N-acetylgalactosamine (GalNAc) – a high-affinity ligand for the hepatocyte-specific 
asialoglycoprotein receptor – was attached to the 3′ end of the sense strand.16 Two doses 
of AGT siRNA were tested (10 and 30 mg/kg), but since the degree of AGT depletion was 
identical with both doses (97.3±1.4% versus 95.9±1.1%; figure S1) data for both doses 
were combined. Losartan and captopril were administered subcutaneously by osmotic 
minipump (model 2ML4, Alzet, Cupertino, CA, USA). Four additional 5/6th Nx animals 
were sacrificed after the recovery period, to establish plasma hormone levels, protein-
uria, renal histology and cardiac hypertrophy before the start of treatment (‘baseline’). 
Eight Sprague-Dawley rats (18 weeks old, weight 407±24 g) were sacrificed to establish 
renal histology in healthy controls. Animals were allocated to treatment groups by 
stratification based on the 3-day average of mean arterial pressure (MAP) and the glo-
merular filtration rate (GFR) measured at baseline. For biochemical measurements, we 
collected 24-hour urine in metabolic cages and blood plasma by venipuncture from the 
lateral tail vein before treatment (baseline), after 2 weeks and after 4 weeks of treatment. 
Blood pressure, heart rate and animal activity were recorded continuously via radiote-
lemetry. At the end of the treatment period, rats were anaesthetized by inhalation of 
isoflurane and exsanguinated: 1 mL blood was collected in 10 mL of 4 mol/L guanidine 
thiocyanate17 (Sigma Aldrich) and used for quantification of angiotensin metabolites; 
remaining blood was supplemented with EDTA and centrifuged at 16000 x g to obtain 
plasma. Kidneys and heart were harvested, weighed, divided into transverse segments, 
and fixated in 4% paraformaldehyde for histological analysis, or snap frozen in liquid 
nitrogen for gene - and protein expression analysis. Mesenteric arteries were isolated 
and used directly in myograph studies.
Biochemical measurements
In plasma, AGT was measured by enzyme kinetic assay as the maximum quantity of Ang 
I generated during incubation, at pH 7.4 and 37°C, with rat kidney renin in the presence 
of a mixture of ACE, angiotensinase, and serine protease inhibitors.18 The lower limit of 
detection of this assay was 0.2 nmol/L. Plasma renin was measured by quantifying Ang 
I generation in the presence of excess porcine AGT (detection limit 0.17 ng Ang I/mL 
per hour).19 In the cases that measurements were at or below the detection limit, this 
limit was applied to allow for statistical analysis. Ang metabolites in plasma, kidney, and 
heart tissue (left ventricle) were measured by LC-MS/MS analysis as described before.20 
Briefly, tissue samples were homogenized under liquid nitrogen and extracted with a 
guanidinium-based extraction buffer. Stabilized whole blood and tissue extracts were 
spiked with stable isotope labeled internal standards for each individual target analyte 
(Sigma Aldrich) before being subjected to C18 based solid phase extraction and subse-
quent LC-MS/MS analysis. table S1 specifies the lower limit of quantification for each 
metabolite. Plasma NT-proBNP was measured with a rat NT-proBNP ELISA kit (detec-
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tion limit 15.6 pg/mL; Aviva Systems Biology, San Diego, USA). Urine total protein was 
measured by the clinical chemistry laboratory of the Erasmus MC. Urinary neutrophil 
gelatinase-associated lipocalin (NGAL) was measured with a rat NGAL ELISA kit (detec-
tion limit 0.1 pg/mL; Abcam, Cambridge, UK).
Quantitative polymerase chain reaction (qPCR)
Total RNA was isolated from snap-frozen kidney using TRI Reagent (Sigma Aldrich) and 
reverse transcribed into cDNA using the QuantiTect Reverse Transcription Kit (Qiagen, 
Venlo, The Netherlands). cDNA was amplified in triplicate in 40 cycles (denaturation at 
95°C for 3 min; thermal cycling at 95°C for 3 sec, annealing/extension at 60°C for 20 sec) 
followed by a melt curve with a CFX384 (Bio-Rad, Veenendaal, The Netherlands) using 
Kapa SYBR® Fast (Kapa Biosystems). Intron-spanning oligonucleotide primers were 
designed with NCBI Primer-BLAST for AGT (forward CCAGCACGACTTCCTGACT, reverse 
GCAGGTTGTAGGATCCCCGA), renin (forward TGTGGTAACTGTGGGTGGAAT, reverse GCAT-
GAAGGGTATCAGGGGC) and β2-microglobulin (B2M; forward ATGGCTCGCTCGGTGACCG, 
reverse TGGGGAGTTTTCTGAATGGCAAGCA). The DDCt method was used for relative 
quantification of mRNA expression levels, using the housekeeping gene B2M for nor-
malization.
Kidney function
Glomerular filtration rate (GFR) was determined at baseline and at the end of treatment, 
by transcutaneous measurement of fluorescein isothiocyanate (FITC)-labeled sinistrin 
(Mannheim Pharma & Diagnostics GmbH, Mannheim, Germany), administered as a bo-
lus injection (0.24 mg/kg dissolved in saline) via the tail vein. A non-invasive clearance 
(NIC)-kidney fluorescent detection device together with partner software (Mannheim 
Pharma & Diagnostics GmbH) were used to generate the elimination kinetics curve of 
FITC-sinistrin. GFR was derived from the excretion half-life (t1/2) of FITC-sinistrin, using a 
conversion factor and formula validated for rats21:
GFR (mL/min per 100g body weight (BW)) = 31.26 (mL/100g BW) / t1/2 FITC-sinistrin 
(minutes).
histology
Kidney segments, fixed in 4% paraformaldehyde, were dehydrated and paraffin-embed-
ded. Transversely sliced and deparaffinized kidney sections (2 mm) were stained with 
periodic acid–Schiff (PAS) and scored semiquantitatively in a blinded fashion by a renal 
pathologist (M.C.C.v.G.) as previously described.22 Focal segmental glomerulosclerosis 
(FSGS) was assessed and graded in all glomeruli of one kidney section per rat, basing on 
an arbitrary scale wherein 0%, <25%, 25-50%, 50-75%, and >75% of glomerular sclerosis 
were represented by grade zero (n0), 1 (n1), 2 (n2), 3 (n3), and 4 (n4), respectively. The 
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glomerulosclerosis index (GSI) was calculated with the formula: [(1χn1)+(2χn2)+( 3χn3)+( 
4χn4)]/(n0+n1+n2 +n3+n4). Tubular atrophy, interstitial fibrosis, and tubulointerstitial 
inflammation were scored in the same kidney section and summed to obtain the tubu-
lointerstitial score (TIS). A score of 0-3 indicated that <25% of tubulointerstitial tissue 
was affected, a score of 4–6 indicated 25–50% and a score of 7–9 indicated >50%. Finally, 
observing dilated tubules and acute thrombotic microangiopathy was used as an indi-
cation of hypertensive kidney injury.
Myograph studies
Mesenteric arteries were carefully dissected and placed in a cold, Krebs bicarbonate 
solution (composed as follows [in mmol/L]: NaCl, 118; KCl, 4.7; CaCl2, 2.5; MgSO4, 1.2; 
KH2PO4, 1.2; NaHCO3, 25 and glucose, 8.3; pH = 7.4), aerated with 5% CO2 in O2 (carbogen). 
Arteries were cut into 2 mm segments and mounted in Mulvany myographs (Danish Myo 
Technology, Aarhus, Denmark) with 6-mL organ baths containing oxygenated Krebs buf-
fer and maintained at 37°C. Changes in tissue tension were measured using a LabChart 
data acquisition system (AD Instruments Ltd, Oxford, UK). After equilibration for at least 
30 min and a wash, the vessel segments were stretched to a tension normalized to 90% 
of 100 mm Hg. After reaching equilibrium, the contractile capacity of the mesenteric 
arteries was examined by adding 30 mmol/L KCl. After washout, the tissue was exposed 
to 100 mmol/L KCl to determine the maximal contraction. Endothelial function was 
checked by verifying relaxation to 10 mmol/L acetylcholine after preconstriction with 
the thromboxane A2 analogue U46619 (10 nmol/L) to >70% of the maximal contraction. 
Next, segments were equilibrated in fresh Krebs buffer for 30 min, and preincubated 
for 30 min with the NO synthase inhibitor L-NAME (Nω-nitro-L-arginine methyl ester 
hydrochloride; 100 μmol/L), the small- and intermediate-conductance Ca2+-activated K+-
channel (SKCa , IKCa) inhibitors apamin (100 nmol/L) and TRAM34 (10 μmol/L), the endo-
thelin type A (ETA) receptor antagonist BQ123 (1 μmol/L), or the ETB receptor antagonist 
BQ788 (1 μmol/L). Thereafter, concentration-response curves (CRCs) were constructed 
to ET-1. To construct CRCs to the endothelium-dependent dilator acetylcholine (ACh) 
arteries were preconstricted with U46619. All drugs were obtained from Sigma-Aldrich.
Statistics
Data are expressed as mean values ± SEM in case of normal distribution and median 
with interquartile range in case of non-normal distribution. Non-normally distributed 
data were log-transformed before statistical analysis. Data were analyzed by one-way 
analysis of variance (ANOVA) and mixed linear models, using treatment and time as 
fixed effects, if appropriate. If significant, selected post-hoc analyses were performed 
between individual groups by controlling for a false-discovery rate of 5%.23 Relaxant 
responses to either ACh or SNAP are expressed as a percentage of the contraction to 
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U46619. Contractile responses to ET-1 are expressed as a percentage of the contraction 
to 100 mmol/L KCl. CRCs were analyzed as described before24 to obtain pEC50 (-10logEC50) 
and Emax values. Data obtained at multiple points in time were analyzed using a repeat-
ed-measures two-way ANOVA, followed by post-hoc correction according to Dunnett 
or Dunn in case of multiple comparisons, if appropriate. Univariate linear associations 
were assessed by calculation of Pearson’s coefficient of correlation. Two-tailed P values 
<0.05 were considered statistically significant. Multiple linear regression analysis was 
applied to determine the variables affecting proteinuria. All analyses were performed 
using Prism version 9.0.0 (GraphPad Software Inc., La Jolla, USA)
ReSultS
Agt siRnA halts the blood pressure rise in the 5/6th nx model
We have reported earlier that MAP in healthy SD rats is 103±1 mm Hg (n=7).25 At 5 weeks 
after 5/6th Nx  (‘baseline’) MAP had increased to 160±6 mm Hg (n=47; figure 1A). MAP 
increased further to 174±5 mm Hg during the subsequent 4 weeks of vehicle treatment. 
AGT siRNA treatment prevented this increase (P<0.05 versus vehicle; figures 1A and 
1B). Losartan lowered MAP by 37±6 mm Hg, P<0.001 versus vehicle). Adding either AGT 
siRNA or captopril on top of losartan diminished (P<0.05 versus losartan) the effect of 
losartan, yielding MAP decreases of 22±7 and 21±6 mm Hg, respectively (both P<0.001 
versus vehicle). As a consequence, MAP was identical during treatment with AGT siRNA 
alone, AGT siRNA + losartan and losartan + captopril, while it was lower in the losartan 
alone group versus the AGT siRNA alone group (P<0.05). No treatment affected heart rate 
(figure 1C), activity (figure 1D), body weight, or food intake (table S2).
Agt SiRnA SuPPReSSeS the CiRCulAting RAS
Plasma renin levels in healthy SD rats are 11.8±0.8 ng Ang I/mL per hour.25 At 5 weeks 
after 5/6th Nx, renin had decreased to 2.6 (range 0.8-3.9) ng Ang I/mL per hour (figure 
2A). All treatments modestly increased renin, although significance (P<0.05 versus 
baseline) was reached for losartan only (at 2 weeks). Plasma renin correlated negatively 
with MAP (figure 2B). As expected, AGT siRNA, either alone or with losartan, diminished 
plasma AGT by >95% (figure 2C). No other treatment affected circulating AGT. Losartan 
increased plasma Ang I (P<0.001 versus vehicle) and II (P<0.01) (figures 2D and 2e), 
while in combination with captopril only plasma Ang I increased (P<0.001). AGT siRNA 
reduced plasma Ang I (P=0.07) and II (P<0.05) in parallel, with the plasma Ang I levels 
becoming undetectable in most animals. Combining AGT siRNA with losartan yielded 
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virtually identical Ang I and II levels as AGT siRNA alone. Only captopril reduced the 
Ang II/I ratio (table S1). Neither Ang-(1-7), nor Ang III or IV were detectable in blood 




 figure 1. Mean arterial pressure (MAP; panel A), ΔMAP (panel B), heart rate (beats per minute, BPM; panel 
C), and locomotor activity (panel D) in Sprague-Dawley rats subjected to 5/6th nephrectomy, and treated 
with either vehicle, angiotensinogen (AGT) siRNA, AGT siRNA + losartan, losartan, or losartan + captopril 
for 28 days. Treatment was started after 5 weeks of recovery. Data are mean±SEM of n=7-12. *P<0.05, 
***P<0.001 versus vehicle; #P<0.05, &P<0.01, %P<0.001 versus indicated group.
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figure 2. Renin (panel A), angiotensinogen (panel C), angiotensin I (panel D) and angiotensin II (panel E) 
in blood plasma of Sprague-Dawley rats subjected to 5/6th nephrectomy, and treated with either vehicle, 
angiotensinogen (AGT) siRNA, AGT siRNA + losartan, losartan, or losartan + captopril for 28 days. Treatment 
was started after 5 weeks of recovery (=baseline). Data are mean±SEM of n=7-12. Panel B displays the rela-
tionship between plasma renin and mean arterial pressure (MAP) during the last 3 treatment days. *P<0.05, 
**P<0.01, ***P<0.001, ***P<0.001 versus indicated group. LLOQ, lower limit of quantification.
Agt SiRnA AnD the RenAl RAS
AGT siRNA, as well as the other treatments, tended to upregulate renal renin expression 
(figure 3A), but no significance was reached. Renal renin expression correlated closely 
(P<0.001) with plasma renin levels (figure 3B). AGT siRNA did not affect renal AGT 
expression (figure 3C), in agreement with its liver-specificity, nor did any of the other 
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treatments affect this expression. Yet, AGT siRNA greatly suppressed renal Ang I and II 
levels (P<0.01 versus vehicle for both; (figures 3D and 3e), while in combination with 
losartan, renal Ang I and II were virtually eliminated (P<0.0001 versus AGT siRNA alone). 
Losartan, with or without captopril, did not affect renal Ang I. Losartan when given 
alone, modestly reduced renal Ang II (P<0.05 versus vehicle), while in combination with 
captopril, it reduced renal Ang II more strongly (P<0.01). As a consequence, the renal Ang 
II/I ratio decreased during both losartan alone and losartan + captopril (P<0.001 versus 
 
figure 3. Renin expression (panel A), angiotensinogen expression (panel B), angiotensin I (panel D), and 
angiotensin II (panel E) in kidneys of Sprague-Dawley rats subjected to 5/6th nephrectomy, and treated with 
either vehicle, angiotensinogen (AGT) siRNA, AGT siRNA + losartan, losartan, or losartan + captopril for 28 
days. Treatment was started after 5 weeks of recovery. Data are mean±SEM of n=7-12. Panel B displays the 
relationship between plasma renin and renal renin expression. *P<0.05, **P<0.01, ***P<0.001, ***P<0.001 
versus indicated group. LLOQ, lower limit of quantification.
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vehicle; table S1), but not during the other treatments. Renal Ang III and Ang IV levels 
were low in the 5/6th Nx model, and rapidly became undetectable after most treatments 
(table S1). In contrast, renal Ang-(1-7) levels were of similar magnitude as the renal Ang 
II levels, and decreased in parallel with Ang I and II after siRNA (with or without losartan), 
but not after losartan alone or losartan + captopril
Agt SiRnA iS RenoPRoteCtive
GFR in healthy SD rats is 1.0±0.04 mL/min per 100 g body weight.25 At 5 weeks after the 
5/6th Nx procedure, GFR had decreased to 0.38±0.10 mL/min per 100 g body weight. 
Neither vehicle, nor any treatment affected GFR over the next 4 weeks (figure 4A). None 
of the treatments altered water intake (table S2), urinary volume (table S2) or urinary 
NGAL excretion (figure 4B), although losartan, with or without AGT siRNA, did tend to 
reduce the latter (P=NS). Proteinuria (13 (range 8.5-16) mg/day in healthy SD rats (n=73, 
unpublished results) was 140 (range 92-170) mg/day at 5 weeks after 5/6th Nx. It rapidly 
increased further during vehicle treatment, and all treatments, whether given alone or 
in combination, fully prevented this rise (figure 4C). Proteinuria correlated significantly 
with MAP (P<0.001; figure 4D) and renal Ang II (P=0.03; figure 4e). Multiple linear regres-
sion confirmed that both MAP (coefficient 0.693, P<0.0001) and renal Ang II (coefficient 
0.246, P=0.023) were independent determinants of proteinuria (adjusted R2=0.60).
FSGS, GSI and TIS all increased over the 8 week period after 5/6th Nx (figure 5), although 
statistical significance for the latter was not reached (P=0.06). The significant increases 
in kidney injury scores versus healthy control disappeared after all treatments, except 
after the treatment with losartan + AGT siRNA. The number of rats with dilated tubules 
increased from 0 out of 8 (0/8) in the healthy control group, to 2/4 at baseline and 
7/10 after 4 weeks of vehicle exposure. Acute thrombotic microangiopathy featured in 
these groups in 0/8, 2/4, and 5/10 rats, respectively, with arterial involvement in 1/10 of 
vehicle-treated rats. AGT siRNA, AGT siRNA + losartan, losartan, and losartan + captopril 
reduced the number of rats with dilated tubules to 5/12, 2/7, 2/8 and 4/8, and acute 
thrombotic microangiopathy to 4/12, 2/7, 1/8, and 2/8 rats (with arterial involvement in 
2/12 AGT siRNA-treated rats and 1/8 losartan + captopril-treated rats) respectively. These 








figure 4. Glomerular filtration rate (GFR, expressed as change versus baseline; panel A), urinary NGAL ex-
cretion (panel B), and proteinuria (panel C) in kidneys of Sprague-Dawley rats subjected to 5/6th nephrecto-
my, and treated with either vehicle, angiotensinogen (AGT) siRNA, AGT siRNA + losartan, losartan, or losar-
tan + captopril for 28 days. Treatment was started after 5 weeks of recovery (=baseline). Data are mean±SEM 
of n=7-12. Panels D and E show the relationship between proteinuria at 4 weeks and mean arterial pressure 
(MAP) during the last 3 treatment days and the renal angiotensin II levels, respectively. *P<0.05, **P<0.01, 
***P<0.001 versus indicated group.
Chapter 5 129
Blood pressure-independent renoprotective effects of small interfering RNA targeting liver angiotensinogen 
in experimental chronic kidney disease
Agt SiRnA iS CARDioPRoteCtive
Cardiac Ang I and II levels in vehicle-treated 5/6th Nx rats were close to or below detection 
limit (figures 6A and 6B). siRNA, with or without losartan, lowered these levels even 
further (P<0.05 vs. vehicle), while losartan alone and losartan + captopril upregulated 
cardiac Ang I (P<0.05). Losartan did not alter cardiac Ang II, while losartan + captopril 
lowered cardiac Ang II (P<0.05). As a consequence, the Ang II/I ratio decreased after both 
losartan and losartan + captopril (P<0.05; table S1). All other angiotensin metabolites 
were undetectable in cardiac tissue of 5/6th Nx rats, and only after losartan and losartan 
+ captopril did Ang-(1-7) occasionally rise above lower limit of quantification (P=NS). No 
treatment lowered NT-proBNP (figure 6C). Yet, all treatments equally prevented the rise 
in HW/TL ratio that occurred over the 4 week period after starting therapy (figure 6D). 
The HW/TL ratio correlated strongly with MAP (P<0.001; figure 6e), but not with cardiac 





figure 5. Focal segmental glomerulosclerosis (FSGS; panel A), glomerulosclerosis index (GSI; panel B), and 
tubulointerstitial score (TIS, panel C) in kidneys of Sprague-Dawley rats subjected to 5/6th nephrectomy, 
and treated with either vehicle, angiotensinogen (AGT) siRNA, AGT siRNA + losartan, losartan, or losartan + 
captopril for 28 days. Treatment was started after 5 weeks of recovery (=baseline), and data in healthy rats 
have been added for comparison. Data are mean±SEM of n=7-12. Panels D-G show representative, PAS-
stained renal histological images of different types of damage illustrating a normal kidney (D), dilated tu-
bules (E), thrombotic microangiopathy of glomeruli and arteriole (F), and a thrombus in a main large vessel 
(G). NS, not significant, *P<0.05, **P<0.01, ***P<0.001 versus indicated group.
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5/6th nx DoeS not AlteR vASCulAR funCtion
Acetylcholine fully relaxed U46619-preconstricted mesenteric arteries of 5/6th Nx rats 
(figure S2 and table S3). Blocking NO (with L-NAME) or EDHF (with TRAM34+apamin) 
marginally prevented this relaxation, and only when combining L-NAME with TRAM34+ 
 
 
figure 6. Cardiac angiotensin I (panel A), cardiac angiotensin II (panel B), plasma NT-proBNP (panel C), 
and heart weight/tibia length ratio (panel D) in Sprague-Dawley rats subjected to 5/6th nephrectomy, and 
treated with either vehicle, angiotensinogen (AGT) siRNA, AGT siRNA + losartan, losartan, or losartan + 
captopril for 28 days. Treatment was started after 5 weeks of recovery (=baseline). Data are mean±SEM of 
n=7-12. Panel  E shows the relationship between cardiac hypertrophy (heart weight/tibia length ratio) and 
mean arterial pressure (MAP) during the last 3 treatment days. NS, not significant, *P<0.05, **P<0.01 versus 
indicated group. LLOQ, lower limit of quantification.
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apamin, did the blockade become significant. This indicates that the ACH response de-
pends on both NO and EDHF, and that the two pathways are interchangeable. No treat-
ment altered this outcome. ET-1 strongly constricted mesenteric arteries of 5/6th Nx 
rats, and the ETA receptor antagonist BQ123, but not the ETB receptor antagonist BQ788, 
blocked this constriction, indicating that it depended entirely on ETA receptor stimula-
tion. No treatment altered this outcome.
DiSCuSSion
This study is the first to demonstrate reno- and cardioprotection in the rat 5/6th Nx model 
after a 4-week treatment with liver-directed AGT siRNA. The model is characterized by 
hypertension, cardiac hypertrophy, proteinuria, reduced GFR, glomerulosclerosis and 
tubulointerstitial fibrosis, and therefore recapitulates important characteristics of 
CKD.26 Although it is known to be responsive to RAS blockade,8-10 we found circulating 
RAS activity in the 5/6th Nx rat to be greatly reduced, while renin upregulation during 
RAS blockade was barely detectable. This may simply reflect the fact that 5/6th of the 
kidneys was removed, reducing the capacity of the kidneys to release renin and/or to 
respond appropriately to RAS blockade.27 In contrast, renin rises during RAS blockade 
(including angiotensinogen suppression) in salt-depleted humans4 and spontaneously 
hypertensive rats6 can easily be >100-fold, thereby allowing Ang II levels to stay in the 
normal range, even when blocking the system by >99%.
We compared the effect of AGT siRNA in the 5/6th Nx model with that of the ARB losartan 
and the ACE inhibitor captopril, two drugs that are commonly used in CKD. Treatment 
was started at 5 weeks after 5/6th Nx, when blood pressure had already increased by 
≈≈60 mm Hg. Clearly, given the >75% reduction in circulating RAS activity, the Ang II-AT1 
receptor axis is unlikely to be a major mediator of this blood pressure rise. Nevertheless, 
losartan did lower blood pressure by 37 mm Hg. This was accompanied by renin and 
Ang II rises. Remarkably, when combining losartan with either AGT siRNA or captopril, 
its blood pressure-lowering effect was diminished, while AGT siRNA alone did not lower 
blood pressure, although it did prevent a further rise in blood pressure after the initial 
5 week period. As a consequence, after 4 weeks of treatment MAP was lower in the 
losartan group than in the AGT siRNA group, while MAP in the losartan + AGT siRNA and 
losartan + captopril groups was identical to that in the AGT siRNA alone group (i.e., ≈40 
mm Hg above that in healthy SD rats25). The most likely explanation for these observa-
tions is that losartan, by upregulating Ang II, allowed concomitant AT2 receptor stimula-
tion, which would result in more substantial blood pressure lowering (given that AT2 
receptors cause vasodilation28-30) than might be expected from blockade of the Ang II-AT1 
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receptor axis alone. This is not possible in combination with either siRNA or captopril, 
since these drugs prevented such a rise in circulating Ang II. However, the relevance of 
AT2 signaling in humans is unclear. Despite the difference in blood pressure reduction, 
losartan, AGT siRNA and losartan + captopril reduced cardiac hypertrophy, proteinuria 
and glomerulosclerosis similarly, and a favorable trend was observed for the tubuloin-
terstitial score and urinary NGAL. These protective effects in kidney and heart therefore 
must reflect the consequence of local RAS blockade. Indeed, AGT siRNA lowered the 
cardiac and renal Ang I and II levels more strongly than the circulating Ang I and II levels. 
Taken together, these data illustrate that cardiac and renal angiotensin generation de-
pend on liver-derived AGT, accumulating at tissue sites either via diffusion or by active 
uptake mechanisms. Our data do not support the concept11 that renal Ang II production 
in the 5/6th Nx rat depends on locally produced AGT and that liver-targeting of AGT siRNA 
would keep renal Ang II formation intact. We stress that AGT mRNA expression did occur 
in renal tissue of the 5/6th Nx rat. In agreement with the liver-specificity of our GalNAc-
labeled siRNA, this expression was unaltered after AGT siRNA, nor was it altered by any 
of the other treatments. Yet, when treating the rats with AGT siRNA + losartan, renal Ang 
II entirely disappeared. The strong suppression of renal Ang II after AGT siRNA + losartan 
lowered proteinuria and cardiac hypertrophy to the same degree as single treatment, 
but no longer improved glomerulosclerosis. This observation supports the concept that 
complete elimination of the renal RAS is undesirable, and may underlie the renal side-
effects of conventional dual and triple RAS blockade.31, 32 However, the latter particularly 
concerns a reduction in GFR, and this was not observed in the present study. In fact, no 
treatment affected the ≈60% GFR reduction in our model, although GFR improvement 
has been observed previously in 5/6th Nx rats after RAS blockade.10 This may relate to the 
larger (>75%) GFR reduction in those earlier studies.
Proteinuria correlated with MAP and the renal Ang II levels. A unifying concept to explain 
our data is therefore that both a decrease in blood pressure and a decrease in renal 
Ang II improve proteinuria, most likely in an additive manner, and involving a reduction 
in glomerulosclerosis. Multiple linear regression confirmed this view. Hence, losartan 
predominantly exerts its effects via blood pressure lowering (likely depending on AT2 
receptor stimulation), while siRNA rather acts by suppressing renal Ang II. A similar 
mechanism (blood pressure lowering and suppression of tissue Ang II generation33) 
may underlie the improvement of cardiac hypertrophy, although the heart weight/tibia 
length ratio correlated significantly with blood pressure only, and not with cardiac Ang 
II. The latter could relate to the fact that cardiac Ang II levels after treatment were often 
below detection limit. No effect of any treatment on NT-proBNP was observed, possibly 
because the blood pressure-lowering effects (with the exception of that of losartan 
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alone) were modest, so that atrial stretch (a major stimulant of BNP synthesis) would be 
reduced only mildly.
Both captopril and losartan suppressed the Ang II/I ratio in kidney and heart. In the case 
of captopril, this simply reflects the degree of ACE inhibition. In the case of losartan, 
like during ACE inhibition, there will be renin upregulation, resulting in enhanced Ang I 
generation. Ang II generation should increase in parallel. However, tissue Ang II reflects 
Ang II that has been internalized via AT1 receptors,33, 34 and consequently, given the fact 
that losartan inhibits this process, ARB treatment may indeed lower the tissue Ang II/I 
ratio, albeit without affecting the Ang II/I ratio in the circulation. Ang-(1-7) has been sug-
gested to be responsible for the beneficial effects of RAS blockade in both kidney and 
heart, as it counteracts the Ang II-AT1 receptor axis.35 In the present study Ang-(1-7) was 
not detectable in either blood or cardiac tissue of 5/6th Nx rats, although it was present 
in the kidney. Nevertheless, AGT siRNA eliminated renal Ang-(1-7), thereby implying that 
its beneficial effects are unrelated to this peptide.
In summary, liver-targeted AGT siRNA exerts beneficial renal and cardiac effects in the 
5/6th Nx rat despite the fact that this is a low-renin CKD model. Its tissue effects are 
likely to represent the maximum effect of RAS blockade, since adding losartan on top of 
AGT siRNA (or combining losartan with captopril) yielded a similar degree of reno- and 
cardioprotection. These effects occur in a blood pressure-independent manner, and 
reflect the dependency of both renal and cardiac Ang II on liver-derived AGT. In view of 
the potential long-lasting effects of siRNA treatment (as with inclisiran, which is dosed 
every six months7) targeting hepatic AGT offers new possibilities for the treatment of 
CKD in humans, especially in non-adherent patients. Future studies will be needed to 
understand both the long-term risks and benefits of such long-term tissue RAS suppres-
sion, considering that too much renal Ang II suppression may not be desirable.
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Ang-(1-10) = Ang i 17 (4, 31) 4 (<3, 3) 6 (<3, 3) 295 (44, 522) & 572 (31, 1098) &
Ang-(1-8) = Ang ii 19 (10, 27) 8 (5, 10) * 9 (4, 15) 145 (30, 189) # 32 (7, 61)
Ang-(1-7) <8 <8 <8 9 (8, 8) 16 (8, 25) *
Ang-(2-8) = Ang iii <3 <3 <3 11 (<3, 14) # 3 (<3, 3)








Ang-(1-10) = Ang i 394 (88, 755) 37 (10, 59) # <6 # 604 (437, 777) 399 (243, 576)
Ang-(1-8) = Ang ii 345 (129, 602) 71 (23, 115) # 4 (3, 3) & 113 (60, 174) * 35 (14, 46) &
Ang-(1-7) 261 (58, 486) 25 (<19, 19) $ <19$ 235 (173, 273) 164 (107, 251)
Ang-(2-8) = Ang iii 14 (<6, 23) 6 (<6, 14) # <6 # <6 # <6 #








Ang-(1-10) = Ang i 8 (6, 10) <6 <6 39 (7, 73) * 46 (6, 47) *
Ang-(1-8) = Ang ii 5 (<3, 7) 3 (<3, 3) * <3* 4 (<3, 7) 3 (<3, 4) *
Ang-(1-7) <19 <19 <19 28 (<19, 31) 30 (<19, 31)
Ang-(2-8) = Ang iii <6 <6 <6 <6 <6




0.52(0.50, 0.50) 0.50(0.50, 0.50) 0.26 (0.08, 0.44) #
0.24 (0.07, 
0.50) #
table S1. Angiotensin (Ang) metabolites measured by LC-MS/MS in blood, kidney, and heart in Sprague-
Dawley rats subjected to 5/6th nephrectomy, and treated with either vehicle, angiotensinogen (AGT) siRNA, 
AGT siRNA + losartan, losartan, or losartan + captopril for 28 days. Treatment was started 5 weeks after 5/6th 
Nx. Data are mean and interquartile range of n=7-12. All data were log-transformed to perform one-way 




parameter vehicle Agt siRnA





body weight (g) 379±11 378±8 388±18 390±14 411±9
Δtreatment 38±8 38±7 46±9 49±8 57±5
food intake 
(mg/day)
baseline 21±1 21±1 21±1 22±1 23±1
T=2 weeks 19±1 21±1 21±1 21±2 21±1
T=4 weeks 17±2 22±4 20±1 21±2 21±1
water intake 
(mL/day)
baseline 52±3 50±3 50±4 51±5 52±2
T=2 weeks 55±3 62±3 56±4 51±6 56±4
T=4 weeks 56±7 48±6 59±6 54±6 60±4
urine (mL/day)
baseline 39±3 34±3 36±4 37±4 37±3
T=2 weeks 44±4 41±3 38±4 37±4 40±5
T=4 weeks 40±3 39±2 39±6 37±4 41±3
table S2. Growth, food and water intake, and 24 hour-urine parameters of Sprague-Dawley rats subjected 
to 5/6th nephrectomy, and treated with either vehicle, angiotensinogen (AGT) siRNA, AGT siRNA + losartan, 
losartan, or losartan + captopril for 28 days. Treatment was started 5 weeks after 5/6th Nx (=baseline), and 
measurements were performed at baseline, after 2 weeks and after 4 weeks of treatment. Data (mean ± SEM 
of n=7-12) were analyzed by paired t-test (baseline vs. 4 weeks) or one-way ANOVA followed by post-hoc 
correction according to Bonferroni.
peC50 control Agt siRnA siRnA+losartan losartan losartan+captopril
ACh 8.0±0.3 8.0±0.2 7.9±0.3 8.5±0.5 8.2±0.3
ACh+L-NAME 7.9±0.4 8.0±0.2 7.6±0.2 7.6±0.3 8.2±0.4
ACh+T+A 7.2±0.2 7.5±0.1 7.2±0.3 7.4±0.2 7.4±0.2
ACh+L-NAME+T+A 7.5±0.4 7.3±0.3 7.4±0.5 7.4±0.6 7.2±0.5
ET-1 8.2±0.1 8.3±0.1 8.3±0.1 8.1±0.2 8.2±0.1
ET-1+BQ123 7.0±0.1* 7.2±0.1 # 7.1±0.04 # 7.2±0.1* 7.0±0.03 &
ET-1+BQ788 8.3±0.5 8.3±0.3 8.4±0.4 8.3±0.3 8.2±0.1
emax control Agt siRnA siRnA+losartan losartan losartan+captopril
ACh 82.6±5.1 90.9±2.7 78.9±8.6 82.3±9.2 84.2±3.4
ACh+L-NAME 70.9±9.0 76.0±6. 65.1±7.9 58.1±11.6 66.9±7.2
ACh+T+A 63.8±11.7 84.8±3.7 68.0±10.3 79.0±7.9 77.0±6.2
ACh+L-NAME+T+A 29.0±6.9 & 43.6±7.0 & 36±7.8 # 45.7±11.7 30.2±5.4 &
ET-1 134.8±11.6 113.4±5.0 134.7±14.4 138.5±14.6 120.6±11.1
ET-1+BQ123 75.0±11.5* 105.6±11.1 110.1±9.2 117.7±20.9 94.4±8.3
ET-1+BQ788 129.7±18.4 107.1±9.6 141.8±19.3 131.1±7.1 114.1±12.4
table S3. Emax (maximum effect) and pEC50 (the negative logarithm of the half-Emax concentration) for vascu-
lar response to acetylcholine (ACh) and endothelin-1 (ET-1) in mesenteric arteries of Sprague-Dawley rats 
subjected to 5/6th nephrectomy, and treated with either vehicle, angiotensinogen (AGT) siRNA, AGT siRNA + 
losartan, losartan, or losartan + captopril for 28 days. Treatment was started 5 weeks after 5/6th Nx. ACh re-
sponses were studied in the absence (control) or presence of the inhibitors L-NAME, TRAM34+apamin (T+A), 
or L-NAME+T+A. ET-1 responses were studied in the absence (control) or presence of the endothelin recep-
tor blockers BQ123 and BQ788. Data (mean ± SEM of n=5-11) were analyzed by one-way ANOVA followed 
by post-hoc correction according to Bonferroni. *P<0.05, #P<0.01, &P<0.001, $P<0.0001 vs. no inhibitor.
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figure S1. Plasma angiotensinogen (AGT) in Sprague-Dawley rats subjected to 5/6th nephrectomy, and 
treated with AGT siRNA 10 or 30 mg/kg biweekly. Treatment was started 5 weeks after 5/6th Nx (=baseline), 
and measurements were performed at baseline, after 2 weeks, and after 4 weeks of treatment. Data are 







figure S2. Vascular response to acetylcholine and endothelin-1 in mesenteric arteries of Sprague-Dawley 
rats subjected to 5/6th nephrectomy, and treated with either vehicle, angiotensinogen (AGT) siRNA, AGT 
siRNA + losartan, losartan, or losartan + captopril for 28 days. Treatment was started 5 weeks after 5/6th 
Nx. Panel A shows the relaxant responses to acetylcholine, expressed as a percentage of the U46619-in-
duced preconstriction, in the absence (control) or absence the inhibitors TRAM34+apamin, L-NAME, and 
L-NAME+TRAM34+apamin. Panel B shows the responses to endothelin-1, expressed as a percentage of the 
response to 100 mmol/L KCl in the absence (control) or presence of the endothelin receptor blockers BQ123 
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Background: Distal diuretics are considered less effective in CKD, but data to support 
this are limited. Here, we hypothesize that distal diuretics are non-inferior to dietary 
sodium restriction in reducing blood pressure in patients with CKD and hypertension.
Methods: In patients with CKD stage G3 or G4 and hypertension, we discontinued anti-
hypertensive drugs and performed a 6-week randomized open-label cross-over trial to 
compare amiloride/hydrochlorothiazide (5/50 mg/day) with dietary sodium restriction 
(60 mmol/day). We analyzed effects on blood pressure, kidney function, and fluid bal-
ance and related this to renal clearance of diuretics.
Results: Twenty-six patients (eGFR 39 ± 13 ml/min/1.73m2) completed both treatments. 
Dietary sodium restriction reduced sodium excretion from 160 to 64 mmol/day. Diuretics 
reduced 24-hour systolic blood pressure more than sodium restriction (138 to 124 vs. 
134 to 129 mmHg, P < 0.05). Both interventions decreased body weight and NT-pro-BNP 
similarly, whereas diuretics had a significantly greater effect on extracellular water, 
eGFR, plasma renin and aldosterone. Neither intervention decreased albuminuria 
significantly, whereas diuretics did significantly reduce urinary angiotensinogen and 
β2-microglobulin excretion. Lower eGFR and higher plasma indoxyl sulfate correlated 
with lower diuretic clearance. However, the diuretic effects on body weight and blood 
pressure at lower eGFR were maintained. During diuretic treatment, higher prostaglan-
din E2 excretion correlated with lower free water clearance, and four patients developed 
mild hyponatremia.
Conclusions: Distal diuretics are non-inferior to dietary sodium restriction in reducing 
blood pressure and extracellular volume in CKD. Diuretic sensitivity in CKD is maintained 
despite lower diuretic clearance.
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SignifiCAnCe StAteMent
Chronic kidney disease (CKD) is characterized by increased extracellular volume and 
salt-sensitive hypertension. It is unknown whether dietary or pharmacological ap-
proaches are preferable to reduce sodium in CKD and whether distal diuretics are still 
effective. To address this, we performed a randomized cross-over trial in patients with 
CKD stage G3 or G4 and hypertension to compare dietary sodium restriction with distal 
diuretics (hydrochlorothiazide and amiloride). Both interventions effectively lowered 
24-hour blood pressure and extracellular volume, with diuretics exerting a stronger ef-
fect.  Although the tubular secretion of diuretics was impaired at lower eGFR, the reduc-
tions in body weight and blood pressure effect were maintained. This shows that – even 
at lower eGFR – dietary sodium restriction and distal diuretics are effective therapies for 




Salt-sensitive hypertension and overhydration are hallmarks of chronic kidney disease 
(CKD) and are associated with adverse outcomes.1-4 Dietary sodium restriction effectively 
lowers blood pressure, extracellular volume, and albuminuria in CKD.5-8 However, given 
the high sodium content of most food products, long-term adherence to dietary sodium 
restriction remains a challenge.9 Therefore, a pertinent question is whether other ap-
proaches to reduce sodium in CKD such as diuretics are similarly effective. In order to 
inhibit sodium reabsorption, diuretics first need to be secreted by the proximal tubule, 
a process that may be impaired in CKD.10
Although “high-ceiling” loop diuretics are commonly used in CKD stages G3-5, “low-
ceiling” distal diuretics are considered less effective.11-13 Whether these assumptions 
are justified is uncertain. Experimental data indicate that the pharmacological targets 
of thiazide diuretics and amiloride – the sodium chloride cotransporter (NCC) and the 
epithelial sodium channel (ENaC) – are upregulated in CKD.14-16 Several small case series 
(n = 5–12)17-23 and one larger study (n = 60)24 analyzed the effects of thiazide or thiazide-
like diuretics on blood pressure in patients with CKD stages G3 to G5D. The majority of 
these studies found that the antihypertensive effect of thiazide diuretics is preserved 
in CKD, except for three studies that included patients with CKD stage G5.11, 22, 23 Two 
small studies analyzed amiloride in CKD and also observed a preservation of its natri-
uretic and anti-kaliuretic effects.25, 26 These observations provide a rationale for a more 
systematic investigation of distal diuretics in CKD. Several investigators have previously 
called for such a study.27-31 In designing this study, we considered it rational to combine 
diuretics to prevent diuretic resistance secondary to upregulation of the uninhibited 
transporter.32-34 Although the efficacy of combining loop and thiazide diuretics has been 
shown previously in CKD33, the effect of combining inhibitors of NCC and ENaC in CKD 
has not been analyzed. Advantages of a combination of distal diuretics could be to 
maintain potassium balance35 and to prevent proteinuria-induced activation of ENaC.36 
Therefore, we set out to address the hypothesis that distal diuretics are non-inferior to 
dietary sodium restriction in reducing blood pressure in patients with CKD. To do so, 
we recruited patients with CKD stage G3 or G4 and hypertension, discontinued their 
anti-hypertensive drugs, and subsequently performed a randomized cross-over trial to 
compare the two sodium-reducing strategies. In addition to the effects of both interven-
tions on clinical parameters, we also analyzed markers of fluid balance, the circulating 
and intra-renal renin-angiotensin system, and renal clearance of diuretics. We demon-
strate that distal diuretics are at least as effective as dietary sodium restriction for the 
treatment of hypertension in CKD.
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MethoDS
Participants
We conducted a single-center, randomized, open-label, cross-over study (figure 1). The 
study was approved by the Medical Ethics Committee of the Erasmus Medical Center 
(MEC-2015-576) and registered at www.clinicaltrials.gov (NCT02875886). The Consoli-
dated Standards of Reporting Trials (CONSORT) flow-diagram and checklist are available 
as Supplemental Material. Patients were recruited from the nephrology outpatient 
clinic of the Erasmus Medical Center between June 2016 and May 2017. Patients aged 
>18 years old with CKD stage G3 or G4 (eGFR 15-59 ml/min/1.73m2) with hypertension 
were eligible for inclusion. Hypertension was defined as 1) current use of antihyperten-
sive drug or 2) no use of antihypertensive drugs, but a mean systolic blood pressure >140 
mmHg after 6 consecutive measurements with an oscillometric blood pressure monitor. 
Exclusion criteria were previous intolerance or allergy to thiazide diuretics or amiloride, 
pregnancy, the presence of certain diseases (nephrotic syndrome, salt-wasting ne-
phropathy, liver cirrhosis with ascites, heart failure class III or IV), electrolyte disorders 
(serum sodium < 136 mmol/l, serum potassium < 3.5 or > 5.5 mmol/l), high likelihood of 
kidney replacement therapy < 4 months, and previous kidney transplantation or use of 
immunosuppressive drugs.
Study design
The study started with a 2-week run-in period during which all antihypertensive medica-
tion was discontinued, except for β-blockers (for cardiac reasons). Patients were pro-
vided with a home blood pressure monitor (Omron HBP-1300, Omron Healthcare, The 
Netherlands) and instructed to measure blood pressure twice daily. If the systolic blood 
pressure (SBP) was ≥ 160 mmHg during three consecutive measurements, amlodipine 
was started (5 mg once daily with possible uptitration to 10 mg once daily). Subse-
quently, patients were randomly assigned to start with sodium restriction (60 mmol/
day) or amiloride/hydrochlorothiazide (combination preparation of 5/50 mg once daily). 
Allocation to treatment order was done by randomization using sequentially numbered, 
opaque, sealed envelopes. Treatment periods lasted for two weeks and were separated 
by a 2-week washout period (figure 1). All patients received dietary counseling by a 
renal dietitian at the start of treatment with sodium restriction. In addition, salt-free 
bread was provided for the complete duration of the dietary intervention. After one 
week of treatment patients were called by the dietitian to increase adherence to the 
diet and provide additional counseling, if necessary. Compliance to sodium restriction 
was monitored with 24-hour urinary sodium excretion and adherence was defined as 
>10% reduction. Two patients repeated the 2-week period of dietary sodium restriction. 
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Adherence to diuretics was evaluated using drug accountability (counting pills) and the 




   
 
 
Figure 1. Overview of the study design. HCTZ, hydrochlorothiazide; Na+, sodium; V, visit. 
 
figure 1. Overview of the study design. HCTZ, hydrochlorothiazide; Na+, sodium; V, visit.
Measurements
Before and after each intervention blood pressure, body weight, and body composi-
tion were measured, and blood and urine were collected. 24-hour ambulatory blood 
pressure measurements (ABPM) were performed with the 90217A Ultralite (Spacelabs 
Healthcare, USA) with masked screen. Blood pressure was measured at 15-minute 
intervals during daytime (16 out of 24 hours) and at 30-minute intervals during night-
time (8 out of 24 hours). The starting time of daytime and nighttime measurements 
was set based on the patient’s sleeping habits. An ABPM was considered successful 
when ≥ 70% of expected measurements were valid (45 valid awake, 11 valid asleep).37 
Extracellular water was measured using a bio-impedance spectroscopy monitor (Body 
Composition Monitor, Fresenius Medical Care, Germany). All urinary measurements 
were performed in 24-hour urine samples. Compliance of 24-hour urine collection was 
determined by creatinine excretion-to-weight-ratio.38 Plasma and urine electrolytes, 
albumin, creatinine, and β2-microglobulin were measured at the Department of Clinical 
Chemistry. Estimated glomerular filtration rate (eGFR) was calculated using the CKD-EPI 
equation.39 eGFR was also recorded up to 1 year after completion of the study. Plasma 
renin was measured using a radioimmunometric assay (Cisbio, France). Urinary renin 
and angiotensinogen were measured using an in-house enzyme-kinetic assay that 
quantifies angiotensin I generation in the presence of excess angiotensinogen and 
recombinant renin, respectively.40, 41 Plasma and urine aldosterone were measured by 
radioimmunoassay (Demeditec, Germany). Prostaglandin E2 (PGE2) and its metabolite 
were measured using an enzyme-linked immusorbent assay (Cayman Chemicals, USA). 
Plasma and urine hydrochlorothiazide and amiloride concentrations were measured 
using liquid chromatography–mass spectrometry (LC-MS; Waters, USA), as previ-
ously described with minor modifications.42 Renal clearance of hydrochlorothiazide 
and amiloride was calculated based on their concentration in 24-hour urine and plasma 
samples that were collected immediately after urine collection. Plasma indoxyl sulfate 
was measured using LC-MS (Agilent Technologies, Germany), as described.43 During the 
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treatments, the following objective side-effects were monitored, including orthostatic 
hypotension (20 or 10 mmHg decrease in SBP or DBP within three minutes of standing 
after 5 minutes of supine rest44), gout, hyponatremia (plasma sodium < 136 mmol/L), 
hypo- and hyperkalemia (plasma potassium < 3.5 or > 5.5 mmol/L), and hyperuricemia 
(plasma uric acid > 7.1 mg/dL).
Statistics
The primary outcome was the change in mean 24-hour SBP from baseline. Secondary 
endpoints included change in extracellular volume, body weight, albuminuria and ad-
verse effects. All endpoints were analyzed per protocol and intention to treat. A power 
calculation based on previous studies indicated that a minimum of 22 patients was 
required to establish non-inferiority of diuretics compared with sodium restriction (α = 
0.05, β = 90%, expected effect of sodium restriction –8.75 ± 8.5 mmHg5, expected effect 
of diuretics –10 ± 8.5 mHg18, correlation coefficient between effects of both treatments 
0.8, variance of difference in treatment effect 5.38, non-inferiority margin -2 mmHg). The 
omnibus K2 test was used to screen for normality.  Results are presented as mean ± 
standard deviation for normally distributed data and median with interquartile range 
for non-normally distributed data. Non-normally distributed data were log-transformed 
for statistical analysis. Grubb’s test was used to detect outliers. One outlier in the urinary 
PGE2 data was not included in the analysis because the result suggested the presence of 
semen in urine, a known cause of very high urinary PGE2 levels.45 Primary and second-
ary outcomes were analyzed by two-way repeated measures ANOVA that also included 
treatment order as between-subject factor. A pretest was performed and indicated that 
the assumption of negligible carryover effects was met.46 A paired T-test was performed 
to analyze if the effects of diuretics or dietary sodium restriction affected the baseline pa-
rameters after wash-out. The possibility of a period effect was analyzed and found to be 
absent.47  Adverse events were analyzed by McNemar’s test. Correlations were analyzed 
on normally distributed or log-transformed data using Pearson’s correlation coefficient. 
If a correlation was present between normally distributed data and log-transformed 
data, non-linear regression using a linear-logarithmic model was used to fit the original 
data. Data were analyzed using SPSS Statistics (IBM, version 24.0) and Graphpad Prism 




Patient Characteristics and Study Compliance
1563 patients were assessed for eligibility of whom 1274 did not meet inclusion criteria, 
and 262 declined to participate (Supplemental figure 1). 27 patients entered the study 
protocol, of whom 1 patient discontinued during the run-in phase (because of study 
burden). Therefore, 26 patients finished both treatments; their baseline characteristics 
are shown in table 1. In 7 out of 26 patients, SBP increased >160 mmHg during the run-
in phase and amlodipine was given until the end of the study protocol (average dose 
5.8 ± 2.0 mg). During the treatment phase with diuretics, there was 100% drug account-
ability and all patients had detectable plasma and urine diuretic concentrations. The 
response in urine electrolyte excretion confirmed study compliance to dietary sodium 
restriction in all patients (figure 2). Urine sodium decreased from 160 to 64 mmol/day 
during dietary sodium restriction (mean difference -95.3 mmol, 95% CI, 67.6–123.1,  P < 
0.01), whereas it remained similar during treatment with amiloride/hydrochlorothiazide 
(154 to 153 mmol/24h, mean difference -0.8 mmol/24h, 95% CI, 26.9–28.6, P = 1.0). Urine 
calcium decreased significantly with both interventions, but more so with amiloride/
hydrochlorothiazide. Finally, urine potassium did not change during both interventions, 
indicating stable dietary potassium intake during the study period. A subanalysis ex-
cluding patients who appeared non-compliant with the 24h urine collection (n = 4), did 
not change these findings.
table 1. Baseline characteristics of study participants (n = 26)
Characteristic value
Age (years) 61 ± 14
Men 17 (65)
Diabetes mellitus 5 (19)
Number of antihypertensive medications 1.8 ± 1.1
   Renin-angiotensin system blockade 23 (89)
   β-blockers 8 (31)
   Calcium channel blockers 8 (31)
   Diuretic 7 (27)
Body mass index (kg/m2) 28.0 ± 4.8
eGFR (mL/min/1.73m2) 39 ± 13
Office systolic blood pressure (mmHg) 140 ± 17
Office diastolic blood pressure (mmHg) 88 ± 15
Albuminuria (mg/24 h) 145 (10, 1050)
Urine sodium (mmol/24 h) 135 (100, 207)
Data are presented as n (%), mean ± SD or median (interquartile range).
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figure 2. Effect of sodium (Na+) restriction or diuretics on urinary electrolyte excretion. Two-way repeated 
measures ANOVA was used for analysis. Urine potassium (K+) was normally distributed, while urine Na+ and 
calcium (Ca2+) were not. * P < 0.05 for difference before versus after treatment, and for difference between 
treatments. NS, not significant.
effect on Blood Pressure and Kidney function
Both treatments reduced mean 24-hour SBP from 134 to 129 mmHg for sodium restric-
tion (mean difference -5 mmHg, 95% CI -1, -9, P < 0.05) and from 138 to 124 mmHg for 
amiloride/hydrochlorothiazide (mean difference -14 mmHg, 95% CI -10, -18, P < 0.01, 
figure 3). The treatment effect of amiloride/hydrochlorothiazide on 24-hour SBP was 
significantly greater compared with sodium restriction (P < 0.01). Intention to treat 
analysis similarly showed that both treatments reduced mean 24-hour SBP (from 134 to 
130 mmHg for sodium restriction (mean difference -4 mmHg, 95% CI 0, -9, P < 0.05; 138 
to 124 mmHg for amiloride/hydrochlorothiazide, mean difference -14 mmHg, 95% CI 
-10, -18, P < 0.01). 24-hour DBP also decreased by both treatments, but this change was 
only significant for the diuretic treatment. SBP was reduced by diuretics in all patients 
and by dietary sodium restriction in 19 patients. The effects of both interventions on day 
and night blood pressure is shown in Supplemental table 2. Albuminuria and plasma 
renin measured at the start of the first treatment period did not correlate with SBP 
responses to both treatments (data not shown). eGFR decreased with both treatments 
and this effect was significantly greater with diuretics compared with dietary sodium 
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restriction (figure 3). Follow-up eGFR’s obtained after the study showed that eGFR 
returned to baseline. No significant change in albuminuria was detected for both treat-






figure 3. Effect of sodium (Na+) restriction or diuretics on blood pressure, kidney function, and plasma po-
tassium (K+). Two-way repeated measures ANOVA was used for analysis. Systolic and diastolic blood pres-
sure (SBP, DBP), estimated glomerular filtration (eGFR), and plasma K+ were normally distributed, while 
albuminuria was not. * P < 0.05 for difference before versus after treatment, and for difference between 
treatments. FU, follow-up; NS, not significant.
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significant carry-over effects of both treatments were present. However, a persisting 
effect of the diuretics on blood pressure and plasma potassium after wash-out was 
observed (figure 4). A sensitivity analysis including patients that first received sodium 
restriction (n = 12) confirmed that diuretics had a stronger antihypertensive effect than 
sodium restriction (138 to 132 mmHg for sodium restriction, P = 0.06; 140 to 125 mmHg 








figure 4. Systolic blood pressure (SBP) and plasma potassium (K+) in patients who started with diuretics or 
dietary sodium (Na+) restriction. The data show that the effect of diuretics but not Na+ restriction persists 
after discontinuation of their use. A paired T-test was used for analysis. * P < 0.05 for difference before versus 
after treatment, or before treatment versus after washout. NS, not significant.
effect on fluid Balance and volume Markers
Both interventions decreased body weight (-1.6 ± 1.1 kg for sodium restriction, P < 0.001; 




Diuretics had a significantly greater effect on extracellular water, plasma renin, and plasma 
aldosterone compared with dietary sodium restriction. Fluid balance and volume markers 






+figure 5. Effect of dietary sodium (Na+) restriction or diuretics on fluid balance. All data were normally 
distributed. Two-way repeated measures ANOVA was used for analysis. * P < 0.05 for difference before ver-
sus after treatment, and for difference between treatments. NT-pro-BNP, N-terminal pro B-type natriuretic 
peptide.
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Clearance of Distal Diuretics in CKD
Lower eGFR’s were associated with lower diuretic clearance, in a non-linear manner, 
indicating reduced tubular secretion of diuretics at lower eGFR (figure 6). To explore 
this further, plasma indoxyl sulfate concentrations were measured, based on previous 
data showing that this uremic toxin competes with the tubular secretion of diuretics in 






figure 6. Correlations between diuretic clearance, eGFR, and plasma indoxyl sulfate and between eGFR 
and the diuretic response in body weight and blood pressure. Clearances were not normally distributed. 
Pearson’s correlation coeff icient was calculated. ClHCTZ, clearance of hydrochlorothiazide; ClAmiloride, clear-
ance of amiloride; eGFR, estimated glomerular filtration rate.
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sociated with significantly lower clearance of both diuretics (figure 6).  To analyze the 
whether these pharmacokinetic effects also had pharmacodynamic consequences, we 
analyzed the diuretic response on body weight and blood pressure across the different 
levels of eGFR. Of note, lower eGFR was associated with a greater reduction in body 
weight and a similar reduction in blood pressure. Prior to diuretic treatment, lower eGFR 
correlated with higher NT-pro-BNP (P < 0.01, r = -0.5), suggesting more fluid overload. In 
contrast to patients with hypertension and a normal kidney function35, plasma renin and 
albuminuria at baseline did not predict the blood pressure response to diuretics (data 
not shown).
thiazide-induced hyponatremia
Diuretic treatment was generally well tolerated with a comparable incidence of adverse 
effects (table 2). The only exception was mild hyponatremia, which developed in four 
patients after diuretic treatment (plasma sodium 135 ± 1 mmol/L). Because thiazide-
induced hyponatremia was recently linked to PGE248, we measured the excretion of PGE2 
and its metabolite (figure 7). Diuretics but not dietary sodium restriction increased 
urine PGE2 excretion. Higher urine PGE2 excretion was associated with lower free water 
clearance.
table 2. Adverse effects.




Orthostatic hypotension 4 (15) 6 (23)
Gout 0 (0) 1 (4)
Hyponatremia 0 (0) 4 (15)
Hypokalemia 0 (0) 0 (0)
Hyperkalemia 0 (0) 1 (4)
Hyperuricemia 17 (65) 22 (85)
Data are presented as n (%). No significant differences by McNemar’s test. Hyponatremia was defined as plasma sodium < 
136 mmol/L, hypo- and hyperkalemia as plasma potassium < 3.5 or > 5.5 mmol/L, and hyperuricemia as plasma uric acid > 
7.1 mg/dL.
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+figure 7. Effects of dietary sodium (Na+) restriction and diuretics on the excretion of prostaglandin E2 and 
its metabolite (PGE2 + M, panel A) and correlation between urinary PGE2 + M excretion with free water 
clearance (ClH2O) in patients treated with diuretics (panel B). ClH2O was normally distributed, while PGE2 + M 
were not. Two-way repeated measures ANOVA and Pearson’s correlation coefficient were used for analysis. 
One patient had 10- to 100-fold higher PGE2 values and this outlier was excluded from the analysis; we 
suspect that his urine was contaminated with semen, which contains high PGE2 levels.45
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effects on urinary Renin, Angiotensinogen, and β2-microglobulin
CKD may activate the intra-renal renin-angiotensin system with urinary angioten-
sinogen and renin as potential markers for the activity of this system.49, 50 Therefore, we 
analyzed whether our interventions changed these parameters. To account for changes 
in the tubular reabsorption of filtered proteins, we also measured β2-microglobulin. Of 
interest, dietary sodium restriction selectively increased urinary renin, whereas diuret-
ics selectively decreased urinary angiotensinogen and β2-microglobulin (figure 8). To 
account for the concurrent changes in plasma renin and eGFR, we also analyzed the 
change in the fractional excretions of renin. This analysis showed that diuretics selec-
tively reduced the fractional excretion of renin.  
 
 
figure 8. Effects of dietary sodium (Na+) restriction or diuretics on urinary renin, angiotensinogen (AGT), 
and β2-microglobulin excretion. All data were normally distributed. Two-way repeated measures analysis 
was used for analysis. FE, fractional excretion.
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DiSCuSSion
This is the first study to investigate the effects of the distal diuretics hydrochlorothia-
zide and amiloride in patients with chronic kidney disease (CKD). The effects of distal 
diuretics on blood pressure and extracellular volume were analyzed in the absence of 
renin-angiotensin inhibition and compared with dietary sodium restriction as active 
comparator. We showed that distal diuretics are non-inferior to dietary sodium restric-
tion in reducing blood pressure and extracellular volume. In fact, diuretics appear to 
exert a stronger antihypertensive effect than dietary sodium restriction, although the 
non-inferiority design of our study precludes a definitive conclusion. In addition, a 
longer treatment period than two weeks may be necessary to obtain the full response to 
dietary sodium restriction on blood pressure and total peripheral resistance.8, 51
The diuretic effects were preserved at lower eGFR despite a lower clearance of diuretics. 
Overall, both dietary sodium restriction and distal diuretics were well-tolerated, except 
for mild diuretic-induced hyponatremia in four patients.
Thiazide diuretics are often considered ineffective in CKD, especially with eGFR < 30 
ml/min.52 Several small case series and pilot studies have challenged this assumption 
by showing that thiazide diuretics can still lower blood pressure when added to other 
antihypertensive drugs.17-19, 21, 53 A larger study by Cirillo et al. also showed that chlortha-
lidone effectively reduced blood pressure, but restricted inclusion to an eGFR between 
30 and 60 ml/min/1.73m2.24 Our study confirms that thiazide diuretics in combination 
with amiloride are still effective in CKD across a wide eGFR-range. Bennett et al. did 
show that some residual kidney function is required, because thiazide diuretics had no 
effect in hemodialysis patients.22 In an acute experiment, Reubi et al. showed that only 
at very low filtration rates (GFR < 15 ml/min) the saluretic effect of chlorothiazide was 
impaired.11 It is difficult to directly compare the blood pressure response in our study to 
previous studies because we discontinued most other antihypertensive drugs. However, 
both interventions showed a clinically relevant blood pressure response.
A novel finding is that the antihypertensive effect of distal diuretics is maintained at 
lower eGFR. Diuretics are secreted by organic anion transporters (OAT) in the proximal 
tubule.34 Renal clearance of diuretics is reduced in CKD, an observation that was also 
confirmed by our study. Several mechanisms can contribute to reduced diuretic clear-
ance in CKD, including lower nephron number and competition for peritubular uptake 
through OATs.10 One of the metabolites that can compete with diuretics for OAT is the 
uremic toxin and organic anion indoxyl sulfate.54 We measured plasma indoxyl levels 
and indeed found a negative correlation with diuretic clearance. The observation that 
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the blood pressure response to diuretics was independent of eGFR may be explained 
by several mechanisms. First, at lower eGFR, the reduction in renal diuretic clearance 
may have been leveraged by increased diuretic sensitivity. Second, single-nephron 
diuretic concentrations may have been higher in patients with lower eGFR because of 
a lower nephron number. Third, non-renal mechanisms such as vasodilation may have 
contributed to the antihypertensive effects, although we did not measure vascular 
tone. The possibility that thiazide diuretics can cause vasodilation is supported by the 
demonstration of thiazide-induced vasodilation in patients with Gitelman syndrome, 
who lack functional NCC.55 In one study, the vasodilatory effect of thiazide diuretics was 
observed only at high plasma concentrations.56 This could imply that these vasodilatory 
mechanisms are more prominent in CKD, because it raises the plasma concentrations 
of diuretics. Whether amiloride can also cause vasodilation is less clear, although ENaC 
is expressed in endothelial cells and involved in vascular tone.57 Endothelial ENaC can 
increase vascular stiffness and reduce nitric oxide.58 Therefore, it would be interesting to 
analyze whether the diuretics increased the nitric oxide indices.
Both interventions decreased eGFR, and this has been a consistent finding in previous 
studies.59, 60 Although this may be interpreted as progression of CKD, the effect on eGFR 
was reversible and is therefore most likely a hemodynamic effect. This is supported by 
the observed neurohumoral activation, and restoration of eGFR after follow-up. Bank et 
al. also observed an initial decrease in eGFR with thiazide diuretics in CKD, but showed 
that eGFR subsequently remained constant or rose toward pretreatment levels.17 Cakal-
aroski et al. showed that long-term treatment with a thiazide diuretic (3 months) did not 
change eGFR in patients with CKD.61 Longer-term studies powered for hard endpoints 
would be required to analyze if thiazide-induced reduction in blood pressure and extra-
cellular volume offset the decrease in eGFR. The initial diuretic-induced eGFR decrease 
is reminiscent of the effects of ACE- and SGLT2-inhibitors.62, 63 Because these drugs are 
renoprotective, this raises the possibility that thiazides may also help preserve eGFR in 
CKD. Several experimental and clinical studies suggest a possible renoprotective effect 
of thiazide diuretics in CKD, especially in combination with renin-angiotensin inhibi-
tion.64-70 Clinical trials, however, are lacking.
In contrast to previous studies, we did not observe a significant decrease in albuminuria 
by distal diuretics or sodium restriction.59, 60 However, previous studies usually com-
bined dietary sodium restriction or diuretics with an inhibitor of the renin-angiotensin 
system.8, 71-73
Diuretics did decrease the excretion of angiotensinogen and β2-microglobulin. Because 
both proteins are reabsorbed in the proximal tubule, this suggests that diuretics increase 
Chapter 6 161
A randomized trial of distal diuretics versus dietary sodium restriction for hypertension in chronic kidney disease
proximal tubular reabsorption. This would also be in agreement with the hypocalciuric 
effect of diuretics.74 Of note, urinary renin increased after dietary sodium restriction. 
Some investigators consider urinary angiotensinogen and renin markers for the intra-
renal renin-angiotensin system and postulate local production by the kidney. However, 
we previously showed that an increase in urinary renin reflects increased glomerular 
filtration or reduced reabsorption rather than conversion of prorenin to renin in the tu-
bular fluid.75 The data in this study also support this conclusion, because dietary sodium 
restriction did not change the fractional excretion of renin, while this was reduced by 
thiazide diuretics. Thus, we propose that the changes in urinary angiotensinogen and 
renin represent changes in renal tubular handling rather than changes in the activity of 
the intrarenal renin-angiotensin system.
Both interventions were generally well-tolerated, but diuretics did cause mild hypo-
natremia in four patients. Hyponatremia is a well-characterized side-effect of thiazide 
diuretics.76 Ware et al. recently linked thiazide-induced hyponatremia to increased pro-
duction of PGE2.48 We also found a negative correlation between urinary PGE2 and free 
water clearance. A final observation is that patients who first received the diuretics had 
a significantly lower blood pressure and plasma potassium after the 2-week wash-out 
than the patients who first received dietary sodium restriction. This suggests that the 
effects of distal diuretics temporarily persist after their discontinuation. This “legacy” 
effect may be related to distal tubule remodeling that was described in mice lacking NCC 
phosphorylation.77
Our study has a number of limitations. First, we used a combination treatment, and 
therefore it is not clear if both diuretics equally contributed to the observed effects. 
Second, we excluded patients with CKD stage G5, and therefore we were not able to 
study the possibility that distal diuretics become ineffective at a certain level of eGFR. 
A sensitivity analysis did show that patients with an eGFR < 30 ml/min/1.73m2 had a 
similar blood pressure response that occurred independent of eGFR. Finally, we did 
not specifically select patients on salt sensitivity or an expanded extracellular volume. 
However, sodium retention is a generally accepted hallmark of CKD.1, 3, 4
In conclusion, distal diuretics are at least as effective as dietary sodium restriction in 
reducing blood pressure and extracellular volume in CKD. These effects were preserved 
at lower eGFR despite a lower clearance of diuretics. Longer-term studies should deter-
mine which sodium-reducing strategy – or combinations thereof – optimally prevents 
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SuPPleMentAl MAteRiAl
Supplemental Methods
Urinary aldosterone measurements were performed using a commercial assay (Demed-
itec, Germany). The detection limit and mean coefficient of variation of the within-run 
and between-run variability of this assay are 1.44 pg/mL, 3.3 % and 8.4 %, respectively. 
Moreover, the antibody used in the immunoassay is highly specific for aldosterone. Ex-
tremely low cross-reactivities were obtained against other naturally occurring steroids 
(cortisone, corticosterone, DHEAs, etc.). Urinary renin and angiotensinogen measure-
ments were performed using an in-house developed enzyme-kinetic assay. The detec-
tion limit and mean coefficient of variation of the within-run and between-run variability 
of this assay are 2 pg/mL, 2.9% and 12.6% for renin measurements and 0.12 ng/mL, 4% 
and 10% for angiotensinogen measurements. Please note that in every enzyme-kinetic 
assay, we measure a set of standard samples allowing us to determine the within- and 
between-run variability. Furthermore, we always include buffer samples to correct for 
background noise. As an example, when measuring renin in the presence of excess 
angiotensinogen, the same amount of excess angiotensinogen is incubated with buffer, 
and the generated amount of angiotensin I is subtracted from the amount of angiotensin 
I generated in the actual sample. This needs to be taken into account, particularly when 
measuring samples with low renin levels like urine.78 In previous studies we have added 
fixed amounts of (pro)renin and angiotensinogen to urine samples, and found recovery 
to be >95%.79, 80 This is not surprising, since the levels of degrading enzymes in urine 
are negligible. Finally, regarding cross-reactivity, it is important to note that the assays 
rely on the detection of angiotensin I making use of an angiotensin I-directed antibody. 
Cross-reactivity of this antibody with other angiotensin metabolites is <0.1%.81 In this 
regard, the correction for background noise as explained above seems to be of greater 
importance, since the assay is performed in the presence of angiotensinase inhibitors, 
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table S2. Effect of sodium restriction and diuretics on day and night systolic blood pressure (SBP), diastolic 
blood pressure (DBP) and mean arterial pressure (MAP).
Na+ restriction P for treatment 
effect




Day SBP (mmHg) –6 ± 2 P < 0.01 –14 ± 2 P < 0.01 P < 0.01
Day DBP (mmHg) –2 ± 1 P = 0.2 –5 ± 1 P < 0.01 P = 0.09
Day MAP (mmHg) –4 ± 1 P < 0.05 –8 ± 1 P < 0.01 P < 0.05
Night SBP (mmHg) –3 ± 2 P = 0.4 –14 ± 2 P < 0.01 P < 0.01
Night DBP (mmHg) 0 ± 2 P = 1 –5 ± 2 P < 0.01 P < 0.05
Night MAP (mmHg) –1 ± 2 P = 0.8 –8 ± 2 P < 0.01 P < 0.01
SBP dipping (%) +2.1 ± 3.4 P = 1 +1.4 ± 3.4 P = 1 P = 1
Treatment effect and treatment interaction were analyzed by two-way repeated measures ANOVA that included treatment 








figure S1. Consolidated Standards of Reporting Trials (CONSORT) diagram.
Treatment order 1: first treatment period diuretics, second treatment period dietary sodium restriction. Treatment order 









figure S2. Effect of sodium (Na+) restriction and diuretics on creatinine clearance.
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In autosomal dominant polycystic kidney disease (ADPKD) activation of the renin-
angiotensin aldosterone system (RAAS) may contribute to hypertension and disease 
progression. Although previous studies focused on circulating RAAS-components, pre-
liminary evidence suggests APDKD may increase urinary RAAS-components. Therefore, 
our aim was to analyze circulating and urinary RAAS-components in ADPKD. We cross-
sectionally compared 60 patients with ADPKD to 57 patients with non-ADPKD chronic 
kidney disease (CKD). The two groups were matched by gender, estimated glomerular 
filtration rate (eGFR), blood pressure, and RAAS-inhibitor use. Despite similar plasma 
levels of angiotensinogen and renin, urinary angiotensinogen and renin excretion were 
5- to 6-fold higher in ADPKD (P<0.001). These differences persisted when adjusting for 
group differences, and were present regardless of RAAS-inhibitor use. In multivariable 
analyses, ADPKD, albuminuria, and the respective plasma concentrations were inde-
pendent predictors for urinary angiotensinogen and renin excretion. In ADPKD, both 
plasma and urinary renin correlated negatively with eGFR. Total kidney volume corre-
lated with plasma renin and albuminuria, but not with urinary renin or angiotensinogen 
excretions. Albuminuria correlated positively with urinary angiotensinogen and renin 
excretions in ADPKD and CKD. In three ADPKD patients who underwent nephrectomy, 
the concentrations of albumin and angiotensinogen were highest in plasma followed by 
cyst fluid and urine; urinary renin concentrations were higher than cyst fluid. In conclu-
sion, this study shows that, despite similar circulating RAAS-component levels, higher 
urinary excretions of angiotensinogen and renin are a unique feature of ADPKD. Future 
studies should address the underlying mechanism and whether this may contribute to 
hypertension or disease progression in ADPKD.
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intRoDuCtion
Hypertension develops early in autosomal dominant polycystic kidney disease (ADPKD), 
usually occurring before a reduction in glomerular filtration rate (GFR) with an average 
age of onset of 30 years 1, 2. Increased activity of the renin-angiotensin-aldosterone 
system (RAAS) has been implicated in the pathogenesis of hypertension in ADPKD. One 
hypothesis is that cyst expansion results in areas of local renal ischemia which increases 
renin release 2, 3. In addition, renin has also been suggested to be produced by the 
epithelial cells lining the cysts and active renin can be found within the cyst fluid 4, 5. 
However, measurement of plasma renin and aldosterone in patients with ADPKD yielded 
equivocal results (table 1). Several studies found that plasma renin and aldosterone 
concentrations were not higher in hypertensive ADPKD patients when compared to 
controls, even during specific interventions (low or high sodium diet, ACE-inhibition, 
angiotensin II infusion) 6-11. Different control groups were used for these studies, includ-
ing normotensive ADPKD patients, normotensive siblings without ADPKD, patients with 
essential hypertension, or healthy volunteers (table 1). The observation that plasma 
renin activity was not consistently higher in hypertensive ADPKD patients is notable, 
because this is contrary to what would be expected if cysts caused local renal ischemia 
2, 3. Therefore, to further address the role of the RAAS in ADPKD, it may be informative to 
analyze RAAS-components in urine, as urinary angiotensinogen and renin have previ-
ously been used as markers of the intra-renal renin-angiotensin system 12. Emerging 
data suggest that filtered or locally produced RAAS-components may activate this intra-
renal renin-angiotensin system and thereby contribute to hypertension 13. Two recent 
studies reported higher urinary angiotensinogen concentrations in hypertensive ADPKD 
patients 14, 15. However, despite its postulated central role in the pathogenesis of hyper-
tension, urinary renin has never been measured in patients with ADPKD. We recently 
showed that it is important to measure urinary renin with standardized assays, because 
commercial assays may produce ≥ 10-fold higher results 16. Therefore, here, we mea-
sured urinary renin in patients with ADPKD using a validated renin immunoradiometric 
assay and an in-house enzyme kinetic assay. In addition, we also measured multiple 
other RAAS-components in plasma and urine, including plasma renin and aldosterone, 
and urine angiotensinogen, prorenin, and aldosterone. As a comparator, and for the 
first time, we used matched patients with non-ADPKD chronic kidney disease (CKD) to 
address whether the type of kidney injury affects the RAAS differently.
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table 1. Comparison of studies measuring RAAS-components in patients with ADPKD. 
Study Cases CKD stage Controls numbers Measurement(s) Difference
Valvo 10 ADPKD + HT 1-3 ADPKD + NT 20 vs. 12 PRA ↔
Bell 3 ADPKD + HT 1-2 ADPKD + NT 9 vs. 7 PRA during low/ 
high Na+ diet + ACEi
↔ but ↑during 
ACEi + high Na+ 
diet
Chapman 2 ADPKD 1 Essential HT 
+ healthy 
controls
14 + 11 vs. 
9 + 13
PRA and aldo during 
ACEi
PRA and aldo ↑ 
in ADPKD + HT
Harrap 17 ADPKD 1 Siblings 19 vs. 20 PRA and aldo PRA and aldo ↑
Watson 11 ADPKD 1-2 Siblings 13 vs. 10 PRA ↔
Barrett 6 ADPKD 1-2 Siblings 21 vs. 12 PRA and aldo during 
low/high Na+ diet, 




ADPKD + HT 2-3 Essential HT 20 vs. 20 PRA, aldosterone, 
ANP, Ang II
↔
Ramunni 9 ADPKD + HT 1-2 ADPKD + NT 17 vs. 17 PRA ↔
Doulton 7 ADPKD + HT 1-2 Essential HT 11 vs. 8 PRA during low/high 
Na+ diet and ACEi
↔
Kurultak 18 ADPKD 1 Healthy 
controls
20 vs. 20 Urinary AGT ↔
Kocyigit 14 ADPKD + HT 1-2 ADPKD + 
NT, healthy 
controls
43 vs. 41 
+ 40
Plasma and urinary 
AGT
Urinary AGT­↑
Park 15 ADPKD 1-5 None 186 Plasma renin+ aldo, 
urinary AGT
Correlation 




ADPKD 3 CKD 69 vs. 58 Plasma + urinary 
AGT, renin, aldo
Urinary AGT + 
renin­↑
ADPKD, autosomal dominant polycystic kidney disease; ACEi, angiotensin converting enzyme inhibitor; AGT, angiotensino-
gen; aldo, aldosterone; Ang II, angiotensin II; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HT, 
hypertension; NT, normotension; PRA, plasma renin activity; BP, blood pressure.
MAteRiAlS AnD MethoDS
Patients
Patients with ADPKD were recruited from one of the centers (Erasmus Medical Center, 
Rotterdam, The Netherlands) participating in a national ADPKD consortium (DIPAK 
study, with inclusion criteria CKD stage 3 at entry into the study and age ≤ 60 years) 
19. Patients were matched to non-ADPKD CKD patients (referred to hereafter as ‘CKD’) 
from the PREVEND cohort (University Medical Center Groningen) 20. The Medical Ethics 
Committees of the Erasmus Medical Center and University Medical Center Groningen ap-
proved the studies (MEC-2012-313 and METC-90/01/022). Patients with ADPKD and CKD 
were individually matched for gender, eGFR (using the Modification of Diet in Renal Dis-
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ease equation 21), use of RAAS-inhibitors (defined as the use of angiotensin-converting 
enzyme inhibitors or angiotensin receptor blockers) and blood pressure (difference in 
systolic blood pressure ≤ 5 mmHg). Patients with a history of diabetes mellitus, or those 
using insulin or oral glucose lowering drugs were excluded, because diabetes mellitus 
may activate the intrarenal renin-angiotensin system 22. From three ADPKD patients who 
underwent elective nephrectomy (not part of the DIPAK cohort), we collected plasma, 
cyst fluid, and urine samples. For this part of the study, a separate approval from the 
Medical Ethics Committee of the University Medical Center Groningen was obtained 
(METC 2014.396).
Data Collection
Detailed description of data collection for both the DIPAK and PREVEND studies has 
been described elsewhere 19, 20. Briefly, participants of both studies collected 24-hour 
urine and visited the outpatient clinic for blood sampling and blood pressure measure-
ments using an automatic oscillometric device. Hypertension was defined as a blood 
pressure > 140/90 mmHg or the use of anti-hypertensive medication. Participants were 
instructed to store urine at 4°C during collection. Upon arrival in the university medical 
center, blood and urine samples were immediately stored at -80°C until further use. We 
have previously shown that in 24-hour urine, prorenin is not converted into renin prior to 
freezing 22. To determine adequate 24-hour urine collection, we calculated the expected 
99% quantile of creatinine excretion based on previously defined criteria 23. Patients 
who exceeded the expected range were excluded (8 patients with ADPKD and 1 patient 
with CKD). ADPKD patients underwent magnetic resonance imaging to determine total 
kidney volume 19. The World Health Organization defined daily dose (DDD) was used to 
calculate daily RAAS-inhibitor use.
Measurements
Plasma and urine samples from the DIPAK and PREVEND cohorts were measured simul-
taneously. Renin in plasma was measured with a commercially available immunoradio-
metric kit (Renin III; Cisbio, Gif-sur-Yvette, France), making use of an active site-directed 
radiolabeled antibody 24. Total plasma renin was determined simultaneously using the 
same kit after the induction of a conformational change in the prorenin molecule with 
aliskiren (10 μmol/l for 48 hours at 4°C), which enabled its recognition by the active site-
directed radiolabeled antibodies applied in the Cisbio kit 25. The detection limit of this 
assay is 1 pg/ml with intra- and inter-assay coefficients of variation (CVs) of 2.4% and 
7.2%. Urinary renin and urinary total renin (after prorenin activation with trypsin) were 
measured with an in-house enzyme kinetic assay (EKA) 26. This measurement involves the 
incubation of the urine sample with excess sheep angiotensinogen and angiotensinase 
inhibitors and the subsequent detection of the generated Ang I by radioimmunoassay. 
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The detection limit of the EKA is 0.05 ng Ang I/ml per hour with intra- and inter-assay 
CVs of 2.9 and 12.6%. Ang I–generating activities were converted to renin concentrations 
based on the fact that 1 ng Ang I/ml per hour corresponds with 2.6 pg human renin/ml 
26. Prorenin was determined by subtraction of renin from total renin. Angiotensinogen in 
plasma and urine was measured as the maximum quantity of Ang I that was generated 
during incubation with excess recombinant renin 27. The detection limit of this assay is 
0.50 pmol/ml with intra- and inter-assay CVs of 4 and 10%. Aldosterone was measured 
by solid-phase radioimmunoassay (Diagnostic Products Corporation, Los Angeles, Cali-
fornia, USA), with a detection limit of 25 pg/ml with intra- and inter-assay CVs of 3.3 and 
8.4% 28.
Statistical Analyses
Results are expressed as mean and standard deviation or median and range, as ap-
propriate. Data were logarithmically transformed before analysis in case of non-normal 
distribution. Levels that were below the detection limit were considered to be half the 
detection limit to allow for statistical analysis 29. Analysis of variance (ANOVA) was used 
for group comparison (using log-transformed data as appropriate). Further analysis was 
performed using analysis of covariance (ANCOVA) to adjust for covariates. To analyze 
which parameters independently predicted urinary angiotensinogen or renin excretion, 
we performed multivariable linear regression. Finally, the Pearson correlation coef-
ficient was analyzed for selected variables. A P-value < 0.05 was considered statistically 
significant. Statistical analyses were performed with SPSS (version 21, IBM).
ReSultS
ADPKD increases urinary Angiotensinogen and Renin excretion
table 2 shows the baseline characteristics and RAAS-component measurements for the 
ADPKD and CKD groups. Patients with ADPKD were younger (47 vs. 68 years), taller (175 
vs. 169 cm), and used more RAAS-inhibitors. While plasma levels of angiotensinogen, 
renin, and aldosterone were similar between the two groups, 24-hour urine volume, and 
urinary albumin, angiotensinogen, renin, and aldosterone excretions were significantly 
higher in patients with ADPKD (P < 0.05 for all). Similarly, when expressed as ratio with 
creatinine, urinary angiotensinogen and renin were also significantly higher in ADPKD 
(urinary angiotensinogen 14.6 vs. 3.3 pmol/mol creatinine, urinary renin 204 vs. 44 pg/
mol creatinine, p < 0.01 for both). Because of the group differences in age, height, DDD, 
and albuminuria, we also performed a second analysis adjusting for these factors (table 
2). This analysis showed that urinary angiotensinogen and renin excretion were still 
significantly higher in ADPKD than CKD (P < 0.001 for both). In addition, a subanalysis 
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was performed in patients (n = 17 vs. 11) with similar age, gender, height and a similar 
degree albuminuria, which also showed that urinary angiotensinogen (286.2 vs. 38.7 
pmol/day) and renin (1874 vs. 398.6 pg/day) excretions were significantly higher in 
ADPKD compared to CKD (P < 0.05 for both).






Clinical data Age, years 47 ± 8 68 ± 8 < 0.001
Male gender, n (%) 25 (42) 25 (44) N.T.¶
Height, cm 175 ± 10 169 ± 9 0.001
Weight, kg 81.6 ± 17.0 81.2 ± 11.9 0.9
Hypertension, n (%)† 56 (93) 49 (86) N.T.
SBP, mmHg 131 ± 14 134 ± 14 N.T.
DBP, mmHg 79 ± 9 76 ± 7 N.T.
RAAS-inhibitors, n (%) 50 (83) 44 (77) N.T.
DDD RAAS-inhibitors, n 1.9 ± 1.5 1.1 ± 0.9 < 0.001
Plasma Creatinine, mg/dL 1.5 ± 0.4 1.4 ± 0.4 0.6
eGFR, ml/min per 1.73 m2 48 ± 11 46 ± 9 N.T.
Angiotensinogen, pmol/mL 1599 (313–8067) 1455 (474–3567) 0.3
Renin, pg/mL 81.3 (9.6–950.0) 68.3 (14.8–464.5) 0.3
Aldosterone, pg/mL 121.7 (16.5–470.1) 105.9 (16.6–546.4) 0.2
urine Volume, mL/day 2233 (800–6500) 1652 (530–3140) < 0.001 0.2
Creatinine, mmol/day 13.3 (5.2–21.2) 10.9 (6.0–18.2) < 0.001 0.8
Albumin, mg/day 40.0 (3.1–266.4) 26.7 (3.4–293.2) 0.05 -
Sodium, mmol/day 150 (40 – 354) 142 (60 – 371) 0.5
Angiotensinogen, pmol/day 194.4 (3.5–3384.0) 36.0 (2.3–1070) < 0.001 < 0.001
Renin, pg/day 2717 (375.7–69248.0) 485.5 (154.7–2293.0) < 0.001 < 0.001
Aldosterone, μg/day 4.6 (0.9–32.8) 3.5 (1.0–18.0) 0.02 0.2
ADPKD, autosomal dominant polycystic kidney disease; CKD, chronic kidney disease; DBP, diastolic blood pressure; DDD, 
defined daily dose; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure.
footnotes:
*  Using analysis of variance (ANOVA) with log-transformed data as appropriate
**   Using analysis of covariance (ANCOVA) with log-transformed data as appropriate and adjustments for age, height, 
defined daily dose, and albuminuria
¶  N.T., not tested (matching criteria). † Defined by use of antihypertensive drugs.
effects of RAAS-inhibitors
Because the use of RAAS-inhibitors increases plasma renin, this may also increase urinary 
renin. Therefore, we also report the plasma and urinary RAAS-components in patients with 
and without RAAS-inhibitor use (figure 1). Plasma renin was indeed significantly higher in 
both ADPKD and CKD patients using RAAS-inhibitors. In patients without RAAS-inhibitors, 
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plasma renin was significantly lower in ADPKD than in CKD. Despite these differences in 
plasma renin, urinary renin excretion was consistently higher in the patients with ADPKD 
than in the patients with CKD regardless of RAAS-inhibitor use (figure 1). Urinary angio-
tensinogen excretion was significantly higher only in patients with ADPKD and RAAS-in-






 figure 1. Plasma concentrations and urinary excretions of angiotensinogen and renin in patients with 
ADPKD or CKD and with or without RAAS-inhibitors. Box-and-whisker plots of plasma concentrations 
and urinary excretions of renin and angiotensinogen for ADPKD (light grey) and CKD (dark grey). Groups 
were subdivided into those with (+) and without (-) use of RAAS-inhibitors (RAASi). Of the 60 patients with 
ADPKD, 10 patients did not use RAASi; of the 57 CKD patients, 13 patients did not use RAASi. Boxes show the 
median, interquartile range and range. ANOVA was used for comparison with * P < 0.05.
Predictors of urinary Angiotensinogen and Renin excretion
Two multivariable linear regression analyses were performed to analyze which factors 
independently predict urinary angiotensinogen or urinary renin excretion (table 3). In 
the model we included the presence of ADPKD, eGFR, age, DDD, plasma concentrations 
of angiotensinogen and renin, and urinary sodium and albumin excretion. For urinary 
angiotensinogen excretion, ADPKD, eGFR, and albuminuria were identified as indepen-
dent predictors. For urinary renin excretion, ADPKD, plasma renin, and albuminuria were 
identified as independent predictors. When the analyses were restricted to patients with 
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ADPKD, only albuminuria predicted urinary angiotensinogen excretion, and only plasma 
renin predicted urinary renin excretion (data not shown).
table 3. Multivariable analysis of factors predicting urinary angiotensinogen and renin excretion. 
variable urinary angiotensinogen excretion urinary renin excretion
β P-value β P-value
Presence of ADPKD 9.6 (3.7 – 24.5) < 0.001 4.9 (2.6 – 9.0) < 0.001
eGFR, ml/min/1.73 m2 0.96 (0.94 – 0.99) 0.002 0.99 (0.98 – 1.01) 0.3
Age, years 1.0 (0.9 – 1.1) 0.2 0.99 (0.97 – 1.02) 0.6
DDD RAAS-inhibitors, n 0.8 (0.7 – 1.0) 0.1 0.9 (0.8 – 1.1) 0.2
Plasma renin, pg/mL 0.5 (0.3 – 1.0) 0.05 1.9 (1.2 – 2.9) 0.007
Plasma AGT, pg/mL 3.0 (0.9 – 10.7) 0.08 1.1 (0.5 – 2.4) 0.9
Urinary sodium, mmol/day 1.6 (0.4 – 7.1) 0.5 1.0 (0.4 – 2.8) 0.9
Albuminuria, mg/day 6.2 (3.6 – 10.7) < 0.001 1.6 (1.1 – 2.3) 0.01
ADPKD, autosomal dominant polycystic kidney disease; AGT, angiotensinogen; DDD, defined daily dose; eGFR, estimated 
glomerular filtration rate; RAAS, renin-angiotensin-aldosterone system.
Correlations with total Kidney volume and Kidney function
Within the ADPKD group, we analyzed whether circulating or urinary RAAS-components 
correlated with total kidney volume and kidney function (eGFR). A higher total kidney 
volume correlated with higher plasma renin, and more albuminuria, but not with 
urinary angiotensinogen or renin excretion (figure 2A). Both higher plasma renin and 
higher urinary renin excretion correlated with lower eGFR (figure 2B). To analyze the 
possible mechanism of urinary angiotensinogen and renin excretion, we analyzed in the 
ADPKD and CKD groups whether these two urinary RAAS-components correlated with 
albuminuria. Indeed, both in patients with ADPKD and CKD, a higher degree of albu-
minuria correlated with higher urinary angiotensinogen or renin excretion, although the 
strength of this correlation was modest (figure 2C). For urinary renin excretion, this 
correlation was of borderline significance in patients with ADPKD (P = 0.06).
Comparison of Concentrations in Plasma, Cyst fluid, and urine
In three patients with ADPKD who underwent nephrectomy, we measured albumin, 
angiotensinogen, prorenin, and renin in plasma, cyst fluid (average concentration of five 
cysts) and urine. For all four parameters, the concentrations were highest in plasma fol-
lowed by cyst fluid and urine (figure 3). Of interest, urinary concentrations were lower 
than cyst concentrations except for renin. Urinary prorenin concentrations were close to 
or below the detection limit.
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figure 2. Correlations of RAAS-components with total kidney volume and kidney function. Pearson 
correlation coefficients were calculated using log-transformed data. Height-adjusted total kidney volume 
was available in 51 patients with ADPKD. Correlations between urinary albumin, angiotensinogen, and re-
nin excretion are shown both for patients with ADPKD and CKD.
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figure 3. Concentrations of Albumin and RAAS-components in plasma, cyst fluid, and urine. With plas-
ma values set to 1, this figure shows the relative mean concentrations of albumin, angiotensinogen (AGT), 
prorenin, and renin in plasma (P), cyst fluid (C) and urine (U). The actual mean plasma concentrations were 
42 g/L, 1814 pmol/L, 573.8 pg/mL, and 81.3 pg/mL, respectively. Measurements were performed in three 
ADPKD patients, who underwent elective nephrectomy to create space for kidney transplantation (45 and 
52 year-old males with eGFRs of 12 and 9 mL/min/1.73 m2, respectively) or because of mechanical discom-
fort (71-year-old female, eGFR 18 mL/min/1.73 m2).
DiSCuSSion
This study reveals a unique feature of patients with ADPKD, namely a consistently 
higher urinary excretion of angiotensinogen and renin compared to patients with 
CKD. Urinary angiotensinogen and renin excretions were 5- to 6-fold higher in patients 
with ADPKD than in patients with CKD, who were matched by eGFR, blood pressure, 
and RAAS-inhibitor use (table 2). ADPKD remained a significant predictor for urinary 
angiotensinogen and renin excretion in adjusted and in multivariable analyses (tables 
2 and 3), and regardless of RAAS-inhibitor use (figure 1). Recent studies found higher 
urinary angiotensinogen to creatinine ratios in normotensive ADPKD patients compared 
to healthy controls 18, or higher levels within ADPKD patients in the presence of hyper-
tension 14 or reduced kidney function 15. The magnitude of the urinary angiotensinogen 
levels reported in these previous studies are comparable to our data. Our study is the 
first to analyze urinary renin and to use patients with CKD as control group (table 1). 
Although our cross-sectional study cannot give definitive answers, our data give direc-
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tions on the possible mechanisms and potential clinical implications of the increased 
urinary excretions.
In principle, urinary angiotensinogen and renin excretion can increase in ADPKD because 
of (1) damage to the glomerular filtration barrier, (2) reduced proximal tubular reabsorp-
tion, (3) enhanced tubular secretion by intact nephrons, (4) differences in degradation, 
or (5) ectopic production by cyst-lining epithelial cells.
When evaluating the first two possibilities, it is important to correct for differences in the 
plasma levels. Although the correlation between total kidney volume and plasma renin 
in ADPKD patients indeed suggests that renal ischemia by cysts can increase plasma 
renin (figure 2A), patients with ADPKD in general do not have higher plasma renin con-
centrations than patients with CKD (table 2). In fact, patients with ADPKD without RAAS-
inhibitors had significantly lower plasma renin concentrations than patients with CKD 
(figure 1). Thus, the higher urinary excretions of angiotensinogen and renin in ADPKD 
are not simply the consequence of elevated plasma RAAS concentrations exposed to 
the same degree of filtration and reabsorption as in CKD patients. In addition, increase 
of cysts (i.e. total kidney volume) did not correlate with increased excretion of urinary 
angiotensinogen or renin. Next, it is important to emphasize that ADPKD is primarily a 
tubular disorder that is less likely to damage the glomerular filtration barrier 30. Indeed, 
previous studies have attributed albuminuria in animal models of ADPKD to disturbed 
endocytosis of albumin in the proximal tubule 30, 31. In these studies, immunohistochem-
istry showed less expression of the chloride channel ClC-5 and megalin, which are both 
involved in the reabsorption of low-molecular weight proteins. Because albumin, angio-
tensinogen, and renin are all reabsorbed by a megalin-dependent pathway, a proximal 
tubular disorder should by definition result in higher urinary angiotensinogen and renin 
excretion, even in the face of identical or lower plasma RAAS-component levels 32, 33. 
In agreement with this concept, we recently showed that patients with Dent’s disease 
(who lack ClC-5) displayed a 20-40-fold rise in urinary angiotensinogen and renin 
levels, although their plasma RAAS levels were in the normal range 33. Similarly, other 
urinary markers of proximal tubule damage, such as fetuin-A and β2-microglobulin, are 
increased in ADPKD 34, 35. The ADPKD component that independently predicted urinary 
angiotensinogen and renin excretion in our multivariable regression analysis therefore 
possibly reflects a difference in tubular reabsorption. We showed that albuminuria cor-
related with total kidney volume (figure 2A), as was shown previously 36. In addition to 
ADPKD, albuminuria also independently predicted urinary renin and angiotensinogen 
excretion. This also suggests that the urinary excretions of albumin, angiotensinogen, 
and renin was at least in part due to similar mechanisms, and argues against selective 
tubular secretion of RAAS-components. This leaves the issue of altered degradation. 
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Reduced reabsorption would also be expected to result in elevated levels of RAAS-
component degrading enzymes, leading to enhanced degradation. Yet, higher levels 
of urinary RAAS-components were found in ADPKD. Combined with data from previous 
studies showing no evidence for urinary degradation of renin or prorenin 22, and identi-
fying all urinary angiotensinogen as intact (and not cleaved) 37, it appears that reduced 
degradation does not underlie the increased urinary excretion of angiotensinogen and 
renin in ADPKD.
The possibility of ectopic RAAS-component production by cyst-lining epithelial cells 
has been suggested by several investigators 38, 39. Although we cannot entirely exclude 
this possibility, such local production should have resulted in angiotensinogen and 
renin concentrations in cyst fluid that would have been at least comparable to, if not 
far above, their plasma concentrations. Remarkably, this was not the case (figure 3). 
In fact, relative to albumin, the concentrations of angiotensinogen, renin and prorenin 
were lower in cyst fluid (figure 3). In other words, when using cyst albumin concentra-
tions as a measure of blood-derived proteins, cyst RAAS-component concentrations 
can be entirely explained on the basis of leakage from blood plasma. Of interest, the 
urinary concentrations of albumin, angiotensinogen, and prorenin were lower than 
their concentrations in cyst fluid. This most likely reflects further dilution and/or tubular 
reabsorption. Surprisingly, this was not the case for renin: its concentrations in cyst fluid 
and urine were similar (figure 3). Moreover, the correlation between albumin and renin 
excretion, although modest, showed a different pattern in ADPKD than in CKD (figure 
2C). Taken together, these data suggest that ADPKD affects the urinary excretion of renin 
differently than of albumin, angiotensinogen and prorenin. This difference between 
renin and prorenin excretion (resulting in urinary prorenin levels that are virtually 
undetectable), has been observed before 22, 33. Of note, we did not measure the sodium 
concentration in cyst fluid; previously, more active renin was found in so-called “gradi-
ent cysts” in which the sodium concentration is low 5.
Many aspects of the intra-renal renin-angiotensin system remain unclear, although some 
groups have suggested that angiotensinogen and renin in tubular fluid may lead to high 
tubular angiotensin II levels 13, 38. Such high local angiotensin II levels could promote re-
nal sodium retention, hypertension, kidney damage, or even cystogenesis 38. Of interest 
in this regard is a recent report where targeting the intra-renal renin-angiotensin system 
reduced cyst growth in an animal model of polycystic kidney disease 40. Based on our 
cross-sectional data, we cannot conclude whether the higher urinary angiotensinogen 
and renin excretions are a cause or a consequence of the kidney damage in ADPKD. In 
other words, it is unclear if higher urinary angiotensinogen and renin excretion should 
be considered as a damage marker or as a potential contributor to kidney damage. 
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Given the experimental link between the intra-renal renin-angiotensin system and 
cystogenesis, this deserves further study.
A number of limitations of this study should be mentioned. First, RAAS-inhibitor use 
could have influenced our results. Ideally, urinary RAAS-components should be mea-
sured before and after starting a RAAS-inhibitor. Previous studies have shown a decrease 
of urinary angiotensinogen and no effects on urinary renin after initiation of an angioten-
sin receptor blocker in patients with chronic kidney disease 41, 42. Therefore, if anything, 
our ADPKD group would be expected to have lower urinary angiotensinogen excretion, 
which was not the case. Second, despite matching of ADPKD with CKD patients by the 
most relevant parameters (eGFR, blood pressure, RAAS-inhibitors), several differences 
remained. The difference in age was inevitable, as eGFR decline occurs much earlier in 
ADPKD than in other forms of CKD. We addressed these differences by using an adjusted 
analysis, multivariable analyses, and a subanalysis (table 2, table 3). Finally, although 
significant, the strength of the correlations observed in this study were modest, suggest-
ing high inter-individual variability or a multifactorial origin.
In conclusion, ADPKD uniquely increases urinary angiotensinogen and renin excretion 
despite their circulating levels being comparable to those in CKD. We believe these find-
ings warrant further analysis in mechanistic or intervention studies.
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Metabolic acidosis is common in patients with chronic kidney disease (CKD) and may 
contribute to progression of CKD and all-cause mortality 1. However, little is known on 
how CKD changes the response to an acute acid load, and whether an altered response 
could contribute to adverse outcomes 2. Therefore, our aim was to characterize the dif-
ferences between the response to an acute oral acid load (to mimic the dietary acid 
load) in patients with CKD and healthy subjects.
To do so, we performed the short acid-loading test with ammonium chloride in 9 males 
with CKD stage G4 and in 16 healthy male subjects (see Supplement for complete 
methods and baseline characteristics) 3. The study was approved by the Medical Ethics 
Committee (MEC-2016-329) and registered at ClinicalTrials.gov (NCT03293446). In the 
patients with CKD, all antihypertensive drugs (except beta-blockers) were discontinued 
for 2 weeks to avoid drug interference. The test started after an overnight fast by giving a 
10% oral solution of ammonium chloride (100 mg/kg body weight) over a period of 1 hour 
together with a standardized meal (25 mmol sodium, 28 mmol potassium) and a water 
load (5 mL/kg followed by 2.5 mL/kg/hour). The response to the acid load was observed 
for 6 hours with repeated sampling of venous blood (at t = 0, 3, and 6 hours) and urine 
(hourly). Group comparisons were performed using repeated measures 2-way ANOVA.
At baseline, blood and urine pH and plasma bicarbonate of the patients with CKD was 
significantly lower (figure 1 and figure S1). After three hours, ammonium chloride 
reduced blood pH and plasma bicarbonate and raised plasma potassium and plasma al-
dosterone similarly in both groups (figure 1 and figure S1). At the end of the test, how-
ever, blood pH, plasma potassium, and plasma aldosterone were returning to normal in 
the healthy subjects, but not in the patients. Plasma renin did not change significantly 
during the test. The patients and healthy subjects adequately lowered urine pH (< 5.3 in 
all participants). The healthy subjects and the patients also increased urine ammonium 
excretion after one hour, but the increase in healthy subjects was significantly greater 
and persisted over time (figure 1). This resulted in a significantly lower cumulative 
ammonium excretion in patients (figure S1). Accordingly, net acid excretion was also 
significantly lower in patients (no difference in titratable acid, figure S1).  The same pat-
tern as for urine ammonium excretion was also observed for urine sodium, chloride, and 
potassium excretion. The urine excretion of creatinine, albumin and the low-molecular 
weight proteins retinol-binding protein and renin also acutely increased after the acid 
load, with normalization thereafter (figure 1 and figure S2). No differences between 
the groups were observed for the courses in creatinine and protein excretion, except for 
urinary renin. In patients with CKD, systolic blood pressure fell during the first two hours 
and increased thereafter, whereas it remained stable in the healthy subjects (figure S2). 
Because patients were significantly older than healthy subjects, we also performed a 
subanalysis with older healthy subjects and found similar results (data not shown).
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figure 1. Effects of an acute acid load with ammonium chloride on venous blood pH and urine pH (A), 
urine ammonium excretion (B), plasma potassium (K+, C), plasma renin and aldosterone (D), urine sodium 
excretion, and cumulative excretion of sodium, chloride, and potassium (e), urine creatinine excretion (f), 
and urine renin excretion (g). Group comparison was performed using repeated measures 2-way ANOVA 
reporting the P-value for interaction. Cumulative excretions were compared with unpaired T-tests. Urine 
renin was not normally distributed and therefore log-transformed for analysis.
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Here, we characterized the response to an acute acid load on acid-base, electrolyte, 
creatinine, and protein handling by the kidney and addressed whether this response is 
altered in patients with CKD. We show that urinary ammonium excretion is reduced in 
patients with CKD increasing the duration of the acidosis. Of note, per-nephron ammo-
nium excretion was likely higher in patients with CKD, although this was not sufficient 
to prevent the acidosis after acid-loading. Persisting acidemia may have contributed to 
the higher plasma potassium in patients with CKD by decreasing sodium-hydrogen ex-
change and sodium-potassium ATPase activity in cells 4. Furthermore, cumulative potas-
sium excretion was lower in patients with CKD, which may also have contributed to the 
rise in plasma potassium. Aldosterone was not a limiting factor for potassium secretion, 
as this increased in the patients with CKD. It is well characterized that metabolic acidosis 
induces natriuresis initially 5-7, and we also observed this.  In patients with CKD sodium 
excretion was lower, although – similar to ammonium – per-nephron sodium excretion 
was likely higher. Patients with CKD developed higher plasma aldosterone levels after 
acid loading, with higher plasma potassium or acidosis as potential drivers 8. Another 
interesting observation was that the acid load acutely increased the excretion of creati-
nine, albumin, and low-molecular weight proteins. This could be caused by glomerular 
hyperfiltration or an effect on the proximal tubule (decreased protein reabsorption, 
increased creatinine secretion). We favor hyperfiltration as explanation, because this 
was previously observed after ammonium chloride loading in children 7 and rats 9, and 
because a previous micropuncture study did not find evidence for inhibition of proximal 
tubular reabsorption 6. However, measurement of glomerular filtration rate would have 
been necessary to differentiate between the two possibilities.
Our data add potential explanations why metabolic acidosis in patients with CKD may 
contribute to adverse outcomes 2. First, longer lasting acidemia causes a greater rise 
in plasma potassium and will therefore increase susceptibility to hyperkalemia and its 
complications 10. Second, the lower pH and higher plasma potassium raise plasma al-
dosterone, which  may promote kidney fibrosis 11. Third, acidosis increases proteinuria, 
which has been identified as risk factor for progression of CKD 12. Although this change 
also occurred in healthy volunteers, the acid load exposes patients with CKD to a greater 
degree of proteinuria, which may contribute to further kidney injury. Moreover, the acid 
load did cause a greater increase in urinary renin in patients than in healthy subjects, 
indicating differences between individual proteins 13.  A limitation of this study is that 
we did not include measurements of glomerular hemodynamics. Future studies are re-
quired to evaluate if the identified differences in the acute response to acid loading also 
play a role in the long-term outcomes of CKD. In summary, we show that CKD alters the 
response to an acute acid load and we propose that this altered response may explain 
some of the associations between metabolic acidosis and outcomes in CKD.
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Patients with chronic kidney disease stage G4 were recruited from our nephrology out-
patient clinic. Healthy volunteers were recruited using flyers on the university campus 
and the hospital. Exclusion criteria for patients were plasma bicarbonate level < 20.0 
mEq/L, plasma potassium > 5.5 mmol/L, use of bicarbonate, citrate or acetazolamide 
in the month preceding the test, heart failure, liver cirrhosis, blood pressure >140/90 
mmHg despite the use of 3 different anti-hypertensive drugs, history of kidney trans-
plantation, use of calcineurin inhibitors, known urea cycle disorder, alcoholism or drug 
abuse, pregnancy, current use of antibiotics, non-steroidal anti-inflammatory drugs, in-
ability to adhere to the study protocol (due to language barrier or intellectual disability).
Study procedure
The study started with a 2-week run-in period during which all antihypertensive medica-
tion was discontinued, except for beta-blockers. Patients were provided with a home 
blood pressure monitor (Omron HBP-1300, Omron Healthcare, The Netherlands) and 
instructed to measure blood pressure twice daily. If the systolic blood pressure (SBP) 
was ≥ 160 mmHg during three consecutive measurements, amlodipine was started (5 
mg once daily with possible titration to 10 mg once daily). 24-hour urine was collected 
during the day prior to the test. Participants remained in supine position for at least 45 
minutes before each measurement and sample collection.
Measurements
Plasma and urine electrolytes, albumin, and creatinine were measured at the Depart-
ment of Clinical Chemistry of the Erasmus Medical Center. Estimated glomerular filtra-
tion rate (eGFR) was calculated using the CKD-EPI equation 14. Venous blood gas analysis 
and the measurement of bicarbonate in urine was performed directly after sample col-
lection on a blood gas analyzer on site (ABL90 Flex Plus, Radiometer, The Netherlands; 
RAPIDLab 1265, Siemens, Germany). Urine pH was measured by a HI991001 pH meter 
(Hannah Instruments, Nieuwegein, The Netherlands) immediately after collection. 
Urine ammonium was measured using the Berthelot-method as described previously 
15, 16. Urine titratable acid (expressed as mEq/L) was calculated by the following method: 
the molarity of NaOH (0.1) times the volume of NaOH that was needed to titrate a urine 
sample to pH 7.40 at 37º C, divided by the volume of the urine sample. Net acid excretion 
was calculated as the sum of urinary ammonium and titratable acid minus bicarbonate 
(all in mEq/L). Plasma renin was measured using a radioimmunometric assay (Cisbio, 
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Saclay, France). Urine renin was measured using an in-house enzyme-kinetic assay that 
quantifies angiotensin I generation in the presence of excess sheep angiotensinogen 
17, 18. In order to convert angiotensin I-generating activity to renin concentration, a 
conversion factor was used based on the fact that 1 ng Ang I/mL per hour corresponds 
with 2.6 pg human renin/mL. Plasma aldosterone was measured by radioimmunoassay 
(Demeditec, Kiel, Germany).
Calculations
Estimated protein intake was calculated using the following formula: [protein intake = 
6.25 * (UUN + 0.031 * body weight) – urinary protein (g/d) if daily urine protein excretion 
≥ 5 g.19 UUN indicates urine urea nitrogen excretion (g/24 hour) and was calculated by 
multiplying the 24-hour urine urea excretion (mmol/day) times 2 (the number of nitrogen 
atoms in urea) and the molecular weight of nitrogen (14.0067 g/mol). Net endogenous 
acid production (NEAP) was calculated using the following formula: NEAP = −10.2 + 54.5 
[protein intake (g/d) / potassium intake (mEq/d). Daily potassium intake was estimated 
using 24-hour urinary potassium excretion 20.
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Age, years 39 ± 17 66 ± 15*
Body mass index, kg/m2 24.7 ± 2.9 27.1 ± 2.9
eGFR, ml/min/1.73m2 101 ± 16 26 ± 8*
Diabetes mellitus, n (%) 0 (0) 4 (44)
Albuminuria, g/day 0.01 (0.00, 0.01) 0.10 (0.01, 1.13)*
Venous pH 7.35 ± 0.008 7.31 ± 0.01*
Urine pH 6.1 ± 0.2 5.4 ± 0.2*
Plasma bicarbonate, mEq/L 27.7 ± 1.5 23.8 ± 2.1*
Estimated protein intake, g/day 93.1 ± 37.7 71.6 ± 18.2
NEAP, mEq/day 55.1 ± 24.6 55.2 ± 16.7
Data are presented as n (%), mean ± SD or median (interquartile range). * P < 0.05 for comparison to healthy controls by 
unpaired T-test or χ2-test. CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; NEAP, net endogenous 
acid production.
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figure S1. Effects of an acute acid load with ammonium chloride on plasma bicarbonate (HCO3-, A), venous 
pCO2 (B), urinary titratable acid excretion (C), net acid excretion (D), cumulative urine ammonium excre-




figure S2. Effects of an acute acid load with ammonium chloride on the urine excretion of chloride and 
potassium (A), and urine excretion of albumin and retinol-binding protein (B), and systolic blood pressure 
(C) Group comparison was performed using repeated measures 2-way ANOVA reporting the P-value for in-
teraction. Cumulative excretion was compared with unpaired T-tests. Urine albumin and retinol-binding 
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Background: Acidosis-induced kidney injury is mediated by the intrarenal renin-angio-
tensin system, for which urinary renin is a potential marker. Therefore, we hypothesized 
that sodium bicarbonate supplementation reduces urinary renin excretion in patients 
with chronic kidney disease (CKD) and metabolic acidosis.
Methods: Patients with CKD stage G4 and plasma bicarbonate 15-24 mmol/l were ran-
domized to receive sodium bicarbonate (3x1000 mg/day, ~0.5 mEq/kg), sodium chloride 
(2x1000 mg/day), or no treatment for 4 weeks (n=15/arm). The effects on urinary renin 
excretion (primary outcome), other plasma and urine parameters of the renin-angioten-
sin system, endothelin-1, and proteinuria were analyzed.
Results: Forty-five patients were included (62 ± 15 years, eGFR 21 ± 5 ml/min/1.73m2, 
plasma bicarbonate 21.7 ± 3.3 mmol/l). Sodium bicarbonate supplementation increased 
plasma bicarbonate (20.8 to 23.8 mmol/l) and reduced urinary ammonium excretion (15 
to 8 mmol/day, both P<0.05). Furthermore, a trend towards lower plasma aldosterone 
(291 to 204 ng/L, P=0.07) and potassium (5.1 to 4.8 mmol/l, P=0.06) was observed in pa-
tients receiving sodium bicarbonate. Sodium bicarbonate did not significantly change 
the urinary excretion of renin, angiotensinogen, aldosterone, endothelin-1, albumin, 
or α1-microglobulin. Sodium chloride supplementation reduced plasma renin (166 to 
122 ng/L), and increased the urinary excretions of angiotensinogen, albumin, and α1-
microglobulin (all P<0.05).
Conclusions: Despite correction of acidosis and reduction in urinary ammonium ex-
cretion, sodium bicarbonate supplementation did not improve urinary markers of the 
renin-angiotensin system, endothelin-1, or proteinuria. Possible explanations include 
bicarbonate dose, short treatment time, or the inability of urinary renin to reflect intra-
renal renin-angiotensin system activity.
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intRoDuCtion
Metabolic acidosis is a common complication in patients with chronic kidney disease 
(CKD). The prevalence of metabolic acidosis (usually defined as a plasma bicarbonate 
concentration <22 mmol/l) increases with higher CKD stage and is 26% and 47% for CKD 
stages G4 and G5, respectively.1, 2 Metabolic acidosis in CKD is associated with a more 
rapid progression of CKD.3-5 A recent systematic review showed that metabolic acidosis 
is a modifiable risk factor for CKD progression as interventions with oral alkali supple-
mentation or an alkaline diet reduce this risk.6 However, the mechanisms of acidosis-
induced kidney injury are incompletely understood.
Current understanding of how acidosis contributes to kidney injury suggests that acid 
retention triggers an adaptive response to increase ammoniagenesis.7 This process is 
orchestrated by activation of the circulating and intrarenal renin-angiotensin systems 
(RAS) and endothelin-1. However, in a chronic setting and at the single-nephron level, 
this adaptive response may become maladaptive with the RAS and endothelin-1 con-
tributing to inflammation and fibrosis.8 For example, it has been shown that locally 
produced ammonium can activate the complement system with subsequent tubulo-
interstitial inflammation and fibrosis.9 In rats, induction of CKD with 2/3rd nephrectomy 
causes acid retention and higher levels of angiotensin II and aldosterone in the kidney; 
alkali treatment reverses these changes.10 In clinical studies, alkali treatment reduced 
plasma and urinary aldosterone in patients with CKD stage G2 and G4.11, 12 Similar find-
ings have been reported for plasma and urinary endothelin-1.10, 13-16 However, the activ-
ity of the intrarenal RAS is difficult to assess, because it is questionable to what degree 
urinary RAS components truly reflect intrarenal RAS activity.17, 18
Previous data suggest that the production of angiotensin II in the kidney depends on 
filtered (i.e., blood-derived) components of the RAS, including renin and angiotensino-
gen.19-21 Accordingly, the modest alkali-induced lowering of urinary angiotensinogen in 
patients with CKD stage G3 could suggest reduced intrarenal angiotensin generation.22 
Alternatively, urinary angiotensinogen may simply follow the same urinary excretion 
pattern as albumin.23 Since this is not the case for urinary renin,23, 24 this marker may 
be a more attractive parameter to assess intrarenal RAS activity. Accordingly, we hy-
pothesized that sodium bicarbonate supplementation reduces urinary renin excretion 
in patients with CKD and metabolic acidosis. To address this, we performed an open-
label clinical trial in which patients were randomized to receive sodium bicarbonate or 
sodium chloride, or served as time-controls. In addition to the measurement of plasma 
and urinary RAS parameters, we also analyzed the effects on urinary endothelin-1, albu-





We conducted an open-label randomized controlled trial at 4 study sites in The Neth-
erlands, including Erasmus Medical Center, Rotterdam, Amsterdam University Medical 
Centers. University Medical Center Groningen and Leiden University Medical Center. The 
study was approved by the Medical Ethics Committee of the Erasmus Medical Center 
(MEC-2013-332). The trial was registered at clinicaltrials.gov with registration number 
NCT02896309. Patients were recruited from outpatient nephrology clinics between April 
2014 and December 2018. All patients with CKD stage G4 (eGFR 15-30 ml/min/1.73m2) 
and with plasma bicarbonate levels between 15.0 and 24.0 mmol/l were eligible for inclu-
sion. Exclusion criteria were sodium bicarbonate use in the month preceding the study, 
heart failure New York Heart Association class 3 or 4, liver cirrhosis with ascites and the 
inability to withdraw diuretics, systolic blood pressure > 140 mmHg despite the use of 
three different antihypertensive drugs, kidney transplantation, and use of calcineurin 
inhibitors. Patients were randomized for 4-week treatment with sodium bicarbonate (3 
x 1000 mg/day, providing a sodium load of 36 mmol per day), sodium chloride (2 x 1000 
mg/day, providing a sodium load of 34 mmol per day) or no treatment (time control). 
Allocation to treatment was done by randomization using sequentially numbered, 
opaque, sealed envelopes. Stratified randomization was used to ensure that a similar 
number of patients were allocated to each intervention at the different study sites.
Measurements
At baseline and after 2 and 4 weeks, blood and 24-hour urine samples were collected 
and office blood pressure was measured. Plasma and urine electrolytes, albumin, cre-
atinine, and a1-microglobulin were measured at the Department of Clinical Chemistry 
of the Erasmus Medical Center. Venous blood gas analysis was performed directly after 
sample collection on a blood gas analyzer (ABL90 Flex Plus, Radiometer, The Nether-
lands; RAPIDLab 1265, Siemens, Germany). Estimated glomerular filtration rate (eGFR) 
was calculated using the CKD-EPI equation.25 Creatinine clearance was calculated based 
on plasma and urinary creatinine excretion. Urinary ammonium was measured using 
the Berthelot-method, as described previously.26 Plasma renin was measured using a 
radioimmunometric assay (Cisbio, Saclay, France). Urinary renin was measured using an 
in-house enzyme-kinetic assay that quantifies angiotensin I generation in the presence 
of excess sheep angiotensinogen.27 In order to convert angiotensin I-generating activity 
to renin concentration, a conversion factor was used, based on the fact that 1 ng Ang I/
mL per hour corresponds with 2.6 pg renin/mL. Urinary angiotensinogen was measured 
as the maximum quantity of Ang I that was generated during incubation with excess re-
combinant renin using the same in-house assay.27 Plasma and urinary aldosterone were 
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measured by radioimmunoassay (Demeditec, Kiel, Germany). Endothelin-1 was mea-
sured using a Quantikine enzyme-linked immunosorbent assay (ELISA; R&D systems, 
Minneapolis, USA). Urine soluble terminal complement complex sC5b-9 was measured 
by ELISA as previously described.28 All urinary excretions were expressed as ratio with 
urine creatinine to correct for any incomplete collections, as reported previously.29
Statistics
Data are presented as frequencies (percentages), mean ± standard deviation and median 
with 10th-90th percentile, as appropriate. The primary outcome was the change in urinary 
renin-to-creatinine ratio. A power calculation based on previous data indicated that a 
minimum of 45 patients (15 per treatment arm) was required to show that sodium bi-
carbonate supplementation would reduce urinary renin excretion by 0.3 ng/L (α = 0.025, 
β = 0.8, standard error 0.26).23 Secondary outcomes included the urinary-to-creatinine 
ratios of angiotensinogen, endothelin-1, albumin and a1-microglobulin. An exploratory 
analysis was performed for the treatment effects on kidney function, blood pressure and 
plasma potassium. The omnibus K2 test was used to test for normality. Non-normally 
distributed data were log-transformed for statistical analysis. Primary and secondary 
outcomes were analyzed using mixed linear models that included treatment and period 
(time) as fixed effects. In case a significant interaction between treatment and period 
was found, post-hoc tests were performed with correction for multiple comparisons 
according to Dunnett. Data were analyzed using SPSS Statistics (IBM, version 24.0). P < 
0.05 was considered statistically significant.
ReSultS
Baseline characteristics
Forty-seven patients entered the study protocol, of whom two patients discontinued 
treatment due to adverse reactions to sodium chloride supplementation (1 patient with 
gastrointestinal symptoms, 1 patient with polydipsia). Forty-five patients completed the 
study protocol (15 patients/arm). All patients that finished the treatment period were 
included in the analysis of the primary and secondary outcomes. The average age was 
62 ± 15 years, 78% were males, the average eGFR was 21 ± 15 ml/min/1.73m2, and the 
average plasma bicarbonate 21.7 ± 3.3 mmol/l (table 1).
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table 1. Baseline characteristics. Cr, creatinine; eGFR, estimated glomerular filtration rate; NaCl, sodium 











Age, years 62 ± 15 61 ± 17 61 ± 14 64 ± 14 0.9
Males, n (%) 35 (78) 11 (73) 14 (93) 10 (67) 0.2
European descent, n (%) 39 (87) 13 (87) 14 (93) 12 (80) 0.6
Comorbidities
eGFR, mL/min/1.73m2 21 ± 5 21 ± 6 22 ± 3 20 ± 4 0.6
Systolic blood pressure, mmHg 137 ± 16 134 ± 10 126 ± 13 135 ± 22 0.3
Use of RAS-inhibitors, n (%) 39 (87) 13 (87) 12 (80) 14 (93) 0.6
Diabetes mellitus, n (%) 7 (16) 2 (13) 2 (13) 3 (20) 0.8
laboratory data
Plasma bicarbonate, mmol/l 21.7 ± 3.3 20.8 ± 3.9 21.8 ± 2.9 22.4 ± 3.1 0.4











Plasma aldosterone, ng/l 301 (175, 449) 236 (188, 427) 349 (155, 604) 332 (169, 415) 0.5




10.6 (8.5, 11.3) 9.8 (7.8. 13.5) 0.2
Urine ammonium, mmol/mmol Cr 1.2 (1.0, 1.6) 1.1 (0.9, 1.6) 1.0 (0.9, 1.9) 1.4 (1.1, 1.6) 0.6
Urine renin, ng/mmol Cr 1.1 (0.7, 2.0) 0.7 (0.5, 1.5) 1.1 (0.7, 2.1) 1.4 (1.0, 2.1) 0.5
Urine aldosterone, ng/mmol Cr 352 (272, 492) 337 (267, 632) 335 (289, 443) 353 (269, 461) 0.8
Urine angiotensinogen, mg/
mmol Cr 3.4 (0.9, 14.5)
2.0 (0.6, 26.8) 7.1 (1.5, 12.3) 2.0 (1.2, 12.6) 0.9










Urine albumin, mg/mmol Cr 30 (5, 102) 30 (7, 93) 39 (6, 87) 16 (4, 96) 0.8
Urine α1-microglobulin, mg/
mmol Cr
3.6 (2.0, 5.3) 3.9 (1.9, 6.4) 2.8 (2.2, 4.0) 3.8 (1.9, 6.2) 0.5
effects on acid-base status and the renin-angiotensin system
Sodium bicarbonate supplementation increased plasma bicarbonate (with 3.0 ± 0.7 and 
2.9 ± 0.8 mmol/L after 2 and 4 weeks of treatment, respectively; P < 0.01 versus baseline) 
and lowered urinary ammonium excretion (with -7.0 ± 1.5 mmol/day and -3.6 ± 1.9 mmol/
day, P < 0.05 versus baseline, figure 1). No significant changes in plasma bicarbonate 
or urinary ammonium excretion occurred with sodium chloride supplementation and 
without treatment. Sodium chloride but not sodium bicarbonate supplementation 
significantly reduced plasma renin (with -9.5 and -7.9 ng/L, P < 0.05 versus baseline, 
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figure 1). A trend towards a reduction in plasma aldosterone was observed with so-
dium bicarbonate supplementation after 4 weeks (-99 ng/L, P = 0.07). No changes in the 
aldosterone-to-renin ratio were observed with either treatment (data not shown).
figure 1. Sodium bicarbonate increased plasma bicarbonate and urinary sodium excretion and lowered 
urinary ammonium excretion, whereas sodium chloride treatment only increased urinary sodium excre-
tion after 2 weeks of treatment. The horizontal black lines represent the median value; the lower and upper 
boundaries of the box represent the 25th and 75th percentiles; the whiskers represent the lowest and highest 
values. HCO3-, bicarbonate; K+, potassium; Na+, sodium; NaCl, sodium chloride; NH4+, ammonium; NaHCO3, 
sodium bicarbonate. * P < 0.05 for the within-group difference from baseline; † P = 0.07 for the within-group 
difference vs. baseline; # P < 0.05 for the difference vs. control.
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Primary and secondary outcomes
In all three treatment groups, no significant within-group differences were detected 
in the urinary renin-to-creatinine ratio after two or four weeks of treatment (table 2). 
In addition, no between group differences were found. Similarly, sodium bicarbonate 
supplementation had no significant effect on any of the secondary outcome parameters 
(table 2). In the within-group comparison, sodium chloride supplementation increased 
urinary angiotensinogen, albumin, and α1-microglobulin excretion; no between-
group differences were shown for these outcomes (table 2). Five patients did not use 
RAS-inhibitors. Two of these patients received sodium bicarbonate and this reduced 
urinary aldosterone (65% and 39% reduction after 2 and 4 weeks), an effect that was 
not observed with the other interventions. No effects on the other outcome parameters 
was observed. In addition, no differences were observed in a sensitivity analysis of the 
primary and secondary outcomes between patients with CKD stage G4a (eGFR 29-23 
mL/min per 1.73m2) and G4b (eGFR 22-16 mL/min per 1.73m2). To determine whether 
correction of metabolic acidosis reduced the activity of the complement system, we also 
measured soluble terminal complement complex sC5b-9 in urine at the end of treat-
ment. Urine sC5b-9 was undetectable in forty patients (< 0.05 U/ml). Of the five patients 
with detectable urinary complement, three had albuminuria > 1 gram/day.
table 2. Treatment effects on urinary renin-angiotensin, endothelin-1, and protein excretions. 
Measurement treatment Baseline 2 weeks 4 weeks
Urine renin, ng/
mmol Cr
NaHCO3 0.7, 0.4-2.2 0.9, 0.3-3.3 0.9, 0.2-3.1
NaCl 1.1, 0.3-3.7 1.1, 0.1-4.3 1.2, 0.2-5.4
Time control 1.4, 0.5-2.8 1.6, 0.5-2.4 1.8, 0.3-3.1
Urine aldosterone, 
ng/mmol Cr
NaHCO3 337, 171-1179 318, 125-513 356, 166-426
NaCl 335, 142-787 337, 126-627† 317, 156-779




NaHCO3 2.0, 0.4-83.5 4.3, 0.4-84.7 4.3, 0.2-104.5
NaCl 7.1, 0.5-22.9 7.7, 0.4-30.9* 6.2, 0.4-39.0*
Time control 2.0, 0.8-61.5 2.9, 0.9-55.3 5.5, 0.8-78.5
Urine endothelin-1, 
ng/mmol Cr
NaHCO3 0.02, 0.01-0.56 0.05, 0.01-0.31 0.02, 0.01-0.29
NaCl 0.02, 0.01-0.07 0.02, 0.01-0.07 0.02, 0.01-0.07
Time control 0.02, 0.01-0.06 0.02, 0.01-0.04 0.02, 0.01-0.05
Urine albumin, mg/
mmol Cr
NaHCO3 30.4, 3.7-208.3 36.7, 5.8-196.9 40.4, 5.1-189.6
NaCl 38.7, 1.6-124.4 46.4, 1.2-130.3* 58.6, 1.4-177.1*




NaHCO3 3.9, 1.4-10.5 5.6, 1.1-11.1 5.2, 1.3-11.1
NaCl 2.8, 1.3-6.1 3.6, 1.3-8.0* 3.4, 1.4-8.1†
Time control 3.8, 1.0-9.3 6.2, 1.5-9.5 4.5, 1.0-10.8
Cr, creatinine; NaCl, sodium chloride; NaHCO3, sodium bicarbonate. * P < 0.05 for the within-group difference vs. baseline; 
† P = 0.06 for the within-group difference vs. baseline.
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effects on kidney function, blood pressure and plasma potassium
Sodium bicarbonate or sodium chloride supplementation did not lead to significant 
changes in eGFR (table 3). However, sodium bicarbonate did cause a small but statisti-
cally significant increase in urinary creatinine excretion after 4 weeks, which was not 
observed with sodium chloride treatment. No significant differences were identified for 
systolic and diastolic blood pressure within or between groups. After 4 weeks, there was 
a trend towards a reduction in plasma potassium with sodium bicarbonate (P = 0.06 for 
difference baseline versus 4 weeks), which was not observed with sodium chloride and 
without treatment.
table 3. Effects of the sodium bicarbonate intervention on exploratory outcomes kidney function, blood 
pressure, and plasma potassium. 
Measurement treatment Baseline 2 weeks 4 weeks
eGFR, mL/min/1.73m2
NaHCO3 21 ± 6 21 ± 5 21 ± 5
NaCl 22 ± 3 22 ± 4 22 ± 4
Time control 20 ± 4 20 ± 4 20 ± 4
Creatinine clearance, 
mL/min
NaHCO3 30 ± 10 29 ± 11 33 ± 12
NaCl 39 ± 12 39 ± 14 39 ± 14
Time control 32 ± 10 33 ± 10 30 ± 8
Creatinine excretion, 
mmol/day
NaHCO3 10.7, 8.7-13.4 10.2, 8.0-11.9 11.1, 10.3-14.0*
NaCl 13.9, 10.9-17.0 12.5, 10.8-18.4 12.6, 10.7-16.6
Time control 10.3, 8.1-17.7 12.9, 7.4-15.2 10.7, 8.0-15.1
Systolic blood pressure, 
mmHg
NaHCO3 134 ± 10 132 ± 18 132 ± 16
NaCl 126 ± 12 125 ± 13 123 ± 13
Time control 135 ± 22 140 ± 24 134 ± 20
Diastolic blood 
pressure, mmHg
NaHCO3 76 ± 10 75 ± 10 75 ± 10
NaCl 78 ± 8 77 ± 9 78 ± 11
Time control 81 ± 12 81 ± 10 78 ± 12
Plasma potassium, 
mmol/l
NaHCO3 5.1 ± 0.7 4.8 ± 0.5 4.8 ± 0.5†
NaCl 5.0 ± 0.6 4.9 ± 0.4 4.9 ± 0.4
Time control 4.9 ± 0.5 4.7 ± 0.4* 4.9 ± 0.5
eGFR, estimated glomerular filtration rate; NaCl, sodium chloride; NaHCO3, sodium bicarbonate. * P < 0.05 for the within-
group difference from baseline; † P = 0.06 for the within-group difference from baseline.
DiSCuSSion
In this open-label, three-arm randomized controlled trial (RCT) we investigated if so-
dium bicarbonate supplementation in patients with CKD and metabolic acidosis lowers 
urinary renin, as a potential measure of the intrarenal RAS. Sodium bicarbonate supple-
mentation corrected metabolic acidosis and lowered urinary ammonium excretion. 
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Despite these effects, we observed no within or between group differences for urinary 
renin. In addition, sodium bicarbonate had no significant effect on the urinary excretion 
of angiotensinogen, aldosterone, endothelin-1, albumin, or α1-microglobulin. Despite 
these negative findings, we believe our study adds three relevant aspects to the evolving 
field of metabolic acidosis in CKD.
First, several other clinical trials with sodium bicarbonate supplementation were also 
unable to show an effect on their primary endpoints. In this regard, our study is most 
comparable to the recent study by Raphael and colleagues who investigated the effect 
of sodium bicarbonate on urinary kidney injury markers.29 In their placebo-controlled, 
double-blind RCT sodium bicarbonate was supplemented for six months in a dose of 
0.5 mEq/kg to patients with type 1 or type 2 diabetes and an eGFR between 15 and 89 
ml/min/1.73m2. Sodium bicarbonate supplementation increased plasma bicarbonate 
and reduced urinary ammonium, but did not reduce urinary TGF-β1, KIM-1, fibronectin, 
NGAL, or albumin. The most likely explanation for a lack of effect is that the dose of 
sodium bicarbonate was too low. Indeed, most RCTs that were unable to show an ef-
fect on the primary endpoint used a dose of 0.3–0.5 mEq/kg29-31, whereas positive RCTs 
used a higher dose of approximately 1.0 mEq/kg.11, 16, 32 To address this issue, Raphael 
et al. recently published a dose-finding study confirming that a higher dose of sodium 
bicarbonate (0.8 mEq/kg) had a stronger effect on plasma bicarbonate and urinary am-
monium compared with a lower dose (0.5 mEq/kg). Wesson et al. showed that 0.5 mEq/
kg sodium bicarbonate supplementation for 30 days did reduce plasma aldosterone 
and endothelin-1 levels in patients with CKD stage G1 or G2.12 In agreement, we also 
observed that sodium bicarbonate reduced plasma aldosterone, although this was of 
borderline significance. The effect of sodium bicarbonate on aldosterone may be medi-
ated by lowering of plasma potassium, although this was also of borderline significance 
in our study. In the RCT by Melamed et al. sodium bicarbonate supplementation also 
increased plasma bicarbonate and reduced plasma potassium.30 In contrast, three previ-
ous studies did find effects of a lower sodium bicarbonate dose (0.3 or 0.5 mEq/kg) on 
urinary aldosterone, endothelin-1, angiotensinogen, albumin, and NAG, although the 
effect sizes were modest.12, 15, 16 Possible explanations for the discrepancy with our study 
is that previous studies applied a longer treatment time (up to five years) and included 
patients with earlier stages of CKD. Finally, the use of RAS-inhibitors (used by 88% of the 
patients in this study) may suppress the RAS to an extent that alkali has no further effect.
A second issue that is raised by our study is if urinary renin can truly be considered as a 
marker of the intrarenal RAS. Determinants of urinary renin excretion include glomeru-
lar filtration, proximal tubular reabsorption, local production in the collecting duct, and 
intratubular conversion of plasma-derived prorenin to renin. In a study including 101 
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patients with or without diabetes mellitus and hypertension, urinary renin did not cor-
relate with plasma renin and especially dissociated in patients with diabetes mellitus or 
on RAS-inhibitors. Accordingly, we proposed urinary renin to be a marker for the intra-
renal RAS.33, 34 In a subsequent study, however, we showed that the glomerular sieving 
coefficient for renin is higher than for albumin and that variation in proximal tubular 
reabsorption explains the different urinary excretion patterns of renin and albumin.34 
We also showed that urinary renin does not reflect converted prorenin. A recent study 
in mice and humans with diabetes confirmed these concepts and did not find evidence 
for local production of renin.35 Together these recent insights suggest that urinary renin 
excretion is mainly determined by variation in glomerular filtration and proximal tubular 
reabsorption and is therefore not a good marker for the intrarenal RAS. It would be of in-
terest to explore whether renin mRNA or protein in urinary extracellular vesicles – which 
are mainly derived from tubular epithelial cells – is a better read-out of intrarenal RAS.36 
This also implies that positive effects of oral alkali may have been obscured by coun-
teracting effects of the sodium load on filtration or reabsorption. We recently showed 
that an acid load increases albuminuria.37 Therefore, correction of acidosis would be 
expected to reduce albuminuria, unless this effect is counterbalanced, for example by 
the sodium load. This could also explain why fruits and vegetables have more positive 
effects than sodium bicarbonate.38 In this regard it would be interesting to assess the 
effect of oral alkali given with another cation. A clinical trial that compares the effects 
of potassium citrate with potassium chloride and placebo on kidney outcomes in CKD 
stage G3b and G4 is currently ongoing and may provide more insight in this matter.39
A third relevant finding in our study is that sodium chloride but not sodium bicarbonate 
increased albuminuria. This is relevant, because the dose-finding study by Raphael et 
al. observed an increase in albuminuria with the high dose (i.e., 0.8 mEq/kg per day) 
but not with the low dose (i.e., 0.5 mEq/kg per day) sodium bicarbonate.40 The effect of 
alkali treatment on albuminuria is most likely the result of hemodynamic changes due 
to the sodium load given with bicarbonate. Another possibility is that a higher urine 
pH resulted in the detection of more intact albumin in the assay.41 However, the results 
in our study and previous studies showing that sodium bicarbonate in both high and 
low doses also lowers albuminuria11, 15, 22 suggest that assay characteristics do not fully 
explain the reported changes in albuminuria.
This is the first study to analyze the effect of sodium bicarbonate on urinary renin excre-
tion. Another strength of this study is the inclusion of two control groups. However, this 
study also has a number of limitations. As discussed above, the dose of sodium bicar-
bonate or treatment time may explain why previously observed effects on aldosterone, 
endothelin-1, and proteinuria were not observed in this study. Although sample size was 
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also modest, we recently showed in a study with a similar sample size that an acute acid 
load caused significant differences in urinary renin excretion between healthy subjects 
and patients with CKD.37 Again, these results suggested that glomerular hyperfiltration 
or reduced proximal tubular reabsorption caused these changes in urinary renin. There-
fore, the lack of effect of sodium bicarbonate supplementation on urinary renin likely 
means that no net changes in filtration or reabsorption occurred.
In conclusion, despite correction of acidosis and reduction in urinary ammonium ex-
cretion, sodium bicarbonate supplementation did not improve urinary markers of the 
renin-angiotensin system, endothelin-1, or proteinuria. Explanations for the lack of ef-
fect include bicarbonate dose, treatment time, or the inability of urinary renin to reflect 
intrarenal renin-angiotensin system activity.
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SuMMARy AnD ConCluSionS
Salt-sensitive hypertension and metabolic acidosis are two common complications of 
chronic kidney disease (CKD). The studies presented in this thesis aimed to provide more 
insight into the pathophysiology of salt-sensitive hypertension and metabolic acidosis 
in CKD. In particular, emphasis is placed on the role of the renin-angiotensin system 
(RAS). Furthermore, new treatment strategies for hypertension in CKD are explored.
Chapter 1 provides a brief introduction into the subject and outlines the aims of the 
thesis.
Chapter 2 consists of a comprehensive review on the distal tubular mechanisms of 
salt-sensitive hypertension in CKD. Apart from reduced GFR, activation of the central 
or sympathetic nervous system, altered vascular reactivity, and increased renal sodium 
reabsorption are important contributors to hypertension in CKD. Regarding the latter, 
six mechanisms are introduced that explain how CKD increases distal tubular sodium 
reabsorption, namely (1) changes in glomerulotubular balance and tubular remodeling, 
(2) renin-independent aldosterone secretion, (3) activation of the intrarenal RAS, (4) the 
role of dietary salt, (5) metabolic acidosis, and (6) proteinuria-induced sodium reabsorp-
tion. The role of dietary salt is discussed with regard to its effects on mineralocorticoid 
receptor signaling and its effects on the immune system. Metabolic acidosis is linked 
to activation of the RAS and proteinuria and is therefore discussed as separate entity 
contributing to salt-sensitive hypertension.
Chapter 3 describes rat studies aimed at dissecting the interaction of dietary salt and 
the RAS in an experimental model of CKD. For this purpose, 5/6th nephrectomies (Nx) 
were performed in rats. 5/6th Nx recapitulates the hallmarks of CKD, namely a reduced 
glomerular filtration rate (GFR), proteinuria and salt-sensitive hypertension. First, 
we showed that 5/6th Nx causes a low-renin salt-sensitive form of hypertension with 
hyperkalemia and unsuppressed aldosterone, mimicking human CKD. Although the ex-
pression of most kidney sodium transporters was reduced after 5/6th Nx, we found that 
the gamma subunit of the epithelial sodium channel (ENaC) and its regulatory proteins 
prostasin and serum and glucocorticoid-regulated kinase 1 (SGK1) were increased. Next, 
several interventions were introduced to selectively block the RAS under normal and 
high dietary salt conditions. We showed that on a normal salt diet hypertension of the 
5/6th Nx model is dependent on aldosterone and angiotensin II. On a high salt diet, hy-
pertension was more severe and the response to angiotensin II type 1 receptor blockade 
with losartan, either given alone or in combination with adrenalectomy, was reduced. 
The only intervention that attenuated hypertension on a high salt diet was treatment 
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with the mineralocorticoid receptor antagonist spironolactone. Moreover, spironolac-
tone increased natriuresis, reduced skin water content, and restored vasorelaxation, 
suggesting that dietary salt increases blood pressure in the CKD-model through miner-
alocorticoid receptor-dependent kidney and vascular mechanisms.
In Chapter 4, a novel RNA-based treatment strategy that targets angiotensinogen for 
the treatment of hypertension is reviewed. A rat study that investigated the effect of 
siRNA directed against angiotensinogen (AGT) on blood pressure and kidney outcomes 
is presented in Chapter 5. Similar to the experiments described in Chapter 3, 5/6th Nx 
was used to model human CKD. A comparison is made between treatment with AGT 
siRNA alone, angiotensin II type 1 receptor blockade with losartan, dual RAS-blockade 
with AGT siRNA and losartan, and dual RAS-blockade with losartan and the angiotensin-
converting enzyme inhibitor captopril. Monotherapy with AGT siRNA prevented the 
ongoing progression of hypertension in the 5/6th Nx model, while losartan, either given 
as single treatment or combined with AGT siRNA or captopril, lowered blood pressure. 
Interestingly, monotherapy with losartan reduced blood pressure more than single treat-
ment with AGT siRNA and both dual treatments, suggesting that its antihypertensive 
effect is dependent on stimulation of vasodilatory angiotensin II type 2 receptors. All 
treatments reduced proteinuria and heart weight (a measure for cardiac hypertrophy) 
to a similar degree, and no intervention improved GFR, while AGT siRNA and losartan 
reduced glomerulosclerosis similarly. AGT siRNA lowered plasma AGT by >95% resulting 
in depletion of angiotensin II at tissue level. Multivariable regression analysis identified 
blood pressure and intrarenal angiotensin II as independent predictors of proteinuria. 
We conclude that AGT siRNA is effective in the treatment of hypertension in experimental 
CKD and that it may offer cardiorenal protection. Moreover, its renoprotective effects are 
blood pressure-independent and rely on suppression of renal angiotensin II formation 
from liver-derived AGT.
Chapter 6 describes a randomized clinical trial comparing two treatments for hyper-
tension in CKD. Previous studies showed that dietary salt restriction effectively lowers 
blood pressure in CKD, but for many patients long-term adherence remains challenging. 
Pharmacological interventions that lower blood pressure are therefore often necessary. 
The study presented here investigated whether the distal diuretics hydrochlorothiazide 
and amiloride are as effective as dietary salt restriction using an open-label crossover 
design. Twenty-six patients with CKD stage G3 or G4 (eGFR 15-60 mL/min per 1.73m2) 
were treated with amiloride/hydrochlorothiazide (5/50 mg/day) and dietary salt restric-
tion (60 mmol/day), with both treatment periods lasting 2 weeks. Dietary salt restriction 
lowered blood pressure, whereas the effect of diuretics on blood pressure was much 
stronger. Both treatments lowered indices of fluid overload (body weight, NT-proBNP 
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and overhydration assessed by bio-impedance analysis) and caused a trend towards 
a reduction in albuminuria. The reduction in blood pressure was accompanied by a 
decrease in eGFR with both interventions, that was again stronger with diuretics. After 
discontinuing treatment, eGFR returned to pretreatment levels. Considering that the 
decrease in eGFR was transient and was associated with increased plasma renin and 
aldosterone levels, we conclude that the effect on eGFR was most likely caused by he-
modynamic changes. Furthermore, in light of the non-inferiority design of the study, we 
conclude that diuretic treatment was at least as effective as dietary salt restriction for 
the treatment of hypertension in CKD.
Chapter 7 focuses on the RAS in patients with autosomal dominant polycystic kidney 
disease (ADPKD). Results from previous studies suggest that certain components of 
the RAS are produced in or around renal cysts. Whether such local production occurs, 
and if these components also end up in plasma or urine and could therefore be used as 
biomarker for intrarenal RAS activation, has not yet been confirmed. To investigate this, 
plasma and urinary angiotensinogen and renin levels were determined in 60 ADPKD 
patients and compared to 57 CKD patients that were matched for sex, eGFR, blood pres-
sure and RAS-blocker use. The results show that urinary excretion of angiotensinogen 
and renin is 5- to 6-fold higher in ADPKD compared to CKD, while plasma renin was lower 
in ADPKD (in patients without RAS-blockers). In a multivariable analysis, the presence 
of ADPKD, low GFR, plasma renin and albuminuria predicted angiotensinogen and renin 
excretion. However, the correlation between albuminuria and urinary renin showed a dif-
ferent pattern in ADPKD than in CKD. Additionally, RAS-measurements in cyst fluid from 
three ADPKD-patients that underwent nephrectomy showed that the concentrations of 
angiotensinogen, prorenin and renin are lower in cysts than in plasma. Angiotensinogen 
and prorenin concentrations in urine were also lower compared to cyst fluid. In case 
of renin, however, fluid and urine concentrations were similar. Overall, our results do 
not provide evidence for ectopic production of renin in the kidney and the changes in 
urinary excretion may be explained by differences in tubular reabsorption in ADPKD and 
CKD.
In Chapters 8 and 9, the interaction between the RAS and acid-base balance in CKD is 
studied. When GFR decreases, the capacity of the kidneys to excrete acid is impaired and 
patients often develop metabolic acidosis. The presence of metabolic acidosis in CKD is 
associated with increased cardiovascular and all-cause mortality. Yet, how metabolic 
acidosis leads to adverse outcomes in CKD is incompletely understood. The currently 
available evidence points towards an important role of the RAS and endothelin-1. Two 
different approaches were used to investigate if and how the RAS responds to changes 
in acid-base homeostasis in CKD.
Chapter 10 233
Summary and conclusions
First, Chapter 8 describes the response of patients with CKD stage G4 (eGFR 15-30 mL/
min per 1.73m2) and healthy subjects to an oral acid load. CKD reduced the capacity for 
acid excretion and increased the duration of acidosis. Moreover, induction of acidosis 
in CKD resulted in higher concentrations of plasma potassium and plasma aldosterone, 
more excretion of urinary albumin and renin, and a reduction of the cumulative excre-
tion of sodium, chloride and potassium. Together, these findings provide potential 
mechanisms that explain the adverse effects of metabolic acidosis in CKD, including the 
deleterious effects of hyperkalemia, aldosterone and proteinuria induced by acidosis.
In Chapter 9, we evaluated the effect of correction of metabolic acidosis on the RAS in 
CKD. Forty-five patients with CKD stage G4 were treated for 4 weeks with either sodium 
bicarbonate, sodium chloride (providing the same dose of sodium as given with sodium 
bicarbonate) or received no treatment. Sodium bicarbonate caused a trend towards a 
reduction in plasma aldosterone and plasma potassium, but did not lead to changes 
in plasma renin or the urinary excretion of renin, angiotensinogen or aldosterone. 
Furthermore, no changes were observed in urinary endothelin-1. The lack of effect on 
urinary outcomes may be explained by the prescribed dose of bicarbonate. Several 
earlier clinical trials that used a similar dose of sodium bicarbonate also failed to show 
a significant effect on the primary outcome, whereas three RCTs that used a higher dose 
were positive. Other explanations may include factors such as CKD stage and treatment 
time, considering that previous studies that showed a (modest) effect of alkali treatment 
on urinary RAS-components also included patients with earlier stages of CKD and had 
treatment times lasting up to five years. Moreover, RAS-inhibitors were used by most 
patients in our study (88%) and may have suppressed the RAS to a point that further 
suppression by alkali treatment was no longer possible. A final explanation for the lack 
of an effect on urinary renin is that urinary renin may not reflect intrarenal activity of the 
RAS. This notion has emerged from recent studies showing that urinary renin excretion is 
mainly determined by glomerular filtration and proximal tubular reabsorption, and not 
by local production (i.e., intratubular conversion from prorenin or tubular secretion).
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SAMenvAtting en ConCluSieS
Zoutgevoelige hypertensie en metabole acidose zijn twee veel voorkomende compli-
caties van chronische nierinsufficiëntie. Het doel van de studies in dit proefschrift is 
om meer inzicht te verkrijgen in de pathofysiologie van zoutgevoelige hypertensie en 
metabole acidose bij patiënten met chronische nierinsufficiëntie. Er wordt een bijzon-
dere nadruk gelegd op de rol van het renine-angiotensine systeem (RAS). Ook worden 
nieuwe behandelingsmogelijkheden voor hypertensie bij chronische nierinsufficiëntie 
onderzocht.
Hoofdstuk 1 geeft een korte introductie over het onderwerp en de doelstellingen van het 
proefschrift worden gepresenteerd.
Hoofdstuk 2 bestaat uit een uitgebreid review waarin de pathofysiologische me-
chanismes van zoutgevoelige hypertensie bij chronische nierinsufficiëntie worden 
uiteengezet. De nadruk ligt specifiek op mechanismes in de distale tubulus van de nier. 
Naast een verlaagde GFR zijn activatie van het centrale of sympathische zenuwstelsel, 
veranderde vasculaire reactiviteit en een verhoogde neiging tot natriumreabsorptie 
door de nier belangrijke bijdragers aan hypertensie bij chronische nierinsufficiëntie. 
In het review worden zes mechanismes geïntroduceerd die verklaren hoe chronische 
nierinsufficiëntie leidt tot meer natriumreabsorptie, namelijk 1) veranderingen in de 
glomerulotubulaire balans en remodelering van de tubulus, 2) renine-onafhankelijke 
aldosteron secretie, 3) activatie van het intrarenale RAS, 4) de rol van zout in het dieet, 
5) metabole acidose, en 6) proteïnurie-geïnduceerde natriumreabsorptie. De rol van 
zout in het dieet wordt besproken in relatie tot de effecten van zout op activatie van de 
mineralocorticoïdreceptor en het immuunsysteem. Metabole acidose wordt gerelateerd 
aan activatie van het RAS en proteïnurie en wordt daardoor besproken als aparte factor 
die kan bijdragen aan zoutgevoelige hypertensie.
Hoofdstuk 3 beschrijft rattenstudies die als doel hebben om de interactie tussen zout in 
het dieet en het RAS te onderzoeken in een experimenteel model voor chronische nier-
insufficiëntie. Hiervoor is bij ratten een 5/6de nefrectomie (Nx) uitgevoerd. Deze operatie 
resulteert in de belangrijkste kenmerken van chronische nierinsufficiëntie, te weten een 
verlaagde glomerulaire filtratie snelheid (in het Engels: glomerular filtration rate, ofwel 
GFR), proteïnurie en zoutgevoelige hypertensie. Als eerste laten we zien dat 5/6de Nx leidt 
tot een vorm van zoutgevoelige hypertensie die lijkt op chronische nierinsufficiëntie bij 
mensen, namelijk met een laag plasma renine, hyperkaliëmie en een niet-onderdrukt 
plasma aldosteron. Ondanks dat de expressie van de meeste natriumtransporters in de 
nier verlaagd waren na 5/6de Nx vonden we dat het gamma-onderdeel van het epitheliale 
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natriumkanaal ENaC, en de regulerende eiwitten prostasin en ‘serum and glucocorti-
coid-regulated kinase 1’ (SGK1) waren verhoogd. Daaropvolgend zijn verschillende 
behandelingen gegeven om selectief onderdelen van het RAS te blokkeren bij ratten die 
een dieet kregen toegediend met een normale hoeveelheid zout of een dieet met veel 
zout (i.e., 10x meer). We laten zien dat hypertensie in het 5/6de Nx model afhankelijk is 
van aldosteron en angiotensine II tijdens een normale zoutinname. Tijdens inname van 
het zoutrijke dieet nam de hypertensie toe en was het bloeddrukverlagende effect van 
angiotensine II type 1 receptor blokkade met losartan – alleen gegeven of in combinatie 
met een adrenalectomie – sterk verminderd. De enige interventie die de bloeddruk 
verlaagde bij de ratten op een zoutrijk dieet was behandeling met de mineralocortico-
idreceptor antagonist spironolacton. Daarnaast leidde behandeling met spironolacton 
ook tot meer natriurese, minder water in de huid en herstel van de relaxatie van bloed-
vaten. Concluderend suggereren onze resultaten dat de bloeddrukstijging door zout 
in het 5/6de Nx model wordt veroorzaakt door mineralocorticoïdreceptor-afhankelijke 
mechanismes in de nier en de bloedvaten.
Hoofdstuk 4 bestaat uit een review waarin een nieuwe behandelmethode om angio-
tensinogeen (AGT) met RNA te onderdrukken wordt beschreven. Aanvullend wordt in 
Hoofdstuk 5 een rattenstudie gepresenteerd waarin het effect van siRNA gericht tegen 
AGT op de bloeddruk en nier-gerelateerde uitkomsten wordt onderzocht. Net als in de 
experimenten die worden beschreven in Hoofdstuk 3 wordt hier ook 5/6de Nx gebruikt 
als model voor chronische nierinsufficiëntie bij mensen. Er wordt een vergelijking ge-
maakt tussen behandeling met alleen AGT siRNA, alleen angiotensine II type 1 receptor 
blokkade met losartan, duale RAS-blokkade met AGT siRNA en losartan en duale RAS-
blokkade met losartan en captopril, een remmer van het angiotensine-converterend-
enzym. Behandeling met alleen AGT siRNA voorkwam de voortdurende progressie van 
hypertensie in het 5/6de Nx model, terwijl losartan, gegeven als enige behandeling of 
samen met AGT siRNA, de bloeddruk verlaagde. Een interessante uitkomst is dat mono-
therapie met losartan de bloeddruk sterker verlaagde dan monotherapie met AGT siRNA 
en beide behandelingen met duale RAS-blokkade. Deze resultaten doen vermoeden 
dat het bloeddrukverlagende effect van losartan afhankelijk is van activatie van de 
vaatverwijdende angiotensine II type 2 receptoren. Alle behandelingen leidden tot een 
gelijkwaardige verlaging van proteïnurie en hartgewicht (een maat voor cardiale hy-
pertrofie) en geen enkele interventie resulteerde in verbetering van de GFR. AGT siRNA 
en losartan verminderden glomerulosclerose in gelijke mate. AGT siRNA verlaagde de 
plasma AGT concentratie met > 95%, wat resulteerde in depletie van angiotensine II op 
weefselniveau. Met een multivariabel regressiemodel werden bloeddruk en intrarenaal 
angiotensine II geïdentificeerd als onafhankelijke voorspellers van proteïnurie. We 
concluderen dat AGT siRNA effectief is voor de behandeling van hypertensie in een 
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experimenteel model voor chronische nierinsufficiëntie en dat deze behandeling bij 
kan dragen aan het voorkomen van hart- en nierschade. Daarnaast is het beschermende 
effect op de nieren niet afhankelijk van de bloeddruk en wel afhankelijk van onderdruk-
king van de productie van angiotensine II in de nier, dat afkomstig van angiotensinogeen 
in de lever.
Hoofdstuk 6 beschrijft een gerandomiseerde klinische studie waarin twee behandelin-
gen voor hypertensie bij patiënten met chronische nierinsufficiëntie worden vergeleken. 
Eerdere studies laten zien dat een zoutbeperking effectief de bloeddruk verlaagd bij 
patiënten met chronische nierinsufficiëntie, maar het is voor patiënten vaak moeilijk om 
dit dieet voor langere tijd vol te houden. Farmacologische middelen om de bloeddruk 
te verlagen zijn daarom vaak nodig. In deze open-label cross-over studie is onderzocht 
of thiazidediuretica even effectief zijn als een zoutbeperking. Zesentwintig patiënten 
met chronische nierinsufficiëntie stadium G3 of G4 (eGFR 15-60 ml/min per 1.73m2) zijn 
behandeld met amiloride/hydrochloorthiazide (5/50 mg/dag) en een zoutbeperking 
(60 mmol/dag). Beide behandelperiodes duurden 2 weken. De behandeling met een 
zoutbeperking verlaagde de bloeddruk, maar het effect van diuretica op de bloed-
druk was veel sterker. Ook verlaagden beide behandelingen maten voor overvulling, 
namelijk lichaamsgewicht, plasma NT-proBNP en ‘overhydratie’ (geanalyseerd met 
bio-impedantiemetingen), en was er een trend naar vermindering van albuminurie. Bij 
beide behandelingen ging de verlaging van de bloeddruk gepaard met een verlaging van 
de eGFR, die ook weer sterker was met diuretica. Na het stoppen van de behandelingen 
normaliseerde de eGFR naar het niveau van voor de behandeling. Omdat de daling van 
de eGFR van tijdelijke aard was en gepaard ging met een stijging van plasma renine en 
aldosteron concentraties, concluderen we dat het effect op de eGFR meest waarschijn-
lijk werd veroorzaakt door hemodynamische veranderingen. Omdat de studie is opgezet 
als ‘non-inferiority’-studie concluderen we daarnaast dat diuretica in ieder geval even 
effectief zijn als een zoutbeperking voor de behandeling van hypertensie bij chronische 
nierinsufficiëntie.
In Hoofdstuk 7 staat de activatie van het RAS bij patiënten met autosomaal dominante 
polycysteuze nierziekte (ADPKD) centraal. Resultaten uit eerdere studies suggereren 
dat er in en rondom cysten in de nier bepaalde componenten van het RAS worden ge-
produceerd. Of dit werkelijk het geval is, en of deze componenten ook in de circulatie 
en in de urine terecht komen, en dus gebruikt zouden kunnen worden als biomarker 
voor activatie van het intrarenale RAS, is nog niet bekend. Om dit te onderzoeken is er 
bij 60 patiënten met ADPKD angiotensinogeen en renine bepaald in plasma en urine 
en werden deze uitkomsten vergeleken met angiotensinogeen- en reninewaarden van 
57 patiënten met chronische nierinsufficiëntie die waren gematcht op geslacht, eGFR, 
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bloeddruk en gebruik van RAS-blokkers. De resultaten laten zien dat de uitscheiding 
van angiotensinogeen en renine in de urine 5 tot 6 keer hoger is bij ADPKD dan bij CKD, 
maar dat plasma renine lager is bij ADPKD (bij patiënten die geen RAS-blokkers gebrui-
ken). In een multivariabel regressiemodel voorspelden de aanwezigheid van ADPKD, 
een lagere eGFR, plasma renine en albuminurie de excretie van angiotensinogeen en 
renine. Echter, de correlatie tussen albuminurie en urine renine liet een ander patroon 
zien bij ADPKD dan bij CKD. Daarnaast lieten RAS-metingen in cystevloeistof bij drie 
patiënten met ADPKD die een nefrectomie ondergingen zien dat de concentraties van 
angiotensinogeen, prorenine en renine lager zijn in cysten dan in plasma. Ook waren de 
concentraties van angiotensinogeen en prorenine in urine lager dan in cystevloeistof. De 
concentraties van renine waren daarentegen wel hetzelfde in cystevloeistof en in urine. 
Concluderend leveren onze resultaten geen bewijs voor ectopische productie van renine 
in de nier en de variaties in excretie kunnen worden verklaard door een verschillende 
mate van tubulaire reabsorptie bij ADPKD en CKD.
In Hoofdstuk 8 en 9 wordt de interactie tussen het RAS en de zuur-base balans bij CKD 
onderzocht. De capaciteit van de nieren om zuur uit te scheiden neemt af als de GFR 
daalt en hierdoor ontwikkelen patiënten vaak een metabole acidose. De aanwezigheid 
van een metabole acidose bij chronische nierinsufficiëntie is geassocieerd met een 
hoger risico op sterfte (zowel cardiovasculair als niet-cardiovasculair). Hoe metabole 
acidose leidt tot schadelijke uitkomsten bij chronische nierinsufficiëntie is niet goed 
bekend. Het huidige beschikbare bewijs suggereert dat het RAS en endotheline-1 een 
belangrijke rol spelen in de pathofysiologie van metabole acidose. In deze hoofdstukken 
worden twee verschillende strategieën gebruikt om te onderzoeken of en hoe het RAS 
reageert op veranderingen in de zuur-base homeostase bij chronische nierinsufficiëntie.
Hoofdstuk 8 beschrijft hoe patiënten met chronische nierinsufficiëntie stadium G4 (eGFR 
15-30 mL/min per 1.73m2) en gezonde controles reageren op een orale zuurbelasting. De 
capaciteit om zuur uit te scheiden werd verminderd door de aanwezigheid van chroni-
sche nierinsufficiëntie en de duur van de acidose was langer bij de patiënten. Daarnaast 
resulteerde inductie van acidose bij chronische nierinsufficiëntie in hogere concentraties 
van plasma kalium en plasma aldosteron, meer excretie van urine albumine en renine, 
en een verminderde cumulatieve excretie van natrium, chloride en kalium. Samenvat-
tend verschaffen deze resultaten potentiele mechanismes die de negatieve effecten van 
metabole acidose bij chronische nierinsufficiëntie kunnen verklaren, zoals de schade-
lijke acidose-geïnduceerde effecten van hyperkaliëmie, aldosteron en proteïnurie.
In Hoofdstuk 9 wordt het effect van correctie van metabole acidose op het RAS geëvalu-
eerd bij chronische nierinsufficiëntie. Vijfenveertig patiënten met chronische nierinsuf-
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ficiëntie stadium G4 werden gedurende 4 weken behandeld met natriumbicarbonaat, 
natriumchloride (met een gelijkwaardige hoeveelheid natrium als werd gegeven met 
natriumbicarbonaat) of geen behandeling. Natriumbicarbonaat veroorzaakte een trend 
naar een verlaging van het plasma aldosteron en het plasma kalium, maar leidde niet 
tot veranderingen van plasma renine of de excretie van renine, angiotensinogeen en 
aldosteron in urine. Daarnaast werden geen veranderingen gezien in de urine excretie 
van endotheline-1. Een mogelijke verklaring voor het feit dat er geen effecten op urine-
uitkomsten zijn gevonden is dat de voorgeschreven dosis van het bicarbonaat te laag 
was. Verschillende eerdere klinische studies waarin een soortgelijke dosering werd 
gebruikt lieten ook geen significante verschillen zien op de primaire uitkomstmaat. Drie 
andere RCT’s waarin een hogere dosering werd gebruikt waren daarentegen wel posi-
tief. Overige factoren die het gebrek aan significante verschillen kunnen verklaren zijn 
het stadium van chronische nierinsufficiëntie en de behandelduur. In eerdere studies 
waarin een effect werd gezien van alkali-behandeling op urine RAS-markers werden ook 
patiënten met een vroeger stadium van chronische nierinsufficiëntie geïncludeerd en 
werden patiënten voor periodes tot 5 jaar behandeld. Daarnaast gebruikten de meeste 
patiënten in onze studie een RAS-blokker (88%) en mogelijk werd het RAS hierdoor 
onderdrukt tot een niveau waarbij geen verdere onderdrukking meer mogelijk was. Een 
laatste verklaring voor de observatie dat de uitscheiding van urine renine niet veranderd 
tijdens correctie van een metabole acidose is dat urine renine geen uitleesmaat is voor 
activiteit van het intrarenale RAS. Deze onderkenning komt voort uit recente studies die 
laten zien dat de excretie van renine in de urine vooral wordt bepaald door glomerulaire 
filtratie en proximale tubulaire reabsorptie, en niet door lokale productie in de nier (i.e., 
intratubulaire omzetting van prorenine of tubulaire secretie).
Chapter 10 239
Discussion and future directions
DiSCuSSion AnD futuRe DiReCtionS
Identifying determinants of hypertension in chronic kidney disease (CKD) is important 
to improve treatment strategies. To do so, a better understanding of the pathophysiol-
ogy of hypertension in CKD is required.1 An important characteristic of hypertension in 
CKD is an increased extracellular fluid volume.2 In Chapter 2 we propose that increased 
sodium reabsorption by the distal nephron is a main driving force for extracellular fluid 
expansion in CKD. Plasma aldosterone and plasma potassium are two important regu-
lators of sodium reabsorption in the distal tubule and both are often elevated in CKD 
(Chapter 2). However, it is incompletely understood if and to what degree both factors 
contribute to hypertension in CKD. While aldosterone is an anti-natriuretic hormone that 
increases activity of the sodium chloride cotransporter (NCC) and the epithelial sodium 
channel (ENaC), plasma potassium acts as a natriuretic factor that suppresses activity 
of NCC. Moreover, plasma potassium also directly stimulates aldosterone secretion. In a 
clinical trial, the potassium binder patiromer reduced hyperkalemia, aldosterone, and 
blood pressure in patients with CKD, suggesting that potassium-induced aldosterone 
secretion contributes to hypertension in CKD.3 How plasma potassium regulates NCC 
is becoming increasingly clear.4 Recent studies indicate that extracellular potassium 
raises the membrane potential of the basolateral membrane of the distal convoluted 
tubule, which leads to an intracellular signaling cascade that dephosphorylates NCC.4 
Essential for this mechanism are the potassium channels Kir4.1 and Kir5.1 which ‘sense’ 
extracellular potassium at the basolateral membrane. In Chapter 3, we analyzed how 
CKD changes the abundance of kidney sodium and potassium transporters in an animal 
model of CKD, namely the 5/6th nephrectomy (Nx) model. Previous experimental stud-
ies demonstrated that induction of CKD in either rats or mice increases the abundance 
of NCC, α-ENaC and γ-ENaC, but the relation between sodium transporter abundance 
and activity of the renin-angiotensin system (RAS) or plasma potassium has not yet 
been investigated.5-7 In our study, 5/6th Nx decreased NCC and α-ENaC, whereas β-ENaC 
remained unchanged and γ-ENaC was increased. Moreover, 5/6th Nx increased Kir4.1, 
whereas it decreased Kir5.1. Further analysis showed that higher plasma renin was asso-
ciated with higher protein abundances of NCC and α-ENaC, and higher serum potassium 
(potassium was measured in serum and not in plasma in our study) was associated with 
lower (p)NCC and Kir5.1, suggesting that both the RAS and potassium regulate sodium 
transporter activity in CKD. Several factors may explain the differences between the 
reported sodium transporter abundances in our study and previous studies, including 
different experimental models of CKD,7 lower serum potassium in other CKD-models,7 
differences in the time-period between the measurement of protein abundances and 
5/6th Nx,5, 6 and alternative methods for protein normalization.5-7 In previous studies, 
transporter abundances were normalized based on protein concentration in the kidney 
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homogenates of healthy and 5/6th Nx rats. However, protein composition changes 
considerably after 5/6th Nx with extracellular matrix expansion and fibrosis due to 
compensatory adaptations of remaining nephrons.8 To account for these changes, we 
used a novel method for normalization based on kidney weight, which approximates 
normalization by nephron number.9, 10
The observation that sodium transporter activity is regulated by potassium suggests 
that increasing dietary potassium intake may be an effective strategy to lower blood 
pressure in CKD. Previous studies in hypertensive patients without CKD showed that a 
higher dietary potassium intake reduces blood pressure.11, 12 Currently, a randomized 
clinical trial is ongoing that will evaluate if dietary potassium supplementation lowers 
blood pressure and is renoprotective in patients with CKD stage G3B and G4.13 However, 
it is equally important to gain more insight in the mechanisms of how dietary potassium 
regulates blood pressure in CKD. At present, the most eligible model to study these 
mechanisms is the 5/6th Nx model, because this model is characterized by the hallmarks 
of CKD, including low GFR, proteinuria, hyperkalemia, and hypertension (Chapter 3). 
Moreover, the 5/6th Nx model shows high reproducibility (e.g., compared to the vascular 
ligation model)14 and offers several practical advantages to models that require other 
species, have much shorter or much longer time courses, or are more time-consuming.15 
As with any animal model, however, a caveat is that 5/6th Nx is not fully representative of 
human CKD as it specifically causes hyperfiltration, which is not a characteristic of many 
CKD-etiologies.8 In addition to determining if and how dietary potassium reduces blood 
pressure (i.e., through vascular or kidney mechanisms), a number of questions should 
be addressed, including whether potassium confers renoprotection (as previously sug-
gested),12 whether potassium can be combined with RAS blockers (i.e., this may lead to 
exaggerated hyperkalemia), and to what degree potassium-induced increases in aldo-
sterone are deleterious in CKD. This last question is particularly relevant considering that 
potassium-induced aldosterone secretion may contribute to hypertension in CKD.3, 16 
If this mechanism exceeds the blood pressure-lowering effects of dietary potassium, 
hyperkalemia should be avoided in CKD. Indeed, data from previous studies indicates 
that plasma potassium concentrations between 4.0 and 5.0 mmol/L are associated with 
a lower rate of adverse outcomes in CKD, whereas higher or lower plasma potassium 
levels are associated with more adverse outcomes.17 Therefore, another question that 
may need to be addressed is whether titrating plasma potassium to a certain concentra-
tion range (e.g., using dietary potassium or potassium binders) is beneficial in CKD.
In Chapter 6 we show that targeting NCC and ENaC with the combination of hydrochlo-
rothiazide and amiloride in patients with CKD stage G3 and G4 effectively lowers extra-
cellular volume and blood pressure. While non-renal effects of hydrochlorothiazide on 
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blood pressure cannot be fully excluded, the pronounced reduction in extracellular vol-
ume suggests that NCC, ENaC, or both are either more active or insufficiently suppressed 
in patients with CKD. Of note, plasma potassium did not change during treatment with 
this combination of kaliuretic and potassium-sparing diuretics. Furthermore, in patients 
with a lower eGFR, diuretic clearance was reduced while the antihypertensive effect re-
mained intact, suggesting that CKD limits pharmacokinetics but not pharmacodynamics 
of distal diuretics (Chapter 6).18 Although several previous studies similarly showed that 
thiazides reduce blood pressure in CKD, large RCTs powered for hard endpoints are still 
missing. Therefore, an important question that needs to be addressed in future studies 
is if distal diuretics also confer cardiovascular- and renoprotection. Moreover, thiazides 
– either in combination with amiloride or given alone – reduce GFR, and long-term 
intervention studies are required to see whether the beneficial effects on extracellular 
fluid volume and blood pressure outweigh the hemodynamic effects on GFR. Another 
issue that should be addressed is whether distal diuretics are more effective in specific 
patient-categories, for instance in women. Data from preclinical studies suggest that NCC 
is more active in females than in males.19-21 Also, several clinical studies in hypertensive 
patients without CKD indicate that women are more responsive to thiazides than men. A 
small randomized placebo-controlled crossover trial demonstrated that premenopausal 
women receiving hormone-replacement therapy show a greater antihypertensive 
response to thiazides than premenopausal women without such therapy.22 Moreover, 
in a secondary analysis of the INCLUSIVE study that included 1005 patients with uncon-
trolled hypertension, female sex was identified as a predictor for the blood pressure 
response to irbesartan/hydrochlorothiazide.23 Also, in a smaller randomized crossover 
trial in 52 hypertensive patients of African descent, the blood pressure response to hy-
drochlorothiazide was stronger in women than in men.24 However, in a larger and more 
heterogeneous population, differences in thiazide-responsiveness between women and 
men were not reported.25 Possibly, this is due to the fact that sex-differences in the blood 
pressure-response to thiazide diuretics are only present in certain subpopulations, such 
as older patients or black patients. Questions regarding thiazide-safety and effective-
ness in CKD are currently addressed in the CLICK trial.26 This study completed its inclu-
sion phase last year and included 131 patients with CKD stage G4. The primary outcome 
of the trial is 24-hour systolic blood pressure and secondary outcomes include adverse 
events and markers of extracellular volume and kidney damage. Furthermore, it will be 
interesting to see how distal diuretics compare with other sodium reducing strategies, 
such as dietary potassium, which is currently under investigation in CKD stage G3B and 
G413, and sodium-glucose co-transporter 2 (SGLT2) inhibitors. SGLT2 inhibitors were 
initially designed with the aim to improve glycemic control in patients with diabetes 
mellitus. These drugs reduce plasma glucose levels by inhibition of sodium-glucose re-
absorption in the proximal tubule. As a result, SGLT2 inhibitors increase glucosuria and 
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natriuresis.27 Interestingly, a recent study showed that SGLT2 inhibition not only targets 
the proximal tubule, but also reverses diabetes-induced NCC activation through inhibi-
tion of Kelch-like 3.28 Indeed, in patients with type 2 diabetes SGLT2 inhibition and NCC 
blockade with thiazide diuretics both reduced blood pressure, body weight and GFR.29 
However, the corresponding rise in plasma renin and plasma aldosterone that usually 
accompanies a reduction in blood pressure and extracellular volume, was much lower 
with SGLT2 inhibition than with thiazide treatment. In another study SGLT2 inhibition 
also lowered extracellular volume (measured by bioimpedance spectroscopy) in pa-
tients with diabetes. In this study, plasma renin and aldosterone were initially increased 
after the initiation of treatment, but the levels normalized after 3 months and were 
reduced after 6 months.30 A similar effect of SGLT2 inhibitors on the RAS was reported 
in experimental CKD. When given to 5/6th Nx rats, the SGLT2 inhibitor TA-1887 increased 
urinary volume and reduced body weight, but plasma renin and kidney angiotensin II 
remained unchanged.31 An explanation for the observation that renin is not consistently 
upregulated during SGLT2 inhibition may be that blockade of proximal tubular sodium 
reabsorption causes suppression of renin secretion due to increased sodium delivery to 
the macula densa.32 Another explanation may be that SGLT2 inhibitors reduce activity of 
the sympathetic nervous system and thereby inhibit renin release.33, 34 These ‘off target’ 
effects of SGLT2 inhibitors on NCC, the RAS and the sympathetic nervous system may 
contribute to the beneficial effects that SGLT2 inhibitors have on blood pressure and 
kidney outcomes and therefore deserve further investigation. Several large placebo-
controlled trials demonstrated beneficial effects of SGLT2-inhibitors on cardiovascular 
endpoints, progression of kidney disease and mortality in patients with type 2 diabetes 
and CKD stage G3-5.35-37 Recently, Heerspink et al. also showed that CKD-patients (eGFR 
25 to 75 mL/min per 1.73 m2) with and without diabetes benefit from treatment with 
SGLT2 inhibitors.38 The SGLT2 inhibitor dapagliflozin reduced blood pressure, slowed 
CKD-progression and lowered the risk of mortality compared to placebo. The most 
frequently observed side-effect of SGLT2 inhibitor treatment was volume depletion 
and the previously reported higher risk of amputation was not found. Future clinical 
studies focusing on SGLT2 inhibitor treatment in CKD should explore if there are factors 
that determine the response to treatment (such as eGFR or the degree of albuminuria), 
identify additional groups of patients that may benefit from SGLT2 inhibitor treatment 
(such as kidney transplant recipients), and determine how SGLT2 inhibitors should be 
used in combination with other glucose-lowering agents.
Chapter 3 demonstrates that the mineralocorticoid receptor (MR) could be a promis-
ing treatment target for hypertension in CKD, especially in the context of high dietary 
sodium intake. Previous studies showed that MR antagonists are effective for resistant 
hypertension in patients with an eGFR > 45 mL/min per 1.73m2.39 Moreover, a recent 
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meta-analysis (n = 5745) concluded that MR antagonists given on top of RAS inhibitors 
may reduce blood pressure and proteinuria in CKD stage G2-3, although the effects 
on mortality, cardiovascular and kidney outcomes were inconclusive.40 Other studies 
showed that spironolactone decreased cardiovascular morbidity and mortality in pa-
tients with end-stage kidney disease.41, 42 Whether MR antagonists lower blood pressure 
and protect against long-term adverse outcomes in patients with an eGFR < 30 mL/
min per 1.73m2 was recently addressed in the FIDELIO trial. This was a large placebo-
controlled trial that included diabetic patients with an eGFR between 25 and 60 mL/
min per 1.73m2.43 Treatment with the novel non-steroidal MR antagonist finerenone 
prevented CKD progression and cardiovascular events. Finerenone was given on top of 
RAS inhibition and had a moderate effect on blood pressure, but lowered albuminuria 
significantly. Hyperkalemia, a common side effect of steroidal MR antagonists that often 
necessitates discontinuation of treatment was present in 11.8% of patients on finere-
none and resulted in treatment discontinuation in 2.3% of patients (compared to 0.9% 
during placebo). No fatal events due to hyperkalemia were reported. Moreover, previous 
studies showed that the risk of hyperkalemia with finerenone is lower than with the 
older MR antagonists spironolactone and eplerenone, indicating that finerenone has a 
more favorable safety profile.44-46 Taken together, the results from the recent finerenone 
trial are encouraging and more studies are necessary to clarify if finerenone is beneficial 
and safe in patients without type 2 diabetes, in patients with an eGFR < 25 mL/min 
per 1.73m2, or in kidney transplant recipients. Finally, head-to-head studies between 
finerenone and the other MR antagonists are warranted to compare their renoprotective 
effects. Data from preclinical and smaller clinical studies comparing finerenone with 
spironolactone and eplerenone suggest that finerenone may be equally effective in 
preventing target organ damage in patients with CKD and heart failure.46 Of note, other 
novel MR antagonists are in clinical development as well, such as the non-steroidal 
KBP-5074. A currently ongoing placebo-controlled trial will evaluate whether KBP-5074, 
when given on top of RAS blocker therapy, lowers blood pressure and prevents CKD 
progression in patients with CKD stage G3B-G4 and resistant hypertension.47
Another line of research investigates the use of drugs targeting Ras-related C3 botulinum 
toxin substrate 1 (Rac1). These drugs are still experimental and clinical studies have not 
been reported. Fujita et al. showed that dietary salt induces MR activation in animal 
models with normal kidney function and that this effect is mediated by Rac1.48, 49 In the 
same studies they subsequently showed that the Rac1 inhibitor EHT1864 reduced blood 
pressure in animals receiving a high salt diet. A recent study also showed that increased 
activation of Rac1 in podocytes causes proteinuria and is important in the pathogenesis 
of proteinuric kidney disease.50 Since proteinuria may increase sodium reabsorption 
(Chapter 2), Rac1 activation in podocytes may contribute indirectly to hypertension 
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in CKD. In Chapter 3 we show that 5/6th Nx causes vascular dysfunction in rats on a 
high salt diet and that blood vessel function under these conditions is improved by 
spironolactone. Interestingly, previous investigators identified Rac1 in endothelial cells 
of the vasculature as a contributor to endothelial damage using isolated vessels from 
hypertensive mice and diabetic mice.51, 52 In a follow-up study, the same investigators 
showed that pharmacological blockade of Rac1 with NSC23766 improved endothelial 
function in veins resected from patients that underwent surgery for venous or  arte-
rial insufficiency.53 Taken together, these data may point towards a role for Rac1 in the 
pathophysiology of hypertension in CKD. Therefore, future experimental studies aimed 
at determining the relevance of Rac1 in blood pressure regulation in CKD are needed. In 
our study (Chapter 3) we did not observe any changes in total kidney expression of Rac1. 
Moreover, to date, no experimental studies have investigated the effects of Rac1 inhibi-
tors in animal models of CKD. If Rac1 is identified as potential target in CKD, a relevant 
question is if Rac1 inhibitors reduce blood pressure in CKD, and, if so, how the effects on 
blood pressure, blood vessel reactivity and sodium transporter activity compare to MR 
antagonists.
Targeting the RAS is an effective strategy to lower blood pressure and slow the progres-
sive loss of kidney function in CKD.54 However, long-term adherence to hypertension 
treatment, whether this consists of dietary advice or pharmacological drug prescrip-
tions, remains challenging for many patients.55 Chapter 4 describes the application of 
a novel RNA-based therapy that suppresses the production of liver-specific angioten-
sinogen (AGT) – the precursor of all angiotensins. The advantages of this new class of 
drugs are that it may be resistant to the counterregulatory rises of renin limiting the 
efficacy of ‘typical’ RAS inhibitors,56 and that the dosing frequency may be reduced to 
a few times per year. At present, multiple RNA-based therapies have been approved 
for clinical use, including drugs for the treatment of familial hypercholesterolemia, 
spinal muscular atrophy, Duchenne muscular dystrophy, and hereditary transthyretin-
mediated amyloidosis. Two types of RNA-based therapies suppressing AGT are currently 
available, namely AGT antisense oligonucleotides (ASOs) and AGT siRNA. In Chapter 5 we 
describe the first preclinical study evaluating the antihypertensive effect of liver-specific 
AGT siRNA in an animal model of CKD (5/6th Nx). We showed that AGT siRNA reduced 
blood pressure, proteinuria and glomerulosclerosis and that the renoprotective effect 
is independent of blood pressure. Interestingly, monotherapy with losartan caused a 
greater reduction in blood pressure than AGT siRNA either given alone or in combina-
tion with losartan. In a previous study in spontaneously hypertensive rats (SHRs), AGT 
siRNA lowered blood pressure to a similar degree as valsartan and captopril, and the 
combination of AGT siRNA and valsartan reduced blood pressure even further.57 Why the 
antihypertensive effect of AGT siRNA is less pronounced in the 5/6th Nx model is unclear. 
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Possibly, this difference is explained by the level of AGT knockdown, which was 97.9 ± 
1.0% after AGT siRNA monotherapy in the SHRs versus 96.5 ± 1.4% in the 5/6th Nx rats. 
Small differences in AGT suppression may matter for the blood-pressure lowering effect, 
considering that 99.8 ± 0.1% knockdown of plasma AGT caused an even greater blood 
pressure-reduction in the SHRs. Another explanation may be that hypertension in the 
5/6th Nx model is less dependent on the RAS than it is in SHRs. The data presented in 
Chapter 3 suggest that hypertension in the 5/6th Nx model (during normal salt intake) 
depends largely on angiotensin II and aldosterone. However, the degree of renin upregu-
lation during RAS blockade is much less pronounced compared to SHRs (approximately 
10 times less), indicating that RAS responsiveness may be limited in this model. Finally, 
more activation of the vasodilatory angiotensin type 2 receptor by angiotensin II in 
the 5/6th Nx model may also explain inter-model differences. Previous studies showed 
that angiotensin type 2 receptor levels are elevated after 5/6th Nx and that treatment 
with losartan increases these levels even further.58, 59 Taken together, the promising 
results of AGT siRNA in experimental studies merit further study aimed at increasing our 
understanding of the mechanisms of RNA-based RAS blockade. Currently, a random-
ized, double-blind, placebo-controlled trial evaluating the antihypertensive effect of a 
single injection of AGT siRNA in patients with mild to moderate hypertension is ongoing 
(www.clinicaltrials.gov, identification number: NCT03934307). Patients are randomized 
to treatment dosages ranging from 10 mg to 200 mg AGT siRNA. A recently presented 
interim analysis including the first 60 patients showed that a single dose of 200 mg AGT 
siRNA suppressed plasma angiotensinogen by 94.9 percent and reduced systolic blood 
pressure by 11 ± 2 mmHg at 8 weeks after injection.60 Moreover, AGT siRNA was well 
tolerated and caused no major side effects, including no kidney function decline, hyper-
kalemia, or hypotension requiring intervention. If AGT siRNA keeps performing well in 
clinical trials, comparator studies will be required to position RNA-based RAS inhibitors 
in the broad landscape of hypertension treatment. First, studies are needed to define 
which patient categories benefit from AGT siRNA treatment. The results presented in 
Chapter 5 show that AGT siRNA confers renoprotection in the 5/6th Nx model, suggesting 
that RNA-based RAS inhibition may be beneficial in CKD. Because RAS inhibitors are 
currently prescribed to virtually all patients with CKD, comparative studies between 
RAS inhibitors and AGT siRNA should be conducted. If similar or better outcomes with 
AGT siRNA are found, a major advantage contributing to clinical implementation will 
be practical applicability (i.e., long-lasting effects after a single injection). However, in 
case AGT siRNA proves inferior to current RAS inhibitors, adding AGT siRNA to other 
pharmacological treatment regimens, including other RAS inhibitors, may still be an 
option. A specific concern of the new RNA-based RAS inhibitor is its long-lasting effect. A 
single dose of AGT siRNA may have a sustained effect on blood pressure lasting weeks to 
months (Chapter 4). In patients that become hypovolemic during AGT siRNA treatment 
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maintaining adequate blood pressure levels may require specific treatments to reverse 
its effects (irrespective of the cause of hypovolemia). Current therapies for excessive RAS 
blockade (e.g., during intoxications with RAS blockers) include intravenous fluid infu-
sion and treatment with vasopressors (e.g., dopamine, norepinephrine). If these agents 
are similarly effective in hypovolemic patients using AGT siRNA should be addressed in 
future studies. Similarly, studies should show how other possible adverse effects of AGT 
siRNA (i.e., hyperkalemia and kidney failure) should be treated. Of interest, the potential 
renal adverse effects of AGT ASOs were recently studied in a preclinical study by Mullick 
et al..61 Administration of a liver-specific AGT ASO to salt-deprived 5/6th Nx rats did not 
result in changes in creatinine clearance or proteinuria, suggesting that it has a more 
favorable safety profile than a non-liver specific AGT ASO that worsened kidney function 
and proteinuria under similar conditions.61 Lastly, too much RAS blockade may be un-
desirable in CKD. Previous studies showed that hyperkalemia, hypotension, and kidney 
failure occur more frequently with dual RAS blockade than with single RAS blockade in 
CKD, without having an additional protective effect on mortality.62 However, a recent 
meta-analysis concluded that dual RAS treatment may be safe in specific patients with 
CKD, specifically those with diabetic kidney disease and hypertension.63 Therefore, dual 
RAS treatment including AGT siRNA may potentially prove beneficial in CKD and future 
studies are required to determine clinical safety.
In Chapter 8 and Chapter 9 we demonstrate that plasma aldosterone is increased during 
metabolic acidosis in CKD. Elevated levels of plasma aldosterone may contribute to fluid 
retention and hypertension in CKD (Chapter 2). However, whether metabolic acidosis 
leads to more fluid retention and hypertension in CKD is incompletely understood. 
Interestingly, a previous study showed that metabolic acidosis augments the blood 
pressure response to exercise in CKD, suggesting dysregulation of blood pressure during 
metabolic acidosis.64 Studies in patients with hypertension and CKD, however, did not 
identify metabolic acidosis as an independent risk factor for hypertension.65 If metabolic 
acidosis contributes to hypertension in CKD, a relevant question is whether correction 
of metabolic acidosis improves hypertension treatment and treatments aimed at fluid 
reduction in CKD. Another focus of research should address if sodium, potassium or the 
accompanying anion is important for antihypertensive and renoprotective effects of 
alkali-treatments in CKD. Multiple studies showed that sodium bicarbonate and dietary 
acid reduction with fruits and vegetables prevent the decline of kidney function in 
patients with CKD and metabolic acidosis.65 However, dietary interventions reduced sys-
tolic blood pressure, whereas sodium bicarbonate had no antihypertensive effect.66, 67 
Possibly, the differences in blood pressure between both interventions is explained by 
the presence of the sodium ion that accompanies bicarbonate. Another explanation 
may be that potassium intake was higher in the diet group, although plasma potassium 
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did not change over time.67 The ongoing ‘K+ in CKD study’ will show whether the anion 
is important as this study evaluates the antihypertensive and renoprotective effects of 
potassium chloride and potassium citrate in CKD.13 To date, only one large randomized 
placebo-controlled trial showed that alkali treatment prevents the decline in kidney 
function and reduces mortality in patients with CKD and metabolic acidosis.68 The pre-
scribed dose of sodium bicarbonate in this trial was titrated to reach a blood bicarbonate 
concentration between 24-28 mEq/L, with the final bicarbonate dose ranging from 0.8 
to 1.1 mEq/kg per day. In contrast, another large randomized controlled trial including 
acidotic patients with CKD failed to show beneficial effects of sodium bicarbonate on 
physical function or renal function and used a lower dose, similar to the dose used in 
the clinical trial presented in Chapter 9 (approximately 0.5 mEq/kg per day).69 The lack 
of clinical effects with lower bicarbonate dosages and the positive outcomes with higher 
dosages suggest that the clinical effects of alkali treatment are dose-dependent. Indeed, 
in a recent dose-finding study, Raphael et al. showed that a sodium bicarbonate dose of 
0.8 mEq/kg per day increased serum bicarbonate and lowered urinary ammonium more 
than a dose of 0.5 mEq/kg per day.70 Therefore, in future trials that aim to evaluate the 
effects of bicarbonate in CKD, bicarbonate dosages of 0.8 mEq/kg per day or higher are 
recommended.
Chapter 8 shows that the excretion of urinary renin is increased after induction of meta-
bolic acidosis in CKD. The increase in renin excretion occurred specifically in patients 
with CKD and not in healthy controls. We did not analyze by which mechanism urinary 
renin excretion increased, but the available evidence indicates that the higher excretion 
pattern was due to hyperfiltration rather than a reduction in proximal reabsorption of 
renin. Indeed, in a previous experimental study in healthy mice, induction of metabolic 
acidosis caused hyperfiltration, which was then followed by a progressive decline in 
kidney function.71 However, whether hyperfiltration contributes to the adverse effects 
of metabolic acidosis in patients with CKD is still unknown. Hyperfiltration may promote 
proteinuria, which is a known risk factor for CKD progression. To what degree filtered 
renin itself contributes to kidney injury during metabolic acidosis is incompletely under-
stood as well. Future studies are needed to address these questions.
Finally, in Chapter 7 we show that the excretion of RAS components including renin and 
angiotensinogen is increased in patients with autosomal dominant polycystic kidney 
disease (ADPKD). This specific pattern of increased renin and angiotensinogen excretion 
was not observed in patients with CKD. In contrast to the mechanism of increased renin 
excretion in patients with CKD and metabolic acidosis (Chapter 8), the increase in renin 
and angiotensinogen excretion in ADPKD is most likely caused by a reduction in proximal 
tubular reabsorption. Whether an increase in urinary excretion of RAS components con-
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tributes to hypertension and cyst formation in ADPKD is incompletely understood, but 
targeting the intrarenal RAS with siRNA did prevent cyst formation in an animal model 
of ADPKD.72, 73 Increases in tubular renin and angiotensinogen concentrations may lead 
to (more) intratubular formation of angiotensin II. However, angiotensin II formation in 
tubule segments distal to the proximal tubule remains uncertain and should be exam-
ined in future studies.
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Ik wil de internisten, longartsen, MDL-artsen, cardiologen, intensivisten en arts-assisten-
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heid, en natuurlijk voor hun inzet om mij klaar te stomen voor de opleiding tot internist! 
Theo, Sonja, Marcel en Armando, door jullie jarenlange begeleiding ben ik gevormd tot 
de persoon die ik nu ben: domo arigato gozaimasu!
Tim, vanaf onze eerste ontmoeting bij de lift delen wij ons onderzoeksplezier en on-
derzoeksleed. Door jou en Geert is mijn leven zoveel vrolijker geworden. Echter, als ik 
een factor aan moet wijzen waardoor mijn PhD langer heeft geduurd ben jij dat, zonder 
twijfel, maar ik heb van elke seconde genoten en van geen moment spijt. Met jou als 
partner in crime is geen enkel opblaasbaar ornament veilig. Ik verwacht je tijdens de 
verdediging in rokkostuum aan mijn zijde. 
Nicolaas, eerst ik jouw getuige, nu jij mijn paranimf. Ik verbaas me soms hoe wij elkaar 
hebben gevonden en zo’n bijzondere vriendschap hebben opgebouwd. Als ik laat in de 
avond thuiskwam van een dag in het lab werden mijn sores direct van tafel geveegd met 
een shotje cachaça. Ik waardeer onze band enorm en ik vind het een eer om jou aan mijn 
zijde te hebben. Deborah, jij hoort hier ook bij, jij hebt zoveel positiviteit aan ons leven 
toegevoegd: dankjewel (‘dank u wel’ in het Vlaams)! Je bent geweldig! Você é ótimo!
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Mandy, Bart, en Laura, jullie maken met Tim en Geert een onlosmakelijk deel uit van de 
‘Stadsdriehoek fissa’-familie. Met jullie in de buurt is het altijd feest – en met jullie in de 
buurt is er altijd liefde! 
Sterre, je bent een baas en op de één of andere manier beleven wij altijd mooie tijden! 
Ook jouw bijdrage in dit geheel wordt zeer gewaardeerd en kan niet onvermeld blijven. 
Kristina, the art-piece that you created for the cover of this thesis is truly magnificent. I 
am proud of our first coproduction! 
 
Naïm, ik kom woorden te kort om onze vriendschap te beschrijven. Ook als we elkaar 
een jaar niet zien is het als vanouds. Brazilië was een life-event (zowel voor onze geest 
als onze darmen)! Bij het volgende carnaval doen we een ander dansje, en hopelijk met 
Nilu erbij dit keer. 
Koen en Nanda, ik waardeer jullie vriendschap enorm en ook jullie bedank ik voor de 
laatste jaren. Ik kijk er altijd weer naar uit om ons wel en wee uit het ziekenhuis te delen. 
Met Eddie erbij wordt het de komende jaren vast nog veel gezelliger.
 
In één adem, maar ieder van onschatbare waarde: Eline, Michele, Tino (en natuurlijk 
Tom), of het nou een champagne-weekje of een whisky-weekendje is, met jullie is elk 
reisje een avontuur, en altijd komen we terug met meer kilo’s in onze koffers. Op naar 
de volgende!  
Karl and Marianne: you are wonderful people and I really enjoyed living with you. The 
fish are dearly missed but surely are better off in your capable hands!      
Ook dank aan de mooie tijden met Frank (van ’t Veer), Niels, Tim (Korevaar), Michele en 
Zineb, Wesley en Daphne, Nick en Harmke, Gijs, Sonja (Boas), Thomas, Leon, Sjoerd en 
Jurre. 
Ron, Karima, Jean-Paul en Daniëlle, ik vind jullie geweldige mensen. Bedankt dat jullie 
mij zo open hebben ontvangen in jullie gezin. Etentjes met jullie zijn altijd prikkelend 
voor zowel de smaakpapillen als de geest. Zonder jullie voorliefde voor de Efteling had 
ik vermoedelijk nooit mijn angst voor achtbanen overwonnen. Ook dit was een (posi-
tieve) ervaring waarvan het belang voor dit proefschrift niet kan worden onderschat. Ik 
hoop nog lang met jullie te mogen genieten van mooie ski-afdalingen, lekkere wijnen, en 
vooral onze goede gezondheid! 
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Mijn steeds groter wordende familie en daarbij ook Annie, ondanks dat we elkaar niet 
altijd even vaak zien heb ik nooit het gevoel dat jullie ver weg zijn. Met de jaren ga ik 
onze warme en bijzondere familieband steeds meer waarderen. En zonder de aange-
name geruststelling dat we er altijd voor elkaar zullen zijn zou mijn leven er zeker anders 
uit zien. Bedankt hiervoor! 
Mijn zus Caroline en natuurlijk Gerard, bedankt dat ik zo nu en dan bij jullie kon neer-
strijken voor een avondje ‘Geordie Shore’ en een biertje. Het maakte nooit uit dat ik de 
eerste 14 seizoenen had gemist want bijpraten kan in 5 minuten – altijd heerlijk ontspan-
nend. Nu Thijs en Fleur erbij zijn kijken we wat anders, maar is het des te leuker!
Mijn vader en moeder bedank ik voor hun jarenlange onvoorwaardelijke steun. Lieve 
pap en mam, alles heb ik aan jullie te danken en ik kan me geen fijnere ouders wensen. 
Jullie staan altijd voor ons klaar en we kunnen alles delen. Door jullie heb ik geleerd wat 
waardevol en belangrijk is in dit leven. Ik hoop dat we nog vele jaren met elkaar kunnen 
beleven. 
Lieve Yv, met jou ben ik zoveel meer. Wie had gedacht dat een lunch-date met ‘dat ene 
meisje waarvan we de naam steeds vergeten’ de vonk heeft doen overslaan. Je hebt 
je eigen theorieën, maar ik had vanaf dag 1 al een oogje op je. Sinds die ‘Tikkie’ zijn 
we (lees: onze telefoons) aan elkaar verbonden en ondanks dat ik weleens op stil sta 
kan mijn Iphone niet meer zonder die van jou. En geloof het of niet, we hebben alles te 
danken aan die BIC-studie, waarvoor ik het langst heb moeten ploeteren en waarvan 
ik het vaakst heb gedacht dat het niets op zou leveren. Integendeel dus. Wellicht ten 
overvloede, de BIC-studie staat beschreven in Hoofdstuk 9 – je had beloofd elke blad-
zijde van dit proefschrift te gaan lezen, maar ik vergeef het je als je naar het einde toe 
wat sneller bent gaan bladeren. Je had het vast niet meer verwacht, maar deze spreuk 
haalt het proefschrift alsnog (in het Engels, wel): “All theory is grey, …, but the golden 
tree of life springs ever green”. Jij kleurt mijn leven groen en goud, en zoveel grijzer is 
het zonder jou – ik hou van je.
